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ABSTRACT 
 
Many studies on human colorectal cancer (hCRC) samples have documented a 
dysbiosis associated with the tumor at different levels.  However a clear picture of the 
microorganisms whose abundance is altered during tumorigenesis and evidences of 
their functional implication in the tumorigenic process have not yet emerged. 
This study is aimed at dissecting the role of bacteria in CRC development by focusing on 
the intestinal mucus barrier as a key mediator in microbiota-host interaction. 
We used the ApcMin/+ murine model to demonstrate that in tumor-bearing mice, similarly 
to what happens in hCRC, the mucus barrier has altered properties.  Mucin expression is 
altered at the level of dysplastic crypts, strictly relating mucus changes with neoplastic 
transformation.  Being the mucus a fundamental component of the intestinal barrier we 
further addressed if bacterial penetrance was compromised in tumor-prone mice.  As 
hypothesised upon oral administration we observe increased Salmonella penetration in 
the intestine and spreading to mesenteric lymph nodes of ApcMin/+ mice compared to wild 
types. 
To address the potential role of mucus alteration in the tumorigenic process we 
exogenously modified the mucus barrier.  Upon treatment with Salmonella, a bacterium 
that is able to interact with the mucus, we observed an increase in colon tumorigenesis 
in ApcMin/+ mice.  Moreover, when we coupled the AOM/DSS protocol of chemically 
induced colitis-associated colon carcinogenesis to mucolytic treatment we observed 
exacerbated colon tumorigenesis. 
We did also investigate whether there was a dysbiosis associated with tumor 
progression, and when it was arising.  Metagenomic analysis in the faeces of mice at 
different ages highlighted a dysbiosis already at 4 weeks of age in ApcMin/+ mice when 
tumors are not yet established.  In particular, Lactobacillus genus was expanded in 
ApcMin/+ mice concomitantly with a contraction in the Clostridium genus.  At the species 
level Clostridium ID4 was underrepresented in ApcMin/+ mice both in the faeces and at 
the level of mucus-associated bacterial community.  Exogenous administration of C. ID4 
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to ApcMin/+ mice did result in neither any major change in tumor multiplicity nor alteration 
in gut resident immune cell populations. 
Finally since epigenetic mechanisms have recently been hypothesised to contribute to 
the loss of heterozygosity of the normal apc allele and bacteria can alter miRNA 
expression we analysed miRNA profiles in WT and ApcMin/+ intestinal tissue observing 
alterations in ApcMin/+ ilei.  We further tested if bacterial stimulation could drive alterations 
in the apc gene expression, possibly mediated by miRNA modulation, in the intestinal 
mucosa.  Salmonella and E. coli, either invasive or not, did not produce alterations in apc 
gene expression in an ex-vivo organ culture model that allows polarized stimulation of 
the intestinal mucosa. 
In conclusion we found that the mucus layer and intestinal barrier properties are altered 
in tumor bearing mice.  This could lead to the establishment of a dysbiosis, although the 
cause-effect relationships of this do not emerge clearly from the present work.  Bacterial 
species that are underrepresented in tumor bearing subjects could be protective and 
their administration could delay tumor progression.  Finally, dysbiosis could induce 
miRNA-mediated control of apc gene expression and this could be a mechanism 
involved in tumor initiation in the model used.  However, even if bacterial stimuli can 
modulate miRNA expression patterns, the ones tested in this work are not efficient in 
modulating apc expression. 
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1 INTRODUCTION 
 
The epithelial surfaces of the human body are continuously challenged by harmful 
environmental agents and their integrity is fundamental in homeostasis maintenance. 
Through the gastrointestinal (GI) tract we introduce every day food antigens and 
microbes our organism has to cope with.  Moreover, the GI tract is the home niche for 
the intestinal microbiota with which a symbiontic relationship is established.  To interact 
with all these agents the organism has evolved a multi-layer barrier that has on one side 
the role of protecting from pathogens and harmful agents and on the other side of 
allowing and promoting tolerance and exchange with the commensal microflora (Hooper 
and Macpherson, 2010).  The endogenous microbiota has a fundamental role in 
maintaining host homeostasis and alterations of the microbal community are usually 
paralleled by disease status (Eberl, 2010; Rescigno, 2008). 
Colorectal cancer (CRC) is a leading cause of cancer-related death and being the 
intestine a protagonist in the mutualism with the gut microbiota lots of effort has been 
made to elucidate its possible role in CRC pathogenesis (Irrazabal et al., 2014). 
This introduction will describe the principles of the intestinal barrier, the intestinal 
microbiota and colorectal cancer, highlighting the interactions among these elements. 
 
 
1.1 The intestinal barrier 
A mucus layer whose characteristics vary along the different GI segments is the first 
level of defense of the organism towards bacteria and fed antigens.  Moreover the GI 
tract is lined by a specialized epithelium containing cells that harbor peculiar functions, 
such as Goblet cells and Paneth cells (Hooper and Macpherson, 2010).  Finally, the 
intestinal lamina propria is patrolled by a number of immune cell populations such as 
IgA-secreting plasmacells, dendritic cells (DCs), T regulatory cells (Tregs) and T helper 
17 (Th17) cells (Hooper and Macpherson, 2010).  All of these elements together form 
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Figure 1-1 The intestinal barrier.  The intestinal barrier is composed by a mucus layer overtopping the 
intestinal epithelium.  Antimicrobial peptides and secretory IgAs are secreted in the gut lumen while the 
lamina propria is patrolled by immune cells.  Adapted from (Hooper and Macpherson, 2010). 
 
1.1.1 The mucus barrier 
The mucus barrier is a fundamental component of the intestinal barrier that has only in 
recent years attracted the attention it actually deserves.  The mucus is the very first 
interface between the host and microbes, both commensals and pathogens, and it has 
the dual role of being the home niche to commensal microorganisms and to protect the 
host from them and from pathogens (McGuckin et al., 2011). 
The mucus is a characteristic of the entire GI tract, but is composition and thickness vary 
in the different tracts according to the different local microenvironment (Figure 1-2).  For 
example in the stomach there is very thick mucus layer (up to 700 µm) that is 
fundamental in protecting the gastric epithelium from the acidic pH of the stomach while 
in the intestine, where absorptive processes do take place, it is thinner (150 to 300 µm).  
Also within the intestine there are substantial differences between the small intestine (SI) 
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where the mucus is patchy and not continuous and the colon where it keeps physically 




Figure 1-2 The mucus barrier.  The GI tract is characterized by the presence of a mucus layer whose 
characteristics and thickness vary among the different segments.  Adapted from (McGuckin et al., 2011). 
 
1.1.1.1 Mucins 
The mucus is formed by high molecular weight filamentous glycoproteins that are 
produced by specialized secretory cells called Goblet cells.  Mucins are synthesised in 
the endoplasmic reticulum and undergo heavy nitrogen (N)- and oxygen (O)-linked 
glycosilations.  Mucins can be either secreted or membrane bound and they form an 
highly hydrated net in the extracellular space (McGuckin et al., 2011). 
Secreted mucins are heavily glycosylated proteins that confer the mucus its gel-like 
properties.  Mucin (MUC) 2, MUC5AC, MUC5B, MUC6 and MUC19 form homooligomers 
through disulfide bonds occurring at the amino (N)- and carboxy (C)-terminal domains, 
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while MUC7 is a non oligomerizing secreted mucin.  An important role of the secreted 
mucins is to form a gel that acting like a sponge retains antimicrobial factors secreted by 
the host, that would otherwise be lost in the luminal space.  The mucus retains important 
molecules such as antimicrobial peptides (e.g. defensins) and secretory (s) IgAs at high 
concentrations in proximity to the epithelium (McGuckin et al., 2011; Ouwerkerk et al., 
2013).  In addition to this mucins can act themselves as antimicrobial determinants as 
has been demonstrated for pyloric gland-secreted mucus, whose terminal 
monosaccharide α(1,4)-linked N-acetylglucosamine inhibits the synthesis of fundamental 
components of  Helicobacter pylori cell wall (Kawakubo et al., 2004).  Moreover Muc5ac 
is upregulated in the caecum of mice infected with the nematode Trichuris muris and it is 
involved in direct reduction of nematode viability and in the establishment of a proper 
IL13-driven Th2 response fundamental for the resolution of the infection (Hasnain et al., 
2011). 
Membrane-bound mucins are an important component of intestinal epithelial cells (IECs) 
glycocalix.  Membrane-bound mucins expressed in the GI tract include MUC1, MUC3A, 
MUC3B, MUC4, MUC12, MUC13, MUC15, MUC16 and MUC17.  During their 
biosynthesis membrane bound mucins are cleaved and subsequently exposed on the 
plasma membrane as two non-covalently linked subunits that interact through a SEA 
module.  Disruption of this interaction leads to the shedding of the extracellular mucin 
domain and is both a naturally occurring process and a mechanism of pathogen 
clearance (Linden et al., 2008; Sheng et al., 2012).  Membrane bound mucins are the 
first elements pathogen that have managed to reach the epithelial layer come in contact 
with.  MUC1 mucin, prevalently expressed in the stomach, has a pivotal role in 
preventing Helicobacter pylori infection.  Most H. pylori strains express adhesins that 
bind to gastric cell-bound MUC1.  MUC1 acts as a decoy receptor that is shed upon 
bacterial binding leading to the release of MUC1 coated bacteria.  Moreover, MUC1 
prevents invasion by H. pylori strains that do not express adhesins by simple steric 
hindrance (Linden et al., 2009).  MUC1 mucin is upregulated in mice upon Citrobacter 
rodentium infection and in humans infected with Salmonella St Paul, Salmonella 
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enteridis, Campylobacter jejuni and Clostridium difficile (Linden et al., 2008).  However 
contrarily to expectations, Muc1-/- mice are protected from dextran sodium sulphate 
(DSS)-induced colitis.  This is explained by increased mucus thickness in these mice, 
compensatory increase in Muc3 expression and reduced recruitment of infiltrating T 
lymphocytes (Petersson et al., 2011).  Mice deficient in the membrane bound mucin 
MUC13 are more susceptible to DSS-induced colitis as a result of increased apoptosis 
and reduced proliferation of colonic epithelial cells, showing a protective role for this 
mucin during inflammation (Sheng et al., 2011). 
Bacteria can bind mucins and establish their niche in the mucus, degrading it and using 
it as an energy source (Ouwerkerk et al., 2013).  Akkermansia muciniphila is an example 
of bacterial species that express mucus-degrading enzymes.  This species has been 
isolated from the human microbiota and is associated with health host status while 
depleted in IBD (Ouwerkerk et al., 2013).  Moreover mucus components can act as 
anchoring sites for pathogens that can subsequently invade the host.  S. typhimurium 
binding to mucus glycoproteins occurs in vivo and is important for invasion (McCormick 
et al., 1988; Nevola et al., 1987; Vimal et al., 2000). 
Membrane-bound mucins also have intracellular domains that take part in signalling 
processes.  As an example of this the intracellular C-terminal domain of MUC1 can be 
bound and phosphorylated by glycogen-synthase kinase (GSK)-3β disrupting its binding 
to β-catenin.  The free β-catenin localizes to E-cadherin adherens junctions rather than 
affecting β-catenin dependant transcriptional activity (Li et al., 1998).  Overexpression of 
MUC1, on the contrary, recruits β-catenin from adherens junctions (Li et al., 1998).  
Moreover both MUC1 and MUC13 are involved in the NF-κB mediated inflammatory 
response triggered by tumor necrosis factor (TNF)-α and TLR and NOD ligands even 
though with opposing effects.  In fact MUC1 and MUC13 act respectively decreasing and 
increasing IkBα phosphorylation and degradation, thus decreasing and increasing NF-kβ 
p65 translocation to the nucleus and the subsequent inflammatory response.  The 
meaning of this opposite effect in the context of intestinal homeostasis could be that 
when MUC13, normally expressed by IECs, comes in contact with microbes that have 
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breached the outer lines of defense it triggers inflammation together with PRRs.  On the 
contrary MUC1 is upregulated upon infection and acts as a “sheddin” preventing 
bacterial binding to epithelial cell surface and shutting down the inflammatory response 
that would otherwise become detrimental for the organism (Sheng et al., 2013). 
In the colon the mucus has a peculiar organization with an inner dense and firm layer, 
closely attached to the epithelium, and an outer loose layer (Figure 1-3).  This structural 
organization has an important functional meaning since bacteria colonize exclusively the 
outer layer (Johansson et al., 2008).  The main component of intestinal mucus is the 
secreted gel-forming mucin MUC2.  The inner firm layer is continuously regenerated by 
Goblet cells, while the outer loose layer is generated from the inner one in a process that 
involves proteolytic cleavage of MUC2 (Johansson et al., 2008).   
 
 
Figure 1-3 The mucus is composed by an inner firmly attached and an outer loose layer.  The inner 
layer is almost sterile while the outer layer is heavily colonized by bacteria.  Immunofluorescence shows 
MUC2 (green) and 16S bacterial DNA (red).  Adapted from (Johansson et al., 2008). 
 
Further evidence of the fundamental role of the mucus layer in homeostasis comes from 
Muc2-/- mice that do spontaneously develop colitis and CRC (Velcich et al., 2002).  
Muc2-/- mice are also more susceptible to Citrobacter rodentium infection (Bergstrom et 
al., 2010) and upon DSS challenge they display worst phenotype compared to wild type 
(WT) mice and translocation of anaerobic bacteria to the spleen (Petersson et al., 2011). 
Mucins are either constitutively expressed or induced upon specific microbial and 
immune signals.  Many probiotics increase mucin expression, thus impeding pathogen 
	   18	  
entry, while some pathogens use mucin downregulation as an invasion mechanism.  For 
example H. pylori infection is associated with reduced gastric expression of MUC5AC 
and MUC6 and the bacterium produces enzymes able to degrade sulphated mucins 
(Sheng et al., 2012).  Moreover many proinflammatory cytokines induce mucin 
expression and secretion both in goblet cells and in intestinal epithelial cells (Sheng et 
al., 2012). 
 
1.1.1.2 The mucus in oral tolerance 
Recent works have highlighted that the mucus does not form a simple physical barrier in 
the intestine but rather has a role in antigen sampling and establishment of oral 
tolerance, the state of local and systemic immune “ignorance” towards commensal 
microbes and food antigens.  McDole and colleagues have shown with intra-vital 
microscopy experiments that Goblet cells are taking up antigens from the intestinal 
lumen and interact with tolerogenic CD103+ DCs on the basolateral side (McDole et al., 
2012).  The formation of these Goblet cell-associated passages (GAPs) is regulated by 
acetylcholine in the small intestine, while in the colon it is tightly regulated through 
MyD88 signalling (Knoop et al., 2014).  Disruption of microbial sensing results in colonic 
GAPs formation and antigen delivery to colonic antigen presenting cells (APCs) (Knoop 
et al., 2014).  Additional work has shown that the uptake of MUC2 coated bacteria 
confers a tolerogenic phenotype to DCs, characterized by reduced expression of 
proinflammatory cytokines and increased production of TGF-β, IL-10 and RA 
metabolizing enzymes.  This tolerogenic microenvironment favours the differentiation of 
Treg cells.  SI DCs bind MUC2 glycosidic residues via Galectin3, Dectin1 and FcγRIIB 
and acquire MUC2 on their surface from SI ECs.  Dectin1 signalling mediates AKT and 
GSK-3β phosphorylation, promoting the stabilization and nuclear translocation of β-
catenin.  Nuclear translocation of β-catenin disrupts NF-κB p50-p65 binding avoiding 
transcription of proinflammatory genes (Shan et al., 2013). 
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1.1.1.3 The mucus barrier in disease 
A number of polymorphisms in mucin genes are associated with inflammatory bowel 
disease (IBD).  As a matter of fact polymorphisms in MUC3 and MUC2 genes are 
associated with Crohn’s disease (CD) while polymorphisms involving MUC4 and MUC13 
with ulcerative colitis (UC) (Sheng et al., 2012).  In addition to mutational alteration of 
mucin genes mucus alterations can arise as a result of aberrant expression, maturation 
or secretion of mucin genes.   
The effect of deficiencies in many mucin genes has been investigated in animal models 
that demonstrate their fundamental role in maintenance of intestinal homeostasis, as 
previously discussed in paragraph 1.1.1.1.  The expression level of some mucins is 
reduced in IBD, while MUC5AC, which is not normally expressed in the healthy intestine, 
is frequently expressed in both UC and CD (Sheng et al., 2012).  Mucin glucidic patterns 
are often altered in IBD leading to incomplete or less complex glycosylation.  Mice 
genetically engineered to lack core O-glycans or to have reduced sulphonation activity 
are generally prone to intestinal inflammation, more susceptible to DSS-induced colitis 
and in the first case do also develop CRC (Sheng et al., 2012). 
Finally it has been demonstrated that the lack of functionality of the NLRP6 
inflammasome causes an impaired mucus secretion due to aberrant autophagy pathway 
in goblet cells (Wlodarska et al., 2014).  The lack of a properly assembled mucus layer 
favours the establishment of a colitogenic microbiota that is transmissible to WT animals 
(Elinav et al., 2011) underlining the importance of host factors in shaping the intestinal 
microbial community that is in turn able to transfer a dominant phenotype to an healthy 
host. 
Mucus alterations occurring in CRC will be discussed in paragraph 1.3.2 
 
1.1.2 The intestinal epithelium 
The intestinal mucosal surface is lined by a monolayer of columnar epithelial cells (ECs). 
IECs are polarized and are in contact at the apical side with the intestinal lumen and at 
the basolateral side with lamina propria resident immune cells.  The apical side of IECs 
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is organized in a brush border to favour absorption of water and nutrients from the diet 
(Brown et al., 2013; Hooper and Macpherson, 2010; Iliev et al., 2007).  Moreover IECs 
are sealed to each other through adherens junctions (AJs) and tight junctions (TJs) 
formed by specialized proteins from the claudin and occludin families preventing bacteria 
to pass in the lamina propria and allowing tight control of pericellular passage of 
molecules (Brown et al., 2013; Hooper and Macpherson, 2010; Iliev et al., 2007). 
The intestinal epithelium does also contain many specialized cell types.   
Microfold cells (M cells) are important components of the follicle-associated epithelium of 
the Peyer’s Patches (PPs), organized secondary lymphoid structures of the mucosal-
associated lymphoid tissue (MALT).  These cells are specialized in transcytosis and 
take-up antigens from the intestinal lumen and pass them to immune cell populations of 
the sub-epithelial dome, such ad B and T lymphocytes, macrophages and DCs (Jang et 
al., 2004). 
Other specialized cell types comprise Goblet cells and Paneth cells, whose functions are 
described in paragraphs 1.1.1 and 1.1.3 respectively. 
But the epithelial barrier is not a mere physical barrier to food and microbes.  Recent 
work has highlighted its active role in sensing the microbial community of the intestine 
(Brown et al., 2013; Iliev et al., 2007).  In fact IECs express pattern recognition receptors 
(PRRs), proteins specialized in the recognition of microbe-associated molecular patterns 
(MAMPs), conserved structures shared among different classes of microbes, both 
pathogens and not (Brown et al., 2013; Iliev et al., 2007).  PRRs include Toll-like 
receptors (TLRs) and nucleotide-binding oligomerization domain (NOD)-like receptors 
(NLRs) (Brown et al., 2013; Iliev et al., 2007).  PRRs sense structures shared among the 
microbial world, such as peptidoglycan (PGN), lipopolysaccharide (LPS), flagellin, 
dsRNA, ssRNA and CpG islands (Brown et al., 2013).  The ability of PRRs to 
discriminate between commensals and invading pathogens is due to their 
compartmentalization (Iliev et al., 2007).  In fact some TLRs are expressed only at the 
basolateral membrane of IECs, thus allowing exclusive response towards invading 
microbes.  An example for this is TLR5 that is expressed on the basolateral membrane 
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of IECs and on DCs.  In this way it is not activated at steady state, but when its ligand 
flagellin invades the lamina propria it participates in the induction of innate responses 
(Eberl, 2010; Iliev et al., 2007).  NLRs are intracellular receptors that can sense ligands 
secreted by pathogens that express type III or type IV secretion system, such as 
Salmonella enterica serovar typhimurium and Helicobacter pylori (Iliev et al., 2007).  
Within this framework MAMPs do not define pathogens but rather pathogenic situations 
in which any microbe could be involved: virtually any microbe can become a pathogen 
depending on the context and on the mutualism with the host (Eberl, 2010). 
Proper sensing of the microbial environment by IECs is fundamental for intestinal 
homeostasis.  Nuclear factor (NF)-κB mediated signaling in IECs is essential in driving 
proper responses towards pathogens.  Mice deficient for IκB kinase (IKK)-β fail in the 
clearance of the intestinal parasite Trichuris muris and develop a detrimental Th1- and 
Th17-dominated response rather than a pathogen-specific Th2 response that is 
fundamental in infection clearance (Zaph et al., 2007). 
Finally, IECs can secrete cytokines that play important roles in the differentiation of 
immune cell populations in the lamina propria.  Accordingly, epithelial cell-derived 
transforming growth factor-β (TGF-β), retinoic acid (RA) and thymic stromal 
lymphopoietin (TSLP) promote the differentiation of human immature DCs into 
tolerogenic CD103+ DCs.  These DCs are fundamental in maintaining homeostasis with 
the commensal microbiota and promoting the generation of functional Tregs (Iliev et al., 
2009b).  In the murine system TSLP is dispensable in this process (Iliev et al., 2009a). 
 
1.1.3 Antimicrobial peptides 
Antimicrobial peptides (AMPs) are small molecules produced and secreted by Paneth 
cells.  The mucus layer entraps AMPs acting like a sponge and keeps their concentration 
higher near the epithelium where they can exert their function and cooperate in keeping 
microorganisms away from the intestinal epithelium (Brown et al., 2013; Hooper and 
Macpherson, 2010).  AMPs, that include defensins and C-type lectins, have different 
mechanisms of action and this allows efficacy towards a wide range of microorganisms 
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(Brown et al., 2013; Hooper and Macpherson, 2010).  For example, most defensins are 
cationic peptides that disrupt Gram-negative outer membrane forming pore-like 
structures, while the C-type lectin regenerating islet-derived protein (REG) III-γ prevents 
Gram-positive bacteria from binding IECs interacting with bacterial PGN.  However while 
many AMPs are microbicidal others, such as human α-defensin (DEF)-6, bind to the 
bacterial surface by forming nets that cause bacterial aggregation and block bacterial 
entry.  Some defensins are constitutively expressed while others are induced upon 
microbial sensing (Brown et al., 2013). 
Studies in murine models have highlighted the fundamental role of AMPs in maintenance 
of homeostasis with the intestinal commensal community.  Transgenic (TG) mice 
overexpressing human defensin DEFA5 have altered small intestinal microbiota in terms 
of composition but not total number of bacteria.  In particular these mice have a 
reduction in Firmicutes and an increase in Bacteroidetes.  Mice lacking the enzyme 
matrix metalloproteinase (MMP)-7, whose proteolytic cleavage is required for murine α-
defensins activation, have on the contrary an increase in Firmicutes and a decrease in 
Bacteroidetes (Salzman et al., 2010).  The species Candidatus arthromitus, belonging to 
the Clostridiales group and better known as segmented filamentous bacteria (SFB), is in 
close contact with IECs in WT mice while it is not present in DEF5A-TG mice, 
underlining the fundamental role of this defensin in tuning the abundance of bacterial 
species in close relationship with the host.  DEFA5-dependant decrease in SFB 
correlated with decreased abundance of lamina propria CD4+ IL17 expressing T cells.  A 
reduction of α-defensin expression is documented in Crohn’s disease.  These alterations 
could lead to dysbiosis that in turn perpetuates inflammation (Salzman et al., 2010). 
Degranulation of Paneth cells to secrete AMPs can be induced by different stimuli, such 
as neurotransmitters activating muscarinergic acetylcholine receptors or bacterial 
determinants.  Studies performed on SI organoids have demonstrated that even if 
Paneth cells do express PRRs they do not degranulate upon MAMPs stimulation.  
However, stimulation with IFN-γ at physiologically relevant concentration causes 
degranulation and secretion of lysozyme and defensins in the organoid lumen (Farin et 
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al., 2014).  Prolonged stimulation with IFN-γ results in Paneth cells extrusion in the crypt 
lumen.  The extruded nuclear deoxyribonucleic acid (DNA) could act as a microbe 
entrapping net similarly to what happens with activated neutrophils.  Natural killer (NK) T 
and CD3 cells activated upon microbial sensing represent the physiological source of 
IFN-γ.  The unresponsiveness of Paneth cells to direct microbial stimulation could be 
aimed at avoiding continuous stimulation by commensals in the gut lumen and 
guarantee degranulation only upon invasion (Farin et al., 2014). 
Moreover, mice deficient in the antimicrobial protein REGIII-γ display alterations in 
mucus distribution and consequent closer bacteria-epithelium interactions in the small 
intestine, resulting in low grade inflammation elicited by innate immune cell infiltrates and 
IL22 (Loonen et al., 2014). 
 
1.1.4 Secretory IgAs 
IgAs are the most abundant antibodies present in mucosal secretions.  IgAs are 
produced in the intestinal lamina propria by IgA-secreting plasmacells and interact with 
the joining (J) chain forming dimers.  Dimeric IgAs bind to the polymeric Ig receprtor 
(pIgR) on the basolateral membrane of IECs that mediates secretion in the gut lumen 
through transcytosis.  sIgA are stabilized by the secretory component (SC). 
IgA producing plasmacells differentiate in the germinal centres (GCs) of PPs and 
isolated lymphoid follicles (ILFs) where DCs, follicular dendritic cells (FDCs) and T 
follicular helper (Tfh) cells produce anti-inflamamtory mediators, such as TGF-β1.  In this 
context plasmacells undergo class switch recombination (CSR) to IgA and somatic 
hypermutation (SHM) to generate the IgA repertoire.  IgA producing plasmacells then 
home to the lamina propria through the chemokine receptor (CCR) 9 and the integrin 
α4β7 and here they produce IgAs that are then secreted in the intestinal lumen (Gutzeit 
et al., 2014). 
IgA induction can be induced also by T cell independent pathways occurring at both 
follicular and extrafollicular sites (Gutzeit et al., 2014).  Intestinal DCs can in fact present 
antigen directly to B cells in the presence of IL6, RA, TGF-β and IL10.  Moreover DCs 
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can release BAFF and APRIL that are involved in IgA CSR and IECs by producing TSLP 
can stimulate DC expression of these two mediators in a feed forward loop that favours 
IgA production in a T cell independent manner (Gutzeit et al., 2014). 
The small intestinal IgA repertoire is more polyclonal than previously thought, with a few 
highly expanded clones and many low frequency clones.  There is high inter-individual 
variability in the IgA repertoire and ageing increases diversity.  Interestingly highly 
expanded clones are present in young mice, meaning that low frequency clones might 
originate from the previous ones through SHM.  IgA diversification depends on 
microbiota, T cells and secondary lymphoid structures since germ-free, CD3-/- and Rorγt-
/- mice have reduced diversity in the IgA repertoire.  Moreover the IgA repertoire before 
and after plasmacell depletion is very similar, suggesting the existence of memory cells 
that are recruited from the periphery to the intestine (Lindner et al., 2012). 
IgA have a fundamental role in maintaining the balance with the commensal community 
avoiding pathogen entry but also in shaping the microbial community of the intestine.  
Activation-induced cytidine deaminase (AID) is an enzyme involved in CSR and SHM 
and mice lacking this enzyme do not have IgA-producing plasmacells.  Sequencing of 
bacterial 16S ribosomal gene highlights a dysbiosis in AID-/- mice with aberrant 
expansion of the anaerobic compartment.  SFB, that normally colonizes the lower small 
intestine in mice, is abundant in the upper SI of IgA deficient mice but is re-confined to 
the ileum upon IgA reconstitution (Suzuki et al., 2004).  Moreover it has recently been 
shown that FoxP3+ T cells differentiate in T follicular regulatory (Tfr) cells in the GCs and 
promote IgA production.  This comes as part of a feed-forward loop where a rich 
microbiota sustains FoxP3+ T cell mediated IgA production that in turn controls the 
diversification of the microbiota pointing out how the adaptive immune response acts to 
favour establishment and maintenance of a diversified microbiota (Kawamoto et al., 
2014). 
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1.1.5 Dendritic cells and macrophages 
Dendritic cells are fundamental players in the maintenance of oral tolerance.  The two 
principal subtypes of phagocytes patrolling the intestinal lamina propria are the tissue 
resident macrophage like chemokine (C-X3-C motif) receptor 1 (CX3CR1) + 
macrophages and the migratory CD103+ DCs.  Phagocytes in the small intestine show 
constitutive expression of TJ proteins such as β-catenin, occluding and claudin-1, while 
zonula occludens (ZO) 1 is induced upon bacterial stimulation.  This allows extrusion of 
dendrites through opening of the TJs that seal the intestinal epithelium without 
compromising its barrier function.  In this way DCs directly sample luminal antigens 
(Rescigno et al., 2001).  Recently Mazzini and colleagues have shown that the different 
antigen presenting cells subsets present in the lamina propria cooperate in the 
establishment of tolerance.  Fed antigen sampling is mainly operated by CX3CR1+ 
macrophages that then transfer it through physical contact to CD103+ DCs.  Antigen 
transfer takes place through gap junctions (GJ) formed by connexin (Cx) 43 
hemichannels.  After antigen acquisition CD103+ DCs migrate to mLNs where they 
promote Tregs differentiation and the establishment of tolerance (Mazzini et al., 2014). 
 
1.1.6 Th1 and Th2 cells 
Naïve T cells can differentiate into different types of effector cells and this fate is guided 
by the cytokine microenvironment determined by the innate arm of immunity. 
CD4 expressing T cells can differentiate in different T helper (Th) cell types each one 
characterized by specefic cytokine profiles and thus effector functions.  The first Th 
subsets to be characterized were Th1 and Th2 subsets. 
Naïve T cells differentiate in Th1 cells upon T cell receptor (TCR) activation in 
concomitant exposure to IFN- γ and IL-12 produced by macrophages, DCs and NK cells 
upon infection.  This causes signal transducer and activator of transcription (STAT) 1 
mediated upregulation of T-bet, the master transcription factor of the Th1 cell subset.  
Cells expressing high levels of T-bet upregulate IL-12Rβ2 and IL-18Rα and become 
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sensitive to IL-12 and IL18.  These mechanisms cooperate in stimulating the production 
of IFN-γ that leads to macrophage and other immune cell types activation and IgG2a 
production by B cells, aimed at the clearance of intracellular pathogens (Weaver et al., 
2007; Zhu and Paul, 2008). 
The Th2 differentiation program is triggered upon TCR stimulation together with STAT6 
activation mediated by IL4 produced by basophils, eosinophils, mast cells and NKT cells.  
STAT6 upregulates the Th2 master transcription factor GATA3 that induces production 
of IL4, IL5 and IL13.  Th2 cells condition B cells to produce IgG1 and IgE.  Th2 cells are 
important in the clearance from extracellular pathogens and helmints (Weaver et al., 
2007; Zhu and Paul, 2008).  TSLP-conditioned DCs or TSLP cytokine alone can prime 
naïve T cells towards a Th2-like phenotype with prominent IL4, IL5 and IL13 production 
(Soumelis et al., 2002; Spadoni et al., 2012). 
Th1 and Th2 responses are finely tuned and an exacerbated response leads to 
autoimmune disease in the first case and allergy in the second.   
 
1.1.7 Th17 cells 
Th17 cells are another T helper subtype playing important roles in the response against 
extracellular pathogens.  The differentiation of Th17 cells from naïve T cells is triggered 
by the concomitant presence of IL6 produced by innate immune cells and TGFβ1 upon 
TLR stimulation.  TGFβ drives the expression of both Rorγt and FoxP3 transcription 
factors, but IL6-mediated STAT3 activation suppresses FoxP3 expression favouring 
accumulation of Rorγt (Atarashi et al., 2011b).  Rorγt is the master transcription factor in 
Th17 cells and drives the production of IL17A and IL17F.  Rorα transcription factor acts 
concomitantly to Rorγt favouring the expression of Th17 specific cytokines, even though 
its expression is not fundamental to the process (Atarashi et al., 2011b).  IL21 is another 
cytokine produced by Th17 cells that sustains and amplifies IL17 expression and leads 
to Th17 expansion.  Moreover IL21 upregulates IL23 receptor (IL23R).  IL23 is important 
for Th17 survival and maturation to a full inflammatory phenotype.  IL6, IL21 and IL23 all 
signal through Stat3 (Atarashi et al., 2011b; Zhu and Paul, 2008).  Th17 cells do also 
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produce IL22 leading to the production of AMPs and epithelial cell proliferation.  
Stimulation through aryl hydrocarbon receptor (AhR) boosts IL22 production by Th17 
cells (Atarashi et al., 2011b). 
Th17 cells constitute a minor percentage of the total CD4+ population in the mLNs and 
PPs, while they are more abundant in the intestine where they represent the 20% and 
10% of the CD4 expressing cells in the SI and colon respectively.  These numbers 
suggest that Th17 cells probably differentiate directly in the lamina propria and they are 
important in intestinal homeostasis.  Mice reared in germ free (GF) conditions or subject 
to antibiotic treatment have reduced Th17 cell percentages, pointing to a role of the 
microbial community in Th17 differentiation (Atarashi et al., 2011b).  The role of the 
commensal microbiota in the development of Th17 compartment will be discussed in 
paragraph 1.2.3.1. 
 
1.1.8 Treg cells 
Tregs cell have the fundamental role of shutting down inflammatory responses and 
avoiding improper activation of immune responses.  In the absence of proinflammtory 
cytokines TGF-β drives Smad3 activation that concomitantly with TCR-induced NFAT 
cause the remodelling of the promoter of the FoxP3 gene resulting in its expression.  
Interestingly FoxP3 inhibits Rorγt-dependent IL17 transcription through direct binding 
and thus blocks Th17 commitment (Atarashi et al., 2011b).  Tregs express CD25, 
glucocorticoid induced TNF receptor family related gene (GITR), and cytotoxic T-
lymphocyte antigen 4 (CTLA4) (Zhu and Paul, 2008).  Treg cells express IL10, 
fundamental in mediating their regulatory effects.  IL10 is expressed also by another 
subset of FoxP3 negative cells called Tr1 (Atarashi et al., 2011b). 
On the basis of their ontogenesis regulatory T cells are distinguished in natural 
regulatory T cells (nTregs) that develop in the thymus and are involved in the regulation 
of auto-reactive T cells in the periphery and inducible regulatory T cells (iTregs) that 
develop at peripheral sites upon exposure to IL2 and TGF-β (Lin et al., 2013).  The most 
common markers used to distinguish these two Treg subsets are Helios, a member of 
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Ikaros transcription factor family, and Neuropilin 1, a receptor for vascular endothelial 
growth factor (VEGF) family members, both of which are prevalently expressed in the 
nTreg compartment (Lin et al., 2013). 
TSLP produced by epithelial cells or DCs is important in tuning the Tregs-Th17 balance 
thus giving fundamental contribution to intestinal homeostasis.  In fact LPS activated 
DCs produce high levels of TSLP that limit Th17 and promotes Tregs differentiation 
resulting in containment of inflammation and protection from colitis (Spadoni et al., 
2012). 
The role of the commensal microbiota and microbial-derived metabolites in the induction 
of Tregs will be discussed in paragraph 1.2.3.2. 
 
 
1.2 The intestinal microbiota 
 
Many sites of the human body are inhabited by a multitude of microorganisms.  These 
include the respiratory tract, the skin, the urogenital tract and the intestine.  All of these 
microorganisms are collectively defined to as the microbiota. 
The intestinal microbiota has in recent years taken the stage and proved to be of 
fundamental importance to a number of physiological processes.  It is composed by 1014 
bacteria, exceeding by two orders of magnitude the number of eukaryotic cells in our 
body, mainly belonging to the phyla Firmicutes, Bacteroidetes, Actinobacteria and 
Proteobacteria (Eckburg et al., 2005; Qin et al., 2010).  Even though the kind of 
relationship that is established between the host and the intestinal microbiota is 
generally defined commensal it is rather a symbiontic one.  In fact the host provides the 
microbiota with a niche and continuous support of nutrients, while the intestinal 
microbiota is involved and contributes to many aspects of our homeostasis such as 
digestive processes, xenobiotic degradation, vitamin metabolism, immune system 
maturation, defense against pathogens and many others (Eberl, 2010).  In this view the 
host and the microbiota can be seen as a single functional unit, a “superorganisms” that 
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assembles the genetic endowment and the metabolic capacity of both and has better 
fitness that the two separate components alone (Eberl, 2010). 
It is well proven that the immune system and the microbiota are intimately connected in 
the intestine and dynamically interact in the maintenance of the homeostatic equilibrium.  
In fact the immune system maintains the containment and balance of the microbiota with 
the production of mucus, AMPs, SIgAs and cytokines but can promptly develop an 
inflammatory response once the equilibrium is broken to re-establish homeostasis.  
Moreover within this frame microorganisms cannot be defined as good or evil.  
Pathogenicity results as a combination of host and microbial factors and every 
microorganism can become a pathogen depending on the context.  This concept has 
given rise to the definition of pathobiont (Eberl, 2010). 
 
1.2.1 The composition of the intestinal microbiota 
The composition of the intestinal microbiota is influenced by a number of factors among 
which diet, antibiotic treatment, genetics of the host and infection are only the most 
relevant. 
The infant gut is sterile at birth, but is promptly colonized by bacteria upon delivery and 
in the initial phases of life.  The delivery route has an important role in defining the 
“pioneer” microbiota, with vaginally delivered infants having a microbiota most similar to 
the mother’s vaginal microbiota and cesarean delivered infants having intestinal 
communities more similar to the mother’s skin microbiota (Dominguez-Bello et al., 2010; 
Kelly et al., 2007).  After lactation there is a drastic change in microbiota composition, 
with the anaerobic component becoming prevalent (Kelly et al., 2007; Mackie et al., 
1999).  Both human and murine intestinal microbiota is dominated by four phyla: 
Bacteroidetes, Firmicutes, Proteobacteria and Actinobacteria.  Together Bacteroidetes 
and Firmicutes constitute more that 90% of the intestinal bacterial community (Eckburg 
et al., 2005; Kelly et al., 2007) and unbalances in the Bacteroidetes versus Firmicutes 
ratio is common to many disorders, as discussed in paragraph 1.2.4.  The composition of 
the intestinal microbiota is conserved between human and mouse at the phylum level, 
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but there is considerable variation at the species level, with operational taxonomy units 
(OTUs) in the Firmicutes accounting most of these differences (Chung et al., 2012; 
Honda and Littman, 2012). 
Despite the broad conservation in the composition of the intestinal microbiota at phylum 
level the MetaHIT consortium has shown that there is high interindividual variation, with 
only 35% of bacterial genes shared on average among individuals (Eckburg et al., 2005; 
Honda and Littman, 2012; Qin et al., 2010).  The interindividual variation in the 
microbiota composition is however not a continuum and study from the MetaHIT 
consortium has characterized three enterotypes by clustering and principal component 
analysis (Arumugam et al., 2011).  Interestingly the three enterotypes differ also in their 
metabolic potential implying the use of different energy sources among those available in 
the intestinal lumen (Arumugam et al., 2011). 
Diversity is a fundamental characteristic of the intestinal microbiota as pinpointed by 
evidences that IBD is associated with a reduced microbial diversity, as discussed in 
paragraph 1.2.4 (Narushima et al., 2014; Qin et al., 2010).  Moreover, Chung and 
colleagues have demonstrated that coevolution of the host and its microbiota has 
selected a host-specific community that has maximal efficacy in promoting the 
maturation of the host immunity and protection from infection.  In fact administration of 
murine microbiota to GF mice is effective in increasing intra-epithelial lymphocytes (IELs) 
abundance, IgA and AMP secretion and protection against infection with Salmonella 
typhimurium while human or rat microbiota fail in doing so (Chung et al., 2012).  
Moreover the complexity and diversity of the microbiota have fundamental importance 
since administration of a single species, namely SFB, is not efficient in promoting full 
maturation of the immune response at the mucosal level (Chung et al., 2012). 
Variations in diet, both long- or short-term, lead to alteration both in the composition of 
the intestinal microbiota and in its gene expression profile (Turnbaugh et al., 2009).  This 
plasticity aims at better extracting energy and nutrients from diet pointing at the maximal 
fitness for the superorganism (De Filippo et al., 2010; Honda and Littman, 2012; 
Turnbaugh et al., 2009).  Both human and mice under western diet (high fat and high 
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carbohydrate content) have higher Firmicutes and lower Bacteroidetes (De Filippo et al., 
2010; Turnbaugh et al., 2009).  On the other hand, the microbiota from African 
individuals has higher Bacteroidetes and Actinobacteria and shows higher richness and 
diversity compared to the European one (De Filippo et al., 2010; Honda and Littman, 
2012). 
The genetic background can also influence microbial composition.  TLR5 deficient mice 
display metabolic syndrome with hyperphagia and increased body weight.  This 
phenotype is transmissible upon transfer of Tlr5-/- microbiota into wild type mice (Arthur 
and Jobin, 2013; Honda and Littman, 2012; Vijay-Kumar et al., 2010).  Interestingly, 
deficiency in the regulatory cytokine IL10 leads to the development of spontaneous 
colitis due to a colitogenic microbiota (Arthur and Jobin, 2013; Arthur et al., 2012).  
Deficiency in AID leads to altered microbial composition in the SI (Suzuki et al., 2004) as 
discussed in paragraph 1.1.4 and ob/ob mice, a murine model for obesity, have a 
dysbiotic microbiota that can transfer the phenotype to WT mice (Turnbaugh et al., 2006) 
as discussed in paragraph 1.2.4. 
The use of antibiotics to target infectious agents has been one of the most striking 
progresses of modern medicine.  However antibiotics are never specific for a given 
pathogen and rather affect multiple bacterial groups of the endogenous microbiota.  
Given that the microbiota is a community that relies on multiple interactions the whole 
community is actually affected.  Antibiotic treatment causes a reduction in microbial 
diversity that is only partially restored upon treatment ceasing (Jernberg et al., 2007; 
Willing et al., 2011).  By affecting microbial homeostasis, antibiotics do also affect host 
health being the host-microbiota mutualism so fundamental for the superorganism 
(Willing et al., 2011).  Interestingly treatment with the antibiotic metronidazole, which 
targets the anaerobic component of the gut microbiota, affects MUC2 expression and 
mucus layer integrity, allowing bacteria to penetrate deeper in intestinal crypts (Pelissier 
et al., 2010; Willing et al., 2011). 
The intestinal microbiota has a complex and dynamic composition, but this is largely 
exceeded by the complexity of the metabolic capacity of the microbiota.  The metabolites 
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produced by the microbiota, collectively referred to as microbial metabolome, have 
fundamental functions in the host homeostasis and immune system maturation 
(Dorrestein et al., 2014).  The complexity of the microbial metabolome and its influences 
on the host has just started to be elucidated and some keypoints regarding microbial 
influence on host immune homeostasis will be described in the following paragraphs. 
 
1.2.2 Influence of the microbiota on the mucus barrier 
The intestinal microbiota plays a fundamental role in the development and maturation of 
the intestinal barrier and immune system.  Gnotobiotes, animal models with a defined 
microbiological status, have been fundamental tools to understand how specific 
microbes can sustain the development of specific immune cell populations. 
In GF animals the mucus layer is thinner, less compact and differentially glycosylated 
when compared to conventionally reared mice (Petersson et al., 2011).  This suggests 
that intestinal microbes play a role in the maintenance of an intact mucus barrier. 
Consistently treatment with bacterial products LPS and PGN restores normal mucus 
thickness (Petersson et al., 2011).  Further experimental evidence shows that the 
expression of mucin genes is upregulated in GF mice compared to conventional ones 
and fecal transplantation in GF mice restores normal mucin expression levels (Comelli et 
al., 2008).  Interestingly fecal transplantation of human microbiota is unable to 
downmodulate mucin genes as the murine one does, underlining another host-specific 
aspect related to the microbiota as discussed in paragraph 1.2.1 (Comelli et al., 2008).  
Moreover, as discussed also in paragraph 1.1.1.1, an increase in mucus secretion is a 
mechanism of pathogen clearance as demonstrated by the increased MUC2 secretion 
upon Citrobacter rodentium infection (Petersson et al., 2011). 
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1.2.3 Influence of the microbiota and its metabolites in intestinal immune 
system development 
GF animals have smaller PPs and mLNs compared to conventionally reared mice.  
Moreover they have lower numbers of IELs, plasmacells and reduced production of IgAs 
and AMPs.  Neonates at birth have PPs and mLNs, but the massive bacterial 
colonization happening at birth and in the first phases of life induces enlargement and 
maturation of these organs.  ILFs, on the contrary, do only develop in the presence of 
the intestinal microbiota (Atarashi et al., 2011b; Eberl, 2010).  These were the first 
evidences that microbial presence and compositions were fundamental in shaping the 
gut resident immune populations.  In the following paragraphs the importance of some 
microbial groups in shaping the two most abundant populations in the intestinal lamina 
propria, namely Th17 and Tregs, will be discussed.   
 
1.2.3.1 SFB and Th17 development 
Ivanov and colleagues demonstrated that a particular component of the murine 
commensal microbiota controls the abundance of Th17 and Tregs in the SI lamina 
propria through a TLR-independent mechanism.  In fact mice reared in GF conditions 
have very few Th17 cells but almost doubled Treg population compared to conventional 
mice.  Moreover treatment of specific pathogen free (SPF) mice with ampicillin or 
vancomycin reduces Th17 abundance in the intestine.  Cohousing of GF or antibiotic 
treated mice with SPF mice restores normal Th17 and Tregs proportions, pointing to a 
role for a subset of bacteria rather than the whole microbial community in determining 
the differentiation of Th17 cells in the SI lamina propria (Ivanov et al., 2008).  
Subsequently 16S metagenomic analysis of the ileal content of Jackson B6 mice (low 
Th17 abundance in the SI) versus Taconic B6 mice (high Th17 abundance in the SI) 
highlighted the correlation between SFB with Th17 abundance.  SFB strictly adhere to 
the surface of IECs (Gaboriau-Routhiau et al., 2009; Ivanov et al., 2009).  Transcriptional 
profiling highlighted the induction of immune and inflammatory transcriptional 
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programmes in the ilei of germ free mice reconstituted with SFB (Gaboriau-Routhiau et 
al., 2009; Ivanov et al., 2009).  The most upregulated gene encodes for serum amyloid A 
(SAA) protein that could be secreted by IECs upon SFB stimulation and condition lamina 
propria DCs to favour Th17 differentiation.  SFB colonized mice are also more resistant 
towards Citrobacter rodentium infection, pointing at the fundamental role of Th17 cells in 
the intestinal immune homeostasis (Ivanov et al., 2009).  Mechanistically intestinal DCs 
acquire antigens from SFB strictly adherent to IECs.  DCs then present SFB antigens in 
major histocompatibility complex class II (MHCII) context to induce SFB specific Th17 
cells (Goto et al., 2014b). 
 
1.2.3.2 Clostridia and Tregs induction 
Tregs are the other T cell subset present in the intestinal lamina propria.  Treg cell 
percentages are not altered in the small intestine of GF mice, while they are strongly 
reduced in the colon.  Notably, in mice the abundance of Treg cells in the colon 
dramatically increases after weaning pointing to a possible correlation with microbial 
stimulation.  Indeed some Clostridium species are strong inducers of IL10 expressing 
Treg in the colonic lamina propria (Atarashi et al., 2013; Atarashi et al., 2011a).  Atarashi 
and colleagues identified and characterized a mixture of 17 strains in the chloroform-
resistant (spore-forming) fraction of the human microbiota by means of 16S rDNA 
sequencing.  These strains belonging to Clostridial classes VI, XIVa and XVII and are 
sufficient for colonic Tregs induction in GF mice.  The different strains somehow 
synergize since the 17 strains taken individually fail in inducing Tregs and a core mix of 5 
strains leads to significant increase of colonic Tregs even if still lower than the one 
elicited by the 17 strains mix.  The 17 strain treatment shows efficacy in vivo against 
different models of murine colitis.  The Clostridia strains produce short chain fatty acids 
(SCFA), namely acetate, propionate, butyrate and isobutyrate that induce TGFβ1 in 
colonic epithelial cell lines (Atarashi et al., 2013).  Among SCFAs, butyrate is the one 
able to induce Tregs in vitro, in vivo and in experimental colitis, and the 17 strains have a 
number of genes involved in butyrate metabolism (Narushima et al., 2014).  Butyrate 
	   35	  
acts at the epigenetic level increasing the acetylation level, and thus accessibility to the 
transcriptional machinery, of the FoxP3 locus and related enhancer elements suggesting 
a possible mechanism for Tregs induction (Furusawa et al., 2013).  GF mice have 
reduced levels of SCFAs, highlighting the importance of the microbiota in their 
biosynthesis (Brestoff and Artis, 2013). 
Apart from inducing iTreg cell differentiation SCFAs have effects also in other immune 
cell types.  In fact SCFAs stimulate neutrophil chemotaxis and activation, and elicit anti-
inflammatory response in DCs as well as in the epithelial cell line Caco-2.  All these 
effects are mediated by the G-protein coupled receptor GPR43 (Brestoff and Artis, 
2013). 
The importance of intestinal microbes in the induction of Tregs and maintenance of 
homeostasis has also been addressed by Geuking and colleagues who observed that 
altered Schaedler flora (ASF), a mixture of eight benign commensals, results in the 
induction of colonic Treg cells that are fundamental in regulating Th1 and Th17 
responses (Geuking et al., 2011).  Single components of the ASF failed in inducing 
Tregs as did the single Clostridial species studied by Atarashi and colleagues (Atarashi 
et al., 2013) highlighting that also in this case synergy and interaction among bacterial 
species are fundamental for host physiology (Geuking et al., 2011). 
 
1.2.3.3 The microbiota and bile acid metabolism 
The intestinal microbiota takes part in bile acid metabolism.  Bile acids are synthetized in 
the liver, stored in the gall bladder and released in the duodenum upon transit of the 
bolus.  Once in the gut primary bile acids are converted into secondary bile acids 
through dehydration reactions that are peculiar to the microbiota.  Secondary bile acids 
are then reabsorbed in the ileum through the enterohepatic circulation.  In the liver they 
are conjugated to glycine and taurine to be secreted again in the intestine.  Bacteria do 
also take part in another important step of bile acid metabolism that is the deconjugation 
of secondary bile acids that leads to secretion, thus regulating their turnover (Brestoff 
and Artis, 2013).  Studies with GF or antibiotic-treated animals demonstrated that in the 
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absence of microbiota there are profound changes in bile acid profiles in the liver, 
intestine and faeces and also at distal sites such as the kidney, heart and plasma (Sayin 
et al., 2013; Swann et al., 2011).  Bile acids can start signalling cascades through 
binding to the membrane G protein-coupled bile acid receptor 1 (GPBAR1) and the 
nuclear farnesoid X receptor (FXR).  The microbiota does also participate in the 
regulation of bile acid synthesis in the liver through an FXR dependent mechanism 
(Sayin et al., 2013).  Moreover in a number of immune cells including monocytes, 
macrophages and DCs bile acid signalling is associated with an anti-inflammatory 
response mediated by the repression of NF-kB dependant transcriptional response.  The 
anti-inflammatory effect of bile acid can probably be translated also to the non-immune 
compartment, as bile acid signalling elicits anti-inflammatory response also in the 
epithelial cell line Caco2 (Brestoff and Artis, 2013). 
 
1.2.3.4 The microbiota and xenobiotic metabolism 
The intestinal microbiota has a fundamental role also in xenobiotic metabolism (Eberl, 
2010).  Recent experimental data demonstrated that the intestinal microbiota is required 
for chemotherapeutic efficacy towards solid tumors (Iida et al., 2013; Viaud et al., 2013).  
Notably the alkylating agent cyclophosphamide elicits dysbiosis in the small intestine and 
provokes the translocation of a population of gram-positive bacteria to secondary 
lymphoid organs, where they induce a pathogenic Th17 population that mediates tumor 
regression.  The development of the pathogenic Th7 population is dependent on MyD88, 
directly linking their development to bacterial sensing.  In the absence of the intestinal 
microbiota pathogenic Th17 cells do not expand and cyclophosphamide is not efficient in 
mediating tumor regression (Viaud et al., 2013).  Further evidence involves the 
chemotherapeutic oxaliplatin, whose mechanisms of action involve reactive oxygen 
species (ROS) production by myeloid cells.  Oxaliplatin mediated tumor regression is 
dependent on MyD88 and antibiotic treatment dampens the efficacy of the treatment 
(Iida et al., 2013). 
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1.2.4 The microbiota in disease 
Aberrant immune responses towards the microbiota or improper sensing of its 
components are associated with pathological state.  Importantly, chronic inflammation 
often leads to reduced diversity compared to healthy individuals, with IBD patients 
having a 25% microbial gene reduction (Qin et al., 2010).  Maintenance of microbial 
diversity is fundamental to perpetuate intestinal and systemic homeostasis (Honda and 
Littman, 2012). 
IBD patients have an increase in adherent-invasive Escherichia coli that physically 
adhere and invade the ileal IECs (Darfeuille-Michaud et al., 2004).  Moreover these 
patients have a reduction in both Bacteroidetes and Firmicutes while Proteobacteria and 
Actibacteria do increase (Atarashi et al., 2011b; Frank et al., 2007; Honda and Littman, 
2012).  IBD patients do also have reduced proportion of butyrate-producing bacteria and 
a reduced expression of butyrate transporter in colonic epithelial cells.  Exogenous 
administration of butyrate ameliorates inflammation in IBD patients suggesting that 
butyrate depletion might play a role in IBD pathogenesis (Brestoff and Artis, 2013; 
Dorrestein et al., 2014; Furusawa et al., 2013; Thibault et al., 2010; Thibault et al., 2007).  
IBD-associated microbiota is also characterized by reduced diversity when compared to 
healthy patients (Qin et al., 2010).  The 17 Treg-inducers Clostridial strains isolated from 
human healthy microbiota (Atarashi et al., 2013) have considerable heterogeneity in 
terms of metabolic properties and this together with the observation that they can 
ameliorate experimental colitis points to the fundamental role of microbial diversity in 
intestinal homeostasis and to the important therapeutic value of restoring diversity upon 
dysbiosis (Narushima et al., 2014). 
The CARD15 locus, encoding the NOD2 receptor, is frequently mutated in Crohn’s 
disease patients (Lesage et al., 2002).  These mutations can either increase NOD2 
activity with consequent hyperactivation of Nf-κB and IL1β secretion or abolish NOD2 
activation with consequent decrease of AMPs secretion.  This last scenario leads to 
increased bacterial stimulation through TLR2 (Strober et al., 2008).  As a result both 
kinds of mutation result in hyperresponsiveness towards the microbiota (Eberl, 2010). 
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Another disease in which the presence of dysbiosis is well documented is obesity 
(Turnbaugh et al., 2006).  Even if the mechanisms lading to the establishment of such a 
dysbiosis are not clear obese patients have an increased proportion of Firmicutes versus 
Bacteroidetes and a general reduction in bacterial richness (Irrazabal et al., 2014; 
Turnbaugh et al., 2006).  The obese microbiota is more efficient than normal in 
extracting energy from nutrients and in particular from polysaccharides and studies in 
murine models demonstrate that the obese phenotype is transferrable upon fecal 
transplantation from ob/ob mice (deficient in the leptin gene) to wild type GF animals 
(Turnbaugh et al., 2006).  This raises an important point regarding the inheritance of the 
disease (Eberl, 2010). 
The contribution of the microbiota in the severity of type-1 diabetes was elucidated with 
NOD murine models deficient in MyD88 (Wen et al., 2008).  MyD88-/-NOD mice are 
resistant to diabetes development and have lower diabetogenic T cells in the pancreatic 
lymph nodes.  Moreover the MyD88-/- microbiota (that has a low Firmicutes versus 
Bacteroidetes ratio) is protective towards diabetes development in NOD mice (Eberl, 
2010; Wen et al., 2008). 




1.3 Colorectal cancer 
 
Colorecral cancer is a leading cause of cancer related death and is therefore a major 
health problem.  From the aetiological point of view CRC is a multifactorial disease, with 
genetic component, diet contribution and inflammation interacting and resulting in the 
disease.  In the last years also intestinal microbiota has been claimed to participate in 
CRC aetiology. 
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1.3.1 The genetics of colorectal cancer 
Colorectal cancer originates from intestinal adenomas that progress to invasive 
carcinoma and ultimately metastasize distal sites as shown in Figure 1-4 (Irrazabal et al., 
2014; Markowitz and Bertagnolli, 2009). 
 
 
Figure 1-4 Colorectal cancer develops from benign adenomas that progress to invasive carcinomas 
and ultimately metastatize to distal organs.  Adapted from (Irrazabal et al., 2014). 
 
Hereditary CRC accounts only for 10% of the cases.  Familial adenomatous polyposis 
(FAP) is an autosomal dominant syndrome characterized by germline mutations in the 
adenomatous polyposis (apc) gene.  FAP patients develop massive polyposis in the GI 
tract during adolescence and have 100% risk of developing CRC by the age of 40 
(Bogaert and Prenen, 2014).  Hereditary non-polyposis colorectal cancer (HNPCC), also 
known as Lynch syndrome, is the most frequent hereditary CRC form accounting for 2-
5% of cases.  It is characterized by germline mutations in mismatch repair genes that 
lead to microsatellite instability (Bogaert and Prenen, 2014). 
In 1990 Fearon and Vogelstein described the genetic alterations leading to sporadic 
CRC as a multistep process that confers a growth advantage to transformed colonocytes 
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(Fearon and Vogelstein, 1990).  More recently genome-wide sequencing data identified 
an average of 80 mutated genes per tumor, even if less that 15 of these are considered 
driver mutations in the pathogenesis (Bogaert and Prenen, 2014; Markowitz and 
Bertagnolli, 2009).   
 
 
Figure 1-5 The genetics of CRC.  The most common initiator events are mutations in APC and in mismatch 
repair genes.  Subsequent accumulation of mutations leads to progression and development of cancer.  
Adapted from (Irrazabal et al., 2014). 
 
There are three main pathways leading to sporadic CRC: chromosomal instability, 
microsatellite instability and CpG island methylation pathway. 
Chromosomal instability is the most common initiator event accounting for 70% of cases.  
It is characterized by chromosomal rearrangements and loss of heterozigosity (LOH).  
Among the oncogens and oncosuppresor genes that are frequently mutated we find 
APC, KRAS, SMAD4, TP53, BRAF and PIK3CA (Bogaert and Prenen, 2014; Markowitz 
and Bertagnolli, 2009) and it is the concomitant presence of these mutations rather than 
their temporal sequence that determines transformation (Fearon and Vogelstein, 1990). 
Microsatellite instability is caused by mutation in mismatch repair genes that results in 
aberrant microsatellite DNA insertion or deletions and subsequent frameshift mutations 
in the coding regions (Bogaert and Prenen, 2014; Markowitz and Bertagnolli, 2009). 
CpG island methylation pathway results in aberrant DNA methylation status of CpG 
dinucleotides in the promoter regions of some genes that leads to the epigenetic 
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silencing of such genes.  This is paralleled by a general hypomethylation status of the 
colorectal genome (Markowitz and Bertagnolli, 2009). 
Moreover, microRNA (miRNA)-mediated modulation of gene expression has been 
investigated as a further epigenetic mechanism contributing to CRC.  Consistently some 
miRNAs such as miR-21, miR-106 and miR-144 are more abundant in faecal samples 
from CRC patients compared to controls and can be used as biomarkers for CRC (Yang 
et al., 2013). 
Activation of the Wnt signalling pathway (Figure 1-6) is considered the initiator event in 
CRC pathogenesis (Markowitz and Bertagnolli, 2009).  Wnt signalling culminates in the 
nuclear translocation of the transcription factor β-catenin and the expression of genes 
related to cellular proliferation.  In differentiated cells the cellular level of β-catenin is 
controlled by the β-catenin degradation complex that targets it for proteolytic 
degradation.  APC is part of the β-catenin degradation complex and its inactivation leads 
to increased β-catenin levels and expression of β-catenin related genes.   
 
 
Figure 1-6 Wnt signalling pathway.  a) In the absence of wnt signal β-catenin is phosphorylated by the β-
catenin degradation complex and targeted for proteasome-mediated cleavage in the cytosol.  In this way β-
	   42	  
catenin is excluded from the nucleus.  b) When wnt ligand binds to frizzled receptor the β-catenin 
degradation complex disaggregates.  This allows β-catenin migration in the nucleus and activation of a 
transcriptional response.  Adapted from (Luo et al., 2007). 
 
Mutations in APC are a characteristic of both hereditary and sporadic CRC, being found 
in nearly 80% of cases.  Less common are mutations that render β-catenin resistant to 
degradation and thus constitutively active (Anastas and Moon, 2013; Markowitz and 
Bertagnolli, 2009). 
 
1.3.2 Mucus alterations in colorectal cancer 
As described in paragraph 1.1.1.3 for IBD, mucin expression and glycosylation is altered 
in CRC. 
MUC1 is described as an oncogene in breast cancer where it is frequently 
overexpressed and in many cases also amplified at the genomic level (Lacunza et al., 
2010) and its expression is frequently enhanced in hCRC (Ajioka et al., 1996).  The 
intracellular domain of MUC1 interacts with β-catenin and its phosphorylation disrupts 
these interactions linking MUC1 with the Wnt signalling pathway, the key player in CRC 
(Sheng et al., 2012).  Moreover by binding β-catenin MUC1 is also involved in the 
dismantling of adherens junctions, and thus possibly in epithelial to mesenchymal 
transition (Sheng et al., 2012).  In addition to this the overexpression of large membrane-
bound mucins by cancer cells, as is MUC1 in breast cancer, is associated with 
topological rearrangements in the plasma membrane involving integrins and adhesion 
molecules.  This is a merely physical process not involving MUC1 signalling properties 
but confers to cancer cells a survival advantage pointing to a contribution of this process 
in epithelial to mesenchymal transition and invasion (Paszek et al., 2014). 
The importance of a proper MUC2 expression is underlined by the observation that 
Muc2-/- mice spontaneously develop CRC (Velcich et al., 2002), as already discussed in 
paragraph 1.1.1.1.  Moreover APC-initiated CRC often displays goblet cell depletion.  
Lack of Muc2 exacerbates tumorigenesis in the ApcMin/+ mice in a dose-dependant 
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manner in all the intestinal tracts, but with a particular penetrance in the colon (Yang et 
al., 2008).  Lack of Muc2 unmasks microbial inflammatory stimuli, as documented by an 
increased expression of AMPs such as RegIII-γ (Yang et al., 2008).  The phenotype 
observed in Muc2-/-Apc1638N/+ mice is similar to the one observed by Tanaka and 
colleagues, who were the first showing that DSS acts as a promoting agent in the 
ApcMin/+ context (Tanaka et al., 2006).  DSS treatment significantly increases the number 
of small intestinal adenomas and profoundly affects tumorigenesis in the colon (Tanaka 
et al., 2006). 
 
1.3.3 Inflammation/immune cells in colorectal cancer 
Inflammation has since a long time been associated with tumorigenesis and CRC is one 
of the cancer types where the involvement of inflammation is widely proven. 
The proinflammatory cytokine IL17A has a tumor promoting role in the ApcMin/+ model 
and its genetic ablation reduces the tumor load in both the SI and colon (Chae et al., 
2010).  Additional work in animal models of APC-driven tumorigenesis has shown that 
loss of barrier function at the tumor site leads to microbial stimulation and entry causing 
recruitment of IL23-producig myeloid cells.  IL23 stimulates recruitment and 
differentiation of Th17 and other IL17A producing cells that create a proinflammatory 
environment that favours tumor growth (Grivennikov et al., 2012).  Recent work has 
proven the role of another member of the IL17 cytokine family in intestinal tumorigenesis.  
IL17C signalling through IL17RE on IECs promotes cell survival and proliferation and 
hence tumorigenesis in a MyD88 dependant fashion (Song et al., 2014). 
Murine models have shown that absence of the suppressive cytokine IL10 leads to 
chronic colitis as a result of exacerbated T cell response.  This inflammatory status acts 
as tumor promoter when Il10-/- mice are challenged with the initiator AOM (Arthur and 
Jobin, 2013).  Il10-/- mice have altered intestinal microbial community if compared to WT 
mice but interestingly AOM/Il10-/- mice do not have dysbiosis if compared with Il10-/- 
counterparts, meaning that the promoting agent in this model is inflammation rather than 
dysbiosis (Arthur and Jobin, 2013).  However, inflammation per se is not sufficient to 
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trigger tumorigenesis as demonstrated by the fact that E. coli NC101 and Enterococcus 
faecalis both induce severe colitis in monoassociated Il10-/- mice with similar infiltrates 
and cytokine profiles, but only the first can induce tumorigenesis in the AOM/Il10-/- model 
(Arthur and Jobin, 2013; Arthur et al., 2012). 
The role of Treg cells in intestinal tumorigenesis is controversial.  Studies in the ApcΔ468/+ 
mice show that there is a massive recruitment of Tregs in the polyps and that these cells 
are highly suppressive in vitro, but they are defective in the production of the cytokine 
IL10 and rather express a Th17-like signature (Gounaris et al., 2009).  These 
proinflammatory Tregs promote polyposis, while adoptive transfer of nTregs from WT 
mice represses it (Gounaris et al., 2009).  Treg cells isolated from polyps show 
contemporary expression of FoxP3 and Rorγt transcription factors and are enriched in 
UC and colitis associated cancer (Blatner et al., 2012).  Rorγt rather than IL17 
expression confers these cells their pathogenic role in polyposis (Blatner et al., 2012).  
Recent work highlighted that sustained β-catenin signalling in CD4+ and FoxP3+ cells is 
driving Rorγt expression conferring them the proinflammatory phenotype and that CD4+ 
T cells with constitutively active β-catenin signalling are able to induce intestinal 
inflammation and tumorigenesis (Keerthivasan et al., 2014). 
 
1.3.4 The microbiota in colorectal cancer 
CRC implies as initiator events the genetic alterations described in paragraph 1.3.1, but 
environmental factors can play a role in tumor progression (Zhu et al., 2013).  The GI 
tract is pervasively colonized by microorganisms and the interactions occurring between 
the tumor and the microbiota upon tumorigenesis have been investigated at different 
levels in the last years.  Even if there is high heterogeneity in the nature of samples 
analysed and techniques used two points emerge clearly from the present literature: first 
there is a dysbiosis associated with CRC and second bacterial metabolites can be 
involved in tumorigenesis (Zhu et al., 2013). 
Primary evidence that the intestinal microbial community plays a role in intestinal tumor 
progression comes from animal models that display reduced disease penetrance if 
	   45	  
reared in GF conditions or treated with anibiotics (Sears and Garrett, 2014; Zhu et al., 
2013).  Moreover, deficiencies in PRRs have been shown to attenuate CRC penetrance, 
implying a role for microbial sensing in disease progression (Zhu et al., 2013). 
Sequencing analysis revealed that the microbial communities of cancerous vs. non-
cancerous tissue from the same patient cluster together, meaning that the intestinal 
microenvironment might be more important than the tumor itself in shaping the microbial 
community (Kostic et al., 2012).  However the tumor tissue shows depletion in 
Firmicutes, particularly in the order Clostridiales, and Bacteroidetes.  The genus 
Fusobacterium is enriched in many, even though not all, adenomas, carcinomas and 
metastases relative to the matched control tissue and also in the feaces of CRC samples 
(Kostic et al., 2013; Kostic et al., 2012).  Moreover, Fusobacterium nucleatum 
exacerbates both small intestinal and colonic tumorigenesis in the ApcMin/+ model of 
genetically driven tumorigenesis without induction of inflammation (Kostic et al., 2013).  
Adenomas from F. nucleatum-trated ApcMin/+ mice have higher myeloid derived 
suppressor cells (MDSCs), tumor-associated macrophages (TAMs) with M2 
characteristics, tumor-associated neutrophils (TANs) and DCs infiltrates (Kostic et al., 
2013).  This is mirrored by a pro-inflammatory Nf-κβ dominated signature that is 
common with F. nucleatum-high human CRC tissues, that is possibly one of the driving 
forces of tumorigenesis (Kostic et al., 2013).  In vitro studies suggest that mechanistically 
F. nucleatum binds to E-cadherin through the activated complex of FadA adhesion and 
activates Wnt- βcatenin signalling cascade (Sears and Garrett, 2014). 
The mechanism by which species that are enriched in tumor tissues could be involved in 
tumorigenesis may imply induction of inflammation, as highlighted by the evidence that 
ApcMin/+ mice chronically colonized with enterotoxigenic Bacteroides fragilis have 
increased STAT3 activation and Th17-driven colonic inflammation and colonic polyposis 
(Sears and Garrett, 2014; Zhu et al., 2013). 
The role of the microbial metabolic activity has been investigated as well and linked to 
intestinal tumorigenesis.  Some enzymatic activities that are peculiar to the microbiota 
can lead to the transformation or release of genotoxic substances possibly implied in 
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tumorigenesis.  An example of this is β-glucuronidase activity.  Toxic compounds are 
metabolized in the liver and excreted in the form of highly soluble glucuronic acid 
conjugates.  Some bacterial species express β-glucuronidase that hydrolyses glucuronic 
acid conjugates releasing the toxic compounds in the intestinal lumen.  As a matter of 
facts CRC patients have high β-glucuronidase activity in the faeces (Sears and Garrett, 
2014; Zhu et al., 2013). 
Intestinal bacteria do play an important role in the metabolism of bile acids, as discussed 
in paragraph 1.2.3.3.  Faecal content of lithocholic and deoxycholic acid are elevated in 
the faeces of CRC patients and these secondary bile acids potentiate tumorigenesis in 
murine models of CRC (Sears and Garrett, 2014).  On the contrary ursodeoxycholic acid 
is beneficial in CRC.  This bile acid is derived from chenodexycholic acid via two 
enzymatic activities, 7α-hydroxysteroid dehydrogenase and 7β-hydroxysteroid 
dehydrogenase, that are peculiar to some bacterial groups, including Clostridia (Sears 
and Garrett, 2014).  Loss of bile acid-induced signalling is detrimental for tumorigenesis 
as AOM/DSS treated FXR-/- mice and FXR-/-ApcMin/+ mice develop more tumors (Modica 
et al., 2008).  One possible player in the FXR mediated attenuation of tumorigenesis is 
taurocholic acid that does attenuate tumorigenesis in ApcMin/+ mice through reducing 
proliferation and increasing apoptosis in the ileum (Smith et al., 2010). 
Additionally, recent work in the ApcMin/+MSH2-/- murine model shows that treatment with 
a diet with low carbohydrate content reduces intestinal polyposis to a level similar to the 
one observed when the same mice are kept under antibiotic regimen.  The explanation 
for this is in the reduction in the luminal abundance of a bacterial metabolite, namely 
butyrate, that promotes epithelial cell proliferation and thus polyposis (Belcheva et al., 
2014). 
Finally, bacterial metabolism can lead to the production of ROS that can directly act as 
genotoxic agents modifying DNA structure or sequence and leading to mutations or 
genetic instability (Zhu et al., 2013).  As an example of this Enterococcus faecalis 
superoxide production increases tumorigenesis in the Il10-/- murine model, while a strain 
deficient in superoxide production does not (Sears and Garrett, 2014).  Phylogenetic 
	   47	  
group B2 Escherichia coli, such as the strain NC101 frequently found as intracellular 
bacteria in hCRC samples, has direct DNA-damaging activity by means of the genotoxin 
colibactin, and its deletion decreases CRC phenotype when compared to the wild type 
strain in the Il10-/-AOM murine model (Arthur et al., 2012) (Arthur and Jobin, 2013) 
(Sears and Garrett, 2014). 
Experimental evidence that the microbial ecosystem is altered upon intestinal 
tumorigenesis poses interesting issues regarding possible therapeutic interventions 
employing bacteria or their metabolic products as treatments.  The use of probiotics has 
been shown to have positive effects on the maintenance of microbial equilibrium, 
inhibition of pathogen colonization and stimulation of host immunity (Kahouli et al., 2013; 
Zhu et al., 2013).  In fact probiotic administration has been shown effective in 
strengthening the epithelial barrier by preventing epithelium leakage and improving 
mucus secretion (Kahouli et al., 2013).  Moreover re-balancing the intestinal bacterial 
ecosystem can both counteract carcinogenic enzymatic activities and remove their toxic 
products (Kahouli et al., 2013).  Probiotics can reduce the cancer-associated genotoxic 
microenvironment and induce apoptosis while preventing proliferation of colonic ECs 
(Kahouli et al., 2013).  Although limited, studies on the use of probiotics concomitantly to 
classical chemotherapy report beneficial effects of the treatment on the health status of 
patients (Kahouli et al., 2013). 	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2 AIM OF THE WORK 
 
The study of the intestinal microbiota and its influence on host physiology has become a 
burning field of investigation in recent years.  In particular, the influence of the microbiota 
on tumor development is an intriguing field of research. 
In this work using the ApcMin/+ murine model we investigated how the microbiota could 
influence intestinal tumorigenesis and whether dysbiosis could somehow influence the 
progression of tumors, possibly mediated by alterations in the mucus layer.  Finally we 
addressed whether bacterial stimuli could alter apc gene expression contributing to 
tumor progression. 
The specific points we have addressed are the following: 
• Verify if the ApcMin/+ model of intestinal tumorignesis has alterations in the mucus 
layer as happens in the human pathology; 
• Address whether alterations in the mucus barrier result in altered barrier properties 
during tumorigenesis; 
• Analyse how exogenous alterations of the mucus barrier impact on tumorigenesis; 
• Analyse the evolution of the intestinal microbial community during tumorigenesis; 
• Address the possible functional impact of species that are differentially abundant 
between wild type and ApcMin/+ mice for the tumorigenic process; 
• Investigate whether bacterial stimuli can modulate apc gene expression 
contributing to tumor progression. 
	   49	  
3 MATERIALS AND METHODS 
 
3.1 Mice 
6 weeks old C57BL/6J female mice were purchased from Harlan Laboratories. 
C57BL/6J-ApcMin/J (referred to as ApcMin/+) mice were obtained as a result of genetic 
mutation induced by treatment with N-ethyl N-nitrosurea.  T to A transversion at position 
2549 of the apc gene causes the generation of a premature stop codon.  These mice 
develop multiple intestinal neoplasia (min) characterized by adenomas in the small 
intestine and colon (Moser et al., 1990).  ApcMin/+ mice colony is maintained as 
heterozygous in our animal facility by breeding ApcMin/+ males with C57Bl6/J females 
purchased from Harlan.  At weaning mice are screened for the presence of the min allele 
by multiplexed PCR on genomic DNA using primers listed in Table 3-1. 
 
Primer Sequence (5’→3’) Allele recognized 
oIMR0033 GCCATCCCTTCACGTTAG Wild type 
oIMR0034 TTCCACTTTGGCATAAGGC Common 
oIMR0758 TTCTGAGAAAGACAGAAGTTA Mutated 
Table 3-1 Primer sequences for ApcMin/+ genotyping assay 
The cycling protocol used is described in Table 3-2. 
 
Temperature (°C) Time N. of cycles 
94 3 minutes 1 
94 30 seconds  
x 35 cycles 55 1 minute 
72 1 minute 
72 2 minutes 1 
Table 3-2 Thermal cycler protocol used for ApcMin/+ genotyping assay 
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The assay amplifies a 600 bp band for the wild type allele and a 340 bp band for the min 
allele as shown in Figure 3-1. 
 
Figure 3-1 ApcMin/+ genotyping assay.  The gel shows bands for the wild type and min apc allele. 
 
Wild type mice used for experiments are littermates from our ApcMin/+ mice colony. 
All mice were maintained in microisolator cages in a specific pathogen-free animal 
facility and experiments were performed in accordance with the guidelines established in 
the Principles of Laboratory Animal Care (directive 86/609/EEC) and approved by the 
Italian Ministry of Health. 
 
3.2 FACS on organs 
To analyse the principal immune cell population peripheral blood and mLN were 
sampled from WT and ApcMin/+ mice at 8, 12, 16 and 20 or more weeks of age.  Red 
blood cells were lysed and mLNs were reduced to single cell suspensions.  Neutrophils 
were stained with Ly6G PE (clone 1A8, BD Biosciences) and CD11b APC (clone M1/70, 
BD Biosciences).  T cells were stained with CD4 FITC (clone RM4-4, BD Biosciences) 
and CD8 APC (clone 53-6.7, BD Biosciences).  B cells were stained with B220 FITC 
(clone RA3-6B2, BD Biosciences) and CD19 APC (clone 1D3, BD Biosciences).  
Samples were acquired at FACSCalibur cytometer (BD Biosciences).  Populations are 
considered as percentage on living cells identified with SSC and FSC. 
To detect neutrophils and inflammatory monocytes in circulating blood of mice treated or 
not with Clostridium ID4 blood was sampled in heparin via tail vein bleeding.  
Erythrocytes were lysed with red blood cell lysis buffer (6 mM NH4Cl, 140 mM NaHCO3, 
16 mM EDTA, pH 7,4).  Cells were stained with CD45.2 PerCP-Cy5.5 (clone 104, 
eBioscience), CD3 PE-Cy7 (clone SK7, BD Biosciences), Ly6G PE (clone 1A8, BD 
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Biosciences), Ly6C FITC (clone AL-21, BD Biosciences) and CD11b APC (clone M1/70, 
BD Biosciences).  Samples were acquired at FACSCantoII (BD Biosciences).  
Inflammatory monocytes were identified as CD11b+ Ly6Chigh cells in the CD45+ CD3- 
gate, while neutrophils were identified as CD11b+ Ly6G+ cells in the CD45+ CD3- gate. 
 
3.3 RT-qPCR assay 
Intestinal chunks from wild type mice, normal ileal chunks and single polyps from ApcMin/+ 
mice were sampled at 10 and 23 weeks of age.  Intestinal tissue was homogenised in 
500 ul of TRIzol (Invitrogen).  RNA was extracted adding 100 µl of chloroform, 
precipitating the aqueous phase with 300 µl of 70% ethanol and purifying RNA with 
RNeasy Mini Kit (QIAGEN) according to the manufacturer’s guidelines.  Genomic DNA 
contamination was removed with DNase-Free DNase set (QIAGEN).  RNA was retro-
transcribed with ImProm-II Reverse Transcriptase kit (Promega) following 
manufacturer’s instruction.  qPCR assay was performed with Fast Sybr Green Master 
Mix (Life Technologies) on 10 ng cDNA template/reaction using exon-spanning primers 
(final concentration 1 µM). 
To isolate RNA from single ileal crypts formalin-fixed swiss rolls from wild type and 
ApcMin/+ mice aged 16 weeks underwent laser-assisted microdissection, allowing fine 
collection of both normal and dysplastic crypts in the ApcMin/+ ilei.  Laser-assisted 
microdissection was performed in Prof. Silvano Bosari laboratory (Department of 
Patophisiology and Transplantation, University of Milan, Italy).  RNA was 
retrotranscribed with High Capacity cDNA Reverse Transcription Kit (Life Technologies) 
and qPCR assay was performed on 10 ng cDNA as previously described. 
Expression levels are normalized to the 60S ribosomal protein gene espression RPL32. 
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Gene Forward primer (5’→3’) Reverse primer (5’→3’) 
Amplicon 
(bp) 
Rpl32 AAGCGAAACTGGCGGAAAC TAACCGATGTTGGGCATCAG 86 
Muc1 TACCCTACCTACCACACTCACG CTGCTACTGCCATTACCTGC 95 
Muc2 CACCAACACGTCAAAAATCG GGTCTCTCGATCACCACCAT 116 
Muc3 CTTCCAGCCTTCCCTAAACC TCCACAGATCCATGCAAAAC 119 
Muc4 GAGAGTTCCCTGGCTGTGTC GGACATGGGTGTCTGTGTTG 101 
Muc5ac ATCTTTCAGGACCCCTGCTC ATGGACCACTGGCGTTAGTC 88 
Muc6 TTGGCTTAATTGAGTTGGCA CCCAAAACTTGTTCTCCACA 102 
Muc13 CAACTCAGCCTTCTGGTGGT TACAGGGGTTAGGGTTGCAG 90 
Muc20 CAACATCTGCATCCACTGCT GTCAGCCGTACAAGGAGGAA 82 
GSK-3β GTGGTTACCTTGCTGCCATC GACCGAGAACCACCTCCTTT 106 
Apc GCCAGGATCCAGCAAATAGA CATGCCTGCTCTGAGATGAC 97 
Table 3-3 qPCR primers 
 
3.4 AB/HID staining 
Ileal and colonic segments were fixed in Carnoy fixative (60% ethanol, 10% acetic acid 
glacial and 30% chloroform) to preserve the mucus layer and transferred in 100% 
ethanol until paraffin embedding (Matsuo et al., 1997).  4 µm sections were rehydrated 
and incubated for 24 hours in high iron diamine solution.  To prepare high iron diamine 
(HID) solution 120 mg N,N-dimethyl-meta-phenylenediamine-dihydrochloride (Sigma-
Aldrich) and 20 mg N,N-dimethyl-para-phenylenediamine-dihydrochloride (Sigma-
Aldrich) were dissolved simultaneously in a Coplin jar in 50 ml of distilled water, then 1,4 
ml of freshly prepared 60% ferric chloride solution (Sigma-Aldrich) was added to obtain 
the final solution.  After washing slides were incubated in 1% alcian blue solution in 3% 
acetic acid (IHC World, NovaUltra).  After washing nuclei were counterstained in neutral 
red solution (0,5% in water, Sigma-Aldrich), deahydrated, cleared and mounted.  Alcian 
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blue in 3% acetic acid stains blue acid mucopolysaccharides and sialomucins, while HID 
solution reacts with sulfomucins forming black precipitates. 
 
3.5 Bacterial strains 
Two Salmonella strains were used: Salmonella enterica serovar Typhimurium (here 
referred to as Salmonella typhimurium) strain SL1344 ΔAroA (invasive Salmonella) and 
Salmonella enterica serovar Typhimurium strain SL1344 ΔAroA InvA- (non-invasive 
Salmonella).  ΔaroA mutant is auxotrophic for aromatic amino acids and this confers 
reduced ability to replicate in vivo, while mutation in the invA gene, a component of the 
SPI-1 encoded type three secretion system (T3SS), results in the inability of the 
bacterium to invade the host.  For infection experiments these strains were grown in 
Luria Broth with appropriate antibiotics until OD(600nm) ≅ 0,6.  Bacteria were 
administered in 5% sodium carbonate solution and bacterial load of the inoculum 
controlled by plating. 
Clostridium ID4 was isolated in Kenya Honda laboratory (IMS RCAI, Yokohama, Japan) 
from fecal pellets coming from littermates of our ApcMin/+ colony as described in (Atarashi 
et al., 2013).  Briefly, faeces were plated on EG agar plates, a number of colonies were 
picked and sequenced using 16S universal primers.  Similarity to Clostridium ID4 was 
checked on both databases and with the sequence retrieved from our metagenomic 
analysis, resulting in 99.3% and 98% respectively.  Bacteria were cultured in EG broth in 
anaerobic conditions until OD(600nm) ≅ 0,6 (about 48 hours of culture).  Bacteria were 
frozen in EG 10% glycerol.  C. ID4 culturing in anaerobic conditions was performed in 
Marika Falcone Laboratory (DRI Unit, Ospedale San Raffaele, Milan, Italy). 
Escherichia coli strain DH5α and a mutant expressing Yersinia enterocolitica invasin (E. 
coli DH5α pInv) were grown in Luria Broth with appropriate antibiotics until OD(600nm) ≅ 
0,6.  Bacterial load of the inoculum was controlled by plating. 
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3.6 Bacterial spreading 
To address bacterial spreading at distal organs wild type littermates and ApcMin/+ mice at 
either 10 or 16 weeks of age were orally administered with 109 CFUs of either invasive 
or non-invasive Salmonella in 5% carbonate buffer, or intravenously injected with 5x104 
CFUs of invasive Salmonella.  72 hours post-infection organs were resected, incubated 
with gentamycin (50 µg/ml) to eliminate extracellular contamination, digested with 
collagenase D (1 mg/ml, Roche) and reduced to single-cell suspension.  A fixed number 
of cells was lysed with 0,5% sodium deoxycholate and plated on TB-agar plates in 
duplicate. 
 
3.7 Salmonella vaccination and administration 
In vaccination experiments littermate and ApcMin/+ mice were orally administered with 109 
CFUs of invasive Salmonella in carbonate buffer every other day for 3 challenges.  
Serum and fecal samples were taken weekly for the 5 weeks following vaccination and 
analysed for the presence of Salmonella-specific IgG and IgA with ELISA assay as 
described in paragraph 3.8. 
To test weather bacterial challenges induced tumorigenesis littermate and ApcMin/+ mice 
were administered from the 8th week of life with 109 CFUs of invasive Salmonella in 
carbonate buffer every other week for four total challenges.  Salmonella was either 
administered alone or 24 hours after treatment with streptomycin (20 mg/mouse) as 
previously described (Barthel et al., 2003).  Serum and faeces were sampled every other 
week and the development of Salmonella-specific IgA and IgG assessed by ELISA 
assay as described in paragraph 3.8 and 3.9.  Mice were sacrificed at the 16th week of 
age and tumor multiplicity in the small intestine and colon assessed. 
 
3.8 ELISA for total IgA and Salmonella-specific IgA and IgG 
For IgA and IgG detection blood was sampled via tail vein bleeding and serum stored at 
-80°.  Fecal pellets were homogenised in 1 ml/0,1 g faeces of 0,1 mg/ml SBTI (Trypsin 
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inhibitor from Glicine max, Sigma Aldrich), centrifuged at 13000 rpm and supernatants 
stored at -80°C.  Sera were tested at 1:100 and faeces at 1:10 dilution in duplicate. 
For total IgA detection plates were coated with 0,2 µg/well purified anti-mouse IgA (clone 
C10-3, BD Biosciences) and blocked in PBS 0,5% BSA.  Samples were diluted in PBS 
0,05% Tween 20 and incubated at 37°C for 2 hours.  After washing plates were 
incubated with 0,2 µg/well biotin anti-mouse IgA (clone C10-1, BD Biosciences) for 1 
hour at room temperature and then with Streptavidin-HRP (R&D systems) for 30 
minutes.  Plates were developed with the colorimetric substrate TMB (Sigma Aldrich) 
and the reaction is stopped with sulphuric acid 2N.  Absorbance signal is red at 450 nm. 
For the detection of Salmonella-specific immunoglobulins plates were coated with 
Salmonella lysate (105 CFU/well) and blocked in PBS 1% BSA 5% sucrose.  After 
washing plates are incubated with the samples as previously described.  After washing 
plates were incubated with anti-mouse IgA-HRP antibody (diluted 1:1000, cat 1040-05, 
SouthernBiotec) for IgA and with anti-mouse IgG-HRP (diluted 1:1000, cat. 1030-05, 
SouthernBiotech) for IgG for 1 hour at room temperature.  Plates were then washed and 
developed as previously described. 
 
3.9 ALT detection 
Alanine transaminases were detected in sera of infected and control mice with ALT 
Microwell Autom kit (Sentinel Diagnostics) following the manufacturer’s instructions.  
Samples were diluted 1:10 in PBS.  Transaminases are involved in protein metabolism 
and are present in different organs, but their detection in the serum is associated with 
liver cell damage.  The kit is based on an enzymatic reaction cascade resulting in the 
development of a colorimetric signal detected at 550 nm.   
 
3.10 AOM/DSS 
C57BL/6J females aged 8 weeks were treated with azoxymethane (AOM) 10 mg/Kg of 
body weight by intraperitoneal injection.  After 7 days control groups received 
respectively nothing and N-acetyl cysteine (NAC) 1% w/v in drinking water (groups 
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AOM/H2O and AOM/NAC).  Two cohorts received DSS 2% w/v in drinking water for 7 
days (AOM/DSS and AOM/DSS NAC).  Both groups were allowed for recovery for 14 
days but while group AOM/DSS received water upon DSS stop, group AOM/DSS NAC 
received NAC 1%.  This schedule was repeated for 3 cycles.  Body weight and survival 
were assessed periodically.  Mice were sacrificed at day 70 of treatment.  Colons were 
fixed in formalin-buffered solution and paraffin-embedded.   
For histopathological examination single 4 µm-thick haematoxylin and eosin stained 
swiss roll sections were evaluated under a light microscope.  The extent of inflammatory 
changes was evaluated according to the score proposed by (Cooper et al., 1993). 
Histological scoring system used to evaluate colitis grade is described in Table 3-4.  
Additionally the number of ulcers and neoplastic lesions was recorded. Classification of 
proliferative lesions has been performed according to (Boivin et al., 2003). 
 
Grade of colitis Description 
0 Normal colonic mucosa 
1 
Minimal inflammation restricted to the mucosa and only slightly expanding 
the lamina propria among crypts or between crypts and muscularis 
mucosae. 
2 
Mild to moderate (usually focal) inflammation in the mucosa with 
shortening of the crypts and occasionally mildly extending to the 
submucosa (usually associated with small ulcers) 
3 
Moderate to severe (multifocal to diffuse) inflammation involving the 
mucosa with shortening or loss of the crypts and moderately to markedly 
extending into the submucosa and occasionally into the tunica muscularis 
(usually associated with large ulcers) 
4 
Severe transmural inflammation involving the mucosa, submucosa, tunica 
muscularis, and subserosa (usually associated with diffuse ulceration). 
Table 3-4  Colitis histological scoring system 
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3.11 DNA extraction from fecal samples 
DNA from faecal pellets and mucus scraped from the small intestine and colon was 
extracted with G NOME DNA isolation kit (MP) following a published protocol (Furet et 
al., 2009).  Briefly, fecal pellets were stored at -80°C until the extraction.  Fecal pellets 
were homogenised in 550 µl Cell Suspension Solution (G NOME DNA Kit).  After 
addition of 50 µl RNase Mixx (G NOME DNA Kit) and 100 µl Cell Lysis/Denaturing 
Solution (G NOME DNA Kit) samples were incubated at 55°C under shaking for 30 
minutes.  After adding 25 µl Protease Mixx (G NOME DNA Kit) samples were incubated 
for further 2 hours at 55°C under shaking.  Samples then undergo mechanical disruption 
of bacterial cells with 0,1 mm glass beads (BioSpec Products) in FastPrep®-24 
homogenizer (MP Biomedicals).  Lysates were retrieved.  Glass beads are washed three 
times with 400 µl of TENP buffer (50 mM Tris pH 8, 20 mM EDTA pH 8, 100 mM NaCl, 
1% PVPP).  Supernatants are pooled with the original lysate and precipitated with 
isopropanol.  DNA pellet was resuspended in 400 µl water and incubated with 100 µl of 
Salt.Out Mixture (G NOME DNA Kit) to remove impurities.  Samples are then 
precipitated in 100% ethanol and DNA pellet washed with 70% ethanol.  DNA pellets are 
dried and resuspended in water.   
 
3.12 Metagenomic analysis 
Faecal material was sampled from littermate and ApcMin/+ mice at 4, 8, 12 and 16 weeks 
of age and DNA purified as described in paragraph 3.11. 
The subsequent steps involving sample preparation for sequencing, the sequencing and 
bioinformatics analysis were conducted in the laboratory of Prof. Graziano Pesole 
(Institute of Biomembranes and Bioenergetics, National Research Council -CNR-, Bari, 
Italy) and will be here summarized. 
V5-V6 hypervariable regions of bacterial 16S rDNA were amplified and processed with a 
modified version of the Nextera protocol.  Metagenomic libraries obtained were 
sequenced with MiSeq Illumina platform with 2x250 paired-end approach.  Samples of 
the four time points were sequenced in four different runs.  Quality check with the tool 
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Trim Galore! removed low quality regions (Phred quality score cut-off = 25) and 
sequences shorter than 50 bp.  Table 3-5 summarizes the number of total reads per run 
and the mean number of reads per sample. 
 
 n° reads/run n° reads/sample 
mean ± SD 
Mean read length ± 
SD (bp) 
4 weeks 22359242 678791 ± 275306,616 249,01 ± 18,72 
8 weeks 24795998 590270 ± 158089,465 249,23 ± 17,07 
12 weeks 24585612 604681 ± 186225,132 248,83 ± 19,60 
16 weeks 23867080 674281 ± 217118,955 248,73 ± 19,96 
Table 3-5  Sequencing data details.  Every time point was sequenced in a single run.  For each run the 
total number of reads, the mean number of reads per sample (mean ± SD) and the mean read length (length 
± SD) is shown.   
 
Forward and reverse reads were overlapped creating consensus sequences.  Reads 
without partner overlapping sequence were excluded from the analysis.  Consensus 
sequences were aligned with the Bowtie 2 tool to the Ribosomal Database Project II 
(RDP II, release 10.29), a database of aligned and annotated rRNA gene sequences 
(Cole et al., 2003).  Mapping data were filtered with a 97% similarity cut-off and 70% of 
coverage of the aligned sequence.  Taxonomic alignment of matching sequences was 
performed with TANGO tool.  Assigned genera were filtered considering as present only 
the ones for which at least 5 reads per samples were present (Table 3-6).  Finally, the 
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 Pre-filtering Post-filtering 
4 weeks 631 74 
8 weeks 551 61 
12 weeks 586 67 
16 weeks 652 81 
Table 3-6  Taxonomic data relative to genera pre- and post-filtering. 
 
3.13 Clostridium ID4 qPCR assay 
Primers specific to Clostridium ID4 were designed in the 16S rDNA in an area of minimal 
overlap to other Clostridium species.  To exclude detection of most known Clostridial 
species primers were tested with in silico PCR tool (http://insilico.ehu.es/PCR/). 
To detect C. ID4 in the faeces or mucus with qPCR assay DNA was extracted as 
described in paragraph 3.11.  10 ng of cDNA were amplified with C. ID4 specific primers 
(final concentration 1 µM) using Sybr Green Master Mix (Life Technologies).  C. ID4 
abundance was normalized to primers amplifying eubacterial 16S (EUB) (Salzman et al., 
2010).  Primer sequences are listed in Table 3-7. 
 
Species Forward primer (5’→3’) Reverse primer (5’→3’) 
Amplicon 
(bp) 
C. ID4 16S CCGGGAATACGCTCTGGAAA GCCAACCAACTAATGCACCG 123 
EUB 16S GGTGAATACGTTCCCGG TACGGCTACCTTGTTACGACTT 172 
Table 3-7  Primers used for qPCR assay on bacterial DNA 
 
3.14 Clostridium ID4 administration to GF and ApcMin/+ mice 
Experiments of gnotobiotic colonization of germ-free mice with Clostridium ID4 were 
performed in Kenya Honda laboratory (IMS RCAI, Yokohama, Japan).  Briefly 5 ICR 
male mice were administered with 250 µl of C. ID4 culture.  After 5 weeks cells were 
isolated from the lamina propria of the small intestine and colon and the abundance of 
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Tregs (percentage of FoxP3+ cells in the CD4+ population), IL17-producing cells 
(percentage of IL17+ cells in the CD4+ or CD8+ population) and IFNγ-producing cells 
(percentage of IFNγ+ cells in the CD4+ or CD8+ population) was evaluated by flow 
cytometry.  C. ID4 gnotobiotic mice were compared with both germ-free and SPF mice. 
To evaluate the effect of exogenous C. ID4 administration WT and ApcMin/+ mice were 
orally administered from 6 to 12 weeks of age twice a week with frozen C. ID4 stocks 
equivalent to 250 µl of culture (see paragraph 3.5) according to the protocol used in 
(Atarashi et al., 2013).  Mice were weekly sampled for faeces to check C. ID4 
abundance as described in paragraphs 3.11 and 3.13.  At 12 weeks of age mice were 
sacrificed, tumor multiplicity in the small intestine and colon assessed.  Neutrophil and 
inflammatory monocyte abundances in circulating blood and Treg, Th1 and Th17 
abundances in small intestinal and colonic lamina propria assessed as described in 
paragraphs 3.2 and 3.15 respectively. 
 
3.15 FACS on LP cells 
To analyse T cell populations in the lamina propria of WT and ApcMin/+ mice small 
intestines and colons were incubated with PBS 5% FCS 1,5 mM EDTA 1mM DTT with 
magnetic stirrer at 37°c for 15 minutes to remove IECs.  Intestinal pieces were then 
mechanically disrupted in RPMI 5% FCS with 2 consecutive cycles of gentleMACS 
Dissociator (Miltenyi Biotec) program m_intestine_01. 
The surface and intranuclear staining for Treg detection cells were incubated with anti 
CD16/CD32 (clone 93, eBioscience) to block Fc receptors.  For membrane staining cells 
were incubated with CD45.2 PerCP-Cy5.5 (clone 104, eBioscience), CD3 PE-Cy7 (clone 
SK7, BD Biosciences), CD4 FITC (clone GK1.5, BD Biosciences), CD25 APC-Cy7 
(Clone PC61, BioLegend) and Fixable Viability Dye eFluor® 450 (eBioscience) to 
exclude dead cells.  Cells were then incubated with Fixation/Permeabilization buffer 
(eBioscience) for 1 hour at 4°C and then stained with FoxP3 PE (clone FJK-16s, 
eBioscience) and Helios Alexa-Fluor 647 (clone 22F6, eBioscience). 
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For Th1 and Th17 detection cells were re-stimulated in vitro with PMA (50 ng/ml, Sigma 
Aldrich), ionomycin (500 ng/ml, Sigma Aldrich) and GolgiStop (4 µl/6ml, BD Biosciences) 
for 4 hours at 37°C.  Membrane and intracellular staining were performed as previously 
described.  For surface markers cells were stained with CD45.2 PerCP-Cy5.5 (clone 
104, eBioscience), CD3 PE-Cy7 (clone SK7, BD Biosciences), CD4 FITC (clone GK1.5, 
BD Biosciences), CD8 APC eFluor 780 (clone 53-6.7, eBioscience) and Fixable Viability 
Dye eFluor® 450 (eBioscience) to exclude dead cells.  Intracellular cytokines were 
stained with IL17 PE (clone TC11-18H10, BD Biosciences) and IFNγ APC (clone 
XMG1.2, BD Biosciences). 
Samples were acquired at FACSCantoII (BD Biosciences). 
 
3.16 miRNA analysis 
To compare miRNA profiles in the intestines of WT and ApcMin/+ mice RNA isolated from 
single ileal crypts was analysed with murine miRNA expression cards.  Sample 
preparation, miRNA profiling and the subsequent analysis were performed in Prof. 
Silvano Bosari laboratory (Department of Patophisiology and Transplantation, University 
of Milan, Italy).  Briefly, RNA was extracted from 8 16 weeks old WT and 8 ApcMin/+ 
formalin-fixed paraffin embedded ileal segments.  Laser-assisted microdissection 
allowed recovery of single crypts from the WT tissue and both normal (N) and dysplastic 
(D) crypts from ApcMin/+ tissue.  RNA was retro-transcribed and amplified (Megaplex RT 
and PreAmp Primers Rodent Pools A+B, Life Technologies).  cDNA obtained from all the 
WT, N and D crypts were pooled and miRNA cards were performed (TaqMan® Array 
Rodent MicroRNA A+B Cards Set, Life Technologies).  Relative quantification was 
calculated relative to the three reference snoRNAs (U6, sno202 and sno135) with 
DataAssist Software (Life Technologies).  BRB Array Tools was used for supervised 
analysis to compare WT vs. N and N vs. D profiles using a cut-off of 10 fold on log2 data. 
 
	   62	  
3.17 Ex-vivo infection of murine colonic mucosa 
To address whether bacterial stimulation could alter apc gene expression we stimulated 
colonic explants with an ex-vivo organ culture model developed in our laboratory 
(Tsilingiri et al., 2012; Tsilingiri et al., 2013).  Briefly, colonic tissue from WT and ApcMin/+ 
mice at 8 weeks of age was incubated in gentamicin (50 µg/ml) to remove contaminants.  
The tissue was then placed on a grid and a cylinder (diameter 6 mm) sealed on it to 
allow polarized stimulation of the mucosa as shown in Figure 3-2.  Samples were 
infected with 102 CFUs in a volume of 50 µl of ΔaroA invA Salmonella thyphimurium, 
ΔaroA Salmonella thyphimurium, E. coli DH5α or E. coli DH5α pInv.  After 2 hour at 37°C 
the infection medium was removed from the cylinder, gentamycin was added to the 
culture medium (50 µg/ml) and samples were incubated for 24 hours in 100% O2 
atmosphere.  RNA extraction was performed and apc gene expression was evaluated as 
described in paragraph 3.3. 
 
 
Figure 3-2  Ex-vivo organ culture method.  A piece of intestinal mucosa is placed on a grid and a cylinder 
is sealed on the luminal side of the tissue.  The stimulus is placed into the cylinder so that the tissue is 
stimulated from the luminal side as happens in physiological conditions.  Adapted from (Tsilingiri et al., 
2012). 
 
3.18 Statistical analysis 
Results are represented as mean ± SEM. Statistical significance was evaluated with 
Student’s t test were evaluated using GraphPad Prism software.  
*p<0.05, **p<0.01, ***p<0.001. 
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4 RESULTS 
 
4.1 ApcMin/+ mice characterization 
4.1.1 ApcMin/+ mice develop adenomas in the small intestine 
The ApcMin/+ mouse is a model of APC driven intestinal tumorigenesis.  It is characterized 
by the min mutation that results in a truncated and non-functional APC protein product 
(Moser et al., 1990).  Truncated APC results in a non functional β-catenin degradation 
complex and β-catenin is free to migrate to the nucleus and activate transcriptional 
programs involved in cell proliferation and survival (Anastas and Moon, 2013).  The min 
mutation is in heterozygosity and the loss of the WT allele leads to the progressive 
accumulation of adenomatous polyps in the SI and colon, with greater incidence in the 
distal portion of the SI (Moser et al., 1990). 
A characterization of ApcMin/+ mice in our housing conditions and experimental setting 
shows that, as described in literature, mice start accumulating polyps in the small 
intestine from the eighth week of life onwards, reaching a plateau at about 14 weeks of 
age (Figure 4-1).  Polyp number is maximal in the distal part of the SI (e.g. in the ileum) 
while it is sporadic in the colon (Figure 4-2).  Figure 4-3 shows a representative picture 
of the different tracts of the small intestine and colon of an ApcMin/+ mouse at 16 weeks of 
age showing the appearance of the polyps. 
 
 
Figure 4-1 Tumor multiplycity in the small intestine of ApcMin/+ mice.  ApcMin/+ mice were sacrificed at 
different weeks of age and tumor number in the SI was assessed. 
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Figure 4-2  Tumor multiplycity in the colon of ApcMin/+ mice.  ApcMin/+ mice were sacrificed at different 
weeks of age and tumor number in the colon was assessed. 
 
 
Figure 4-3 Polyp appearance in the intestine of ApcMin/+ mice.  Representative picture of a longitudinally 
opened intestine and colon to show the appearance of the adenomas.  Intestines were fixed with Hollandes 
fixative and longitudinally opened.  The picture shows from top to bottom colon, ileum, jejunum and 
duodenum.  Arrows point to polyps. 
 
4.1.2 ApcMin/+ mice develop hematopoietic disorders  
It is reported that ApcMin/+ mice have hematological alterations characterized by thymic 
atrophy, B and T cell depletion and reduction of NK cell abundance while myelopoiesis is 
enhanced if compared to WT mice (Coletta et al., 2004)(Guglietta S., unpublished). 
An analysis of the principal immune cell populations by FACS staining showed that 
ApcMin/+ mice had comparable T (CD4+ and CD8+) and B (B220+ CD19+) cell 
abundance in circulating blood compared to littermates until 16 weeks of age (Figure 
4-4).  However at later time points we observed a reduction in the mature B cell 
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CD11b+) both in circulating blood and in mesenteric lymph nodes as previously reported 
(Figure 4-4, Figure 4-5) (Coletta et al., 2004)(Guglietta S., unpublished). 
 
 
Figure 4-4 Neutrophil, T and B cell abundance in the peripheral blood of WT and ApcMin/+ mice.  FACS 
analysis showing the abundance of neutrophils (Ly6G+ CD11b+), T cells (CD4+ and CD8+) and B cells 
(B220+ CD19+) in the peripheral blood of WT and ApcMin/+ mice at different weeks of age.  Data are shown 
as percentages of the total population.  Graphs show mean ± SEM.  n=3/6.  * p<0,05; *** p<0,001. 
 
 
Figure 4-5 Neutrophil, T and B cell abundance in the mesenteric lymph node of WT and ApcMin/+ mice.  
FACS analysis showing the abundance of neutrophils (Ly6G+ CD11b+), T cells (CD4+ and CD8+) and B 
cells (B220+ CD19+) in the mLNs of WT and ApcMin/+ mice at different weeks of age.  Data are shown as 
percentages of the total population.  Graphs show mean ± SEM.  n=3/6.  *** p<0,001. 
 
 
4.2 The mucus barrier is altered in intestinal tumorigenesis 
4.2.1 Mucin expression is altered in the early phases of tumorigenesis in 
ApcMin/+ mice 
Mucin expression and post-traslational modification status is altered in pathological 
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whether in murine models of intestinal tumorigenesis as for the human disease the 
mucus barrier is altered we analysed mucin expression in ApcMin/+ intestines. 
RNA from intestines of wild type mice, normal intestinal tissue and single polyps of 
ApcMin/+ mice was analysed by RT-qPCR assay for a panel of mucins.  Intestinal samples 
were taken from mice at both an early (10 weeks of age) and very late (23 weeks of age) 
stage of tumor progression.  Results about the ileum show that mucin expression profile 
in the tumor of ApcMin/+ mice is altered both at 10 and 23 weeks of age (Figure 4-6).  In 
particular, mucins that are normally not expressed or expressed at very low levels in the 
intestine such as Muc1, Muc5ac, Muc6 and Muc20 increase in tumors while the 
expression of mucins that are constitutively expressed in the gut such as Muc3 and 
Muc13 decreases (Figure 4-6).  Interestingly Muc1 expression is altered already in the 
normal tissue of ApcMin/+ mice while Muc2 expression is only slightly reduced in the 
tumors of ApcMin/+ mice at 23 weeks of age (Figure 4-6). 
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Figure 4-6  Mucin expression profile is altered in the ileum of ApcMin/+ mice.  Ileal tissue from WT (WT) 
and both normal ileal tissue (N) and tumors (T) from ApcMin/+ ilei at 10 and 23 weeks of age was analysed by 
RT-qPCR for the expression of Muc1, Muc2, Muc3, Muc4, Muc5ac, Muc6, Muc13 and Muc20.  Expression 
levels are normalized to Rpl32.  Graphs show mean ± SEM.  n=3/4.  * p<0,05. 
 
Altered mucin expression was evident also when single crypts isolated by laser-assisted 
microdissection were analysed (Figure 4-7).  Dysplastic crypts isolated from ApcMin/+ ilei 
showed increased expression of Muc5ac and Muc20 compared to wild type crypts and 
normal crypts from ApcMin/+ ileum, while Muc3 and Muc13 were reduced (Figure 4-7). 
Taken together these data show that mucin expression level is altered in the polyps and 
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Figure 4-7  Mucin expression profile is altered in the dysplastic crypts of ApcMin/+ mice.  Single crypts 
from WT (WT) ileum and both normal (N) and dysplastic (D) crypts from ApcMin/+ ileum at 16 weeks of age 
were analysed by RT-qPCR for the expression of Muc1, Muc3, Muc5ac, Muc13 and Muc20.  Expression 
levels are normalized to Rpl32.  Graphs show mean ± SEM.  n=3/4.  * p<0,05. 
 
On the contrary mucin expression profile in the colon of ApcMin/+ mice showed only minor 
alterations (Figure 4-8).  As colon tumorigenesis is a sporadic event in the ApcMin/+ model 
data regarding colonic tumors at 10 and 23 weeks of age are represented together.  In 
both the normal colonic tissue and polyps of ApcMin/+ mice we observed a trend towards 
a reduction in Muc2, Muc3 and Muc13 (Figure 4-8).  The reduced expression of these 




























































	   69	  
 
Figure 4-8  Mucin expression profile is only partially altered in the colon of ApcMin/+ mice.  Colonic 
tissue from WT (WT) and both normal colon tissue (N) and tumors (T) from ApcMin/+ ilei at 10 and 23 weeks 
of age was analysed by RT-qPCR for the expression of Muc1, Muc2, Muc3, Muc4, Muc5ac, Muc6, Muc13 
and Muc20.  Expression levels are normalized to Rpl32.  Data about tumors from 10 and 23 week-old 
ApcMin/+ mice are represented together.  Graphs show mean ± SEM.  n=3/4.  * p<0,05. 
 
Since we observed increased expression of Muc1 in ileal polyps and dysplastic crypts of 
ApcMin/+ mice and Muc1 intracellular domain interacts with GSK-3β (Li et al., 1998) we 
tested whether its transcription was altered in our model.  We found that GSK-3β 
expression is reduced in ApcMin/+ polyps (Figure 4-9).  As GSK-3β-mediated MUC1 
phosphorylation disrupts its interaction with β-catenin (Li et al., 1998), the parallel 
increase in Muc1 and decrease in GSK-3β expression in the polyps of ApcMin/+ mice 
could contribute in the alteration of β-catenin cellular pools and thus deregulation of the 
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Figure 4-9  GSK-3β expression is reduced in the polyps of ApcMin/+ mice.  Ileal tissue from WT (WT) 
and both normal ileal tissue (N) and tumors (T) from ApcMin/+ ilei at 10 and 23 weeks of age was analysed by 
RT-qPCR for the expression of GSK-3β.  Expression levels are normalized to Rpl32.  Graph shows mean ± 
SEM.n=3/4.  * p<0,05. 
 
4.2.2 Mucus sulphonation is not altered in ApcMin/+ intestine 
Mucins are highly glycosylated proteins (McGuckin et al., 2011) and their glycosylation 
pattern is often altered in pathological conditions of the intestine, including CRC (Sheng 
et al., 2012).  Sulphonation is an important post-traslational modification of intestinal 
mucins and is fundamental in the maintenance of proper barrier functions including 
resistance to colitis and enteric infection (Dawson et al., 2009).  We therefore assessed 
if mucus sulphonation in addition to mucin expression is altered in the ApcMin/+ model.  
Sulphonation was visualized with high iron diamine (HID) coupled alcian blue (AB) 
staining on ileal and colonic sections. 
In the small intestine of WT and ApcMin/+ mice we barely detected any sulphonation 
signal (Figure 4-10), with no differences between WT and ApcMin/+ mice in both the 
proximal and distal portions of the small intestine.  In the colon we detected a 
sulphonation signal that was more intense in the distal part of the colon (Figure 4-11).  
However also in the colon we did not detect any difference between wild type and 
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Figure 4-10  Mucus sulphonation is not altered in the small intestine of ApcMin/+mice.  4 µm small 
intestinal sections from WT and ApcMin/+ mice were stained with AB/HID.  Representative pictures from 
proximal and distal SI are shown.  Blue: sialomucins, black: sulphomucins. 
 
 
Figure 4-11  Mucus sulphonation is not altered in the colon of ApcMin/+ mice.  4 µm colon sections from 
WT and ApcMin/+ mice were stained with AB/HID.  Representative pictures from proximal and distal colon are 
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4.3 Intestinal permeability is altered in ApcMin/+ mice 
4.3.1 Salmonella preferentially localizes in the mLN, small intestine and 
polyps of ApcMin/+ mice 
It has been reported that intestinal adenomas lead to altered intestinal permeability 
(Grivennikov et al., 2012).  Having observed altered mucus composition in tumor bearing 
mice we addressed whether this altered barrier properties resulted in altered bacterial 
penetration.  To this extent we employed Salmonella typhimurium, a microorganism that 
is able to interact and digest the mucus (McCormick et al., 1988; Nevola et al., 1987; 
Vimal et al., 2000) and thus could better highlight differences due to alterations in the 
mucus barrier.  We orally administered ΔaroA S. typhimurium to WT and ApcMin/+ mice at 
10 weeks of age and bacterial dissemination to organs was assessed at 72 hours post 
infection (hpi) (Figure 4-12).  Bacterial burden was higher in the mLNs of ApcMin/+ mice 
when compared to WT littermates, while there was no difference in the CFU titre 
recovered from the spleen (Figure 4-12).  Consistently we did also recover more CFUs 
from the small intestine of ApcMin/+ mice than from littermates (Figure 4-12).  In this 
experiment mice were at an early stage of tumorigenesis and it was possible to analyse 




Figure 4-12 ApcMin/+ mice have increased bacterial permeability at early stages of tumorigenesis.  10 
weeks old WT and ApcMin/+ mice were orally infected with 109 CFUs of ΔaroA S. typhimurium.  CFU load in 
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We did also address bacterial penetrance at a later stage of tumor development to test 
whether intestinal permeability was altered also at the level of the polyps.  We infected 
littermates and ApcMin/+ mice at 16 weeks of age with ΔaroA S. typhimurium and 
analysed bacterial load at 72 hpi (Figure 4-13).  Again bacterial spreading to the mLNs 
was higher in ApcMin/+ Mice compared to littermates and we recovered higher bacterial 
loads from the polyp-free intestinal tissue of ApcMin/+ mice.  Interestingly we observed 
significantly higher bacterial titre both in the tumors and in the normal ileum of ApcMin/+ 
mice when compared to wild type ilei.  In neither cases we observed differences in CFU 
numbers recovered from the spleens (Figure 4-13).  These data highlight a differential 
intestinal permeability in ApcMin/+ mice upon challenge with invasive Salmonella at both 
early and late stages of tumor development. 
 
 
Figure 4-13 ApcMin/+ mice have increased bacterial permeability at late stages of tumorigenesis.  16 
weeks old WT and ApcMin/+ mice were orally infected with 109 CFUs of ΔaroA S. typhimurium.  CFU load in 
the spleen, mLN and SI was addressed at 72 hpi.  Graphs show mean ± SEM.  n=6/9.  * p<0,05, ** p<0,01. 
 
To rule out the possibility that the difference in bacterial spreading observed was due to 
the invasiveness of the Salmonella strain used we performed the bacterial spreading 
assay using the non-invasive invA ΔaroA S. typhimurium strain administered via the oral 
route (Figure 4-14).  Bacterial penetration to the mLNs was significantly higher in ApcMin/+ 
mice also when the non-invasive Salmonella strain was used.  Moreover, ileal polyps 
contained higher bacterial loads than the ileal tissue from either ApcMin/+ and littermate 
mice, while bacterial titres recovered from the spleen were also in this case identical 
(Figure 4-14).  This indicates that the higher bacterial penetrance observed in ApcMin/+ 
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mice was due to leakiness of the intestinal barrier rather than to the invasiveness of the 
bacterial strain used.  The intestinal barrier could in this frame display higher 
permeability also to components of the endogenous microbial flora upon tumorigenesis. 
 
 
Figure 4-14 Permeability to bacterial challenge is altered in ApcMin/+ mice also when a non-invasive 
Salmonella strain is used.  16 weeks old WT and ApcMin/+ mice were orally infected with 109 CFUs of invA 
ΔaroA S. typhimurium.  CFU load in the spleen, mLN and SI was addressed at 72 hpi.  Graphs show mean ± 
SEM.  n=9/10.  * p<0,05, ** p<0,01. 
 
Infection of WT and ApcMin/+ mice via intravenous route with the ΔaroA S. typhimurium 
resulted in similar bacterial spreading profiles to the mLNs, implying that the differences 
we observe when using the oral administration route are due to an alteration of the 
intestinal barrier properties rather than intrinsic capacity to respond to the infection 
(Figure 4-15).  However we observed massive bacterial localization in ApcMin/+ polyps, 
confirming the tropism of this bacterium for tumoral lesions (Pawelek et al., 2003). 
 
 
Figure 4-15  Infection via the intravenous route leads to similar bacterial spreading in WT and 
ApcMin/+ mice.  16 weeks old WT and ApcMin/+ mice were intravenously infected with 5x104 CFUs of ΔaroA 
S. typhimurium.  CFU load in the spleen, mLN and SI was addressed at 72 hpi.  Graphs show mean ± SEM.  
n=4/6.  * p<0,05, ** p<0,01. 
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4.3.2 ApcMin/+ mice develop an IgA-skewed response upon oral vaccination 
with Salmonella 
Having observed altered barrier properties in ApcMin/+ mice we analysed their ability to 
mount a mucosal response after oral vaccination with ΔaroA S. typhimurium.  WT and 
ApcMin/+ mice were orally challenged every other day for three times with Salmonella and 
mice were followed-up for 6 weeks for the development of antibody titres in the serum 
and in the feaces (Figure 4-16, Figure 4-17).  We found that ApcMin/+ mice developed 
higher Salmonella-specific IgA titres in the serum when compared to WT mice while 
antigen specific IgG where lower (Figure 4-16).  The total IgA titre was comparable 
between the two strains for the whole time course (Figure 4-17).  At the fecal level there 
was no significant difference in the Salmonella-specific IgA response elicited by the 
vaccination (Figure 4-17). 
 
 
Figure 4-16  ApcMin/+ mice develop higher Salmonella-specific IgA titres upon oral vaccination.  8 
weeks old WT and ApcMin/+ mice were vaccinated with 3 oral challenges of 109 CFUs of ΔaroA S. 
typhimurium every other day.  Total IgA and Salmonella-specific IgA and IgG in the sera were evaluated by 
ELISA assay.  Graphs show mean ± SEM.  n=6.  * p<0,05. 
 
 
Figure 4-17  Fecal Salmonella-specific IgA titres are similar in WT and ApcMin/+ mice.  8 weeks old WT 
and ApcMin/+ mice were vaccinated with 3 oral challenges of 109 CFUs of ΔaroA S. typhimurium every other 
Salmonella-specific IgA



















































	   76	  
day.  Salmonella-specific IgA and IgG in the sera were evaluated by ELISA assay.  Graph shows mean ± 
SEM.  n=6. 
 
6 weeks after the vaccination mice were challenged with ΔaroA S. typhimurium and 24 
hours later serum was collected and the level of circulating alanine transaminase (ALT) 
evaluated (Figure 4-18).  Vaccinated ApcMin/+ mice displayed circulating ALT levels 
similar to untreated mice, while vaccinated WT mice had significantly increased ATL 
levels (Figure 4-18).  The lower ALT level in vaccinated ApcMin/+ mice is probably due to 
the protection to the rechallenge conferred by the higher Salmonella-specific IgA titres. 
 
 
Figure 4-18  Vaccinated ApcMin/+ mice are less susceptible to liver damage upon Salmonella 
rechallenge.  8 weeks old WT and ApcMin/+ mice were vaccinated with 3 oral challenges of 109 CFUs of 
ΔaroA S. typhimurium every other day.  After 6 weeks mice were rechallenged with 109 CFUs of ΔaroA S. 
typhimurium.  24h later seric ALT levels were measured with colorimetric assay.  Graph shows mean ± 
SEM.  n=6.  * p<0,05. 
 
Taken together these data show that there is higher bacterial penetrance at the intestinal 
level in ApcMin/+ mice compared to WT littermates, leading to higher spreading to the 
mLNs.  This higher permeability could lead to the development of higher IgA titres upon 
vaccination.  Salmonella-specific IgA are protective towards rechallenge as shown by 
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4.4 Disruption of the mucus barrier enhances intestinal 
tumorigenesis 
It has been demonstrated that genetic ablation of the Muc2 gene leads to spontaneous 
colorectal carcinogenesis in mice (Velcich et al., 2002).  Moreover ablation of Muc2 in 
murine models of Apc-driven intestinal tumorignesis increases the phenotype both in the 
small intestine and in the colon (Yang et al., 2008).  We investigated whether exogenous 
disruptions of the mucus layer had an effect on tumorigenesis.  We used two different 
approaches to disrupt the endogenous mucus barrier.  The first was by orally 
administering Salmonella, a bacterium that binds to and degrades the mucus 
(McCormick et al., 1988; Nevola et al., 1987; Ouwerkerk et al., 2013; Vimal et al., 2000).  
In the second approach we employed N-acetyl cysteine treatment coupled to the 
chemically induced colitis associated CRC model AOM/DSS. 
 
4.4.1 Repeated Salmonella challenges favour colon tumorigenesis in the 
ApcMin/+ model 
Salmonella is able to bind and degrade the mucus (McCormick et al., 1988; Nevola et 
al., 1987; Ouwerkerk et al., 2013; Vimal et al., 2000).  To address whether Salmonella-
induced mucus perturbation was altering intestinal tumorigenesis we orally administered 
ΔaroA S. typhimurium to littermate and ApcMin/+ mice starting at 8 weeks of age once a 
week for a total of four administrations.  Salmonella was administered either alone or 
after treating the mice with streptomycin, according to a published protocol of 
Salmonella-induced colitis (Barthel et al., 2003).  Mice were followed up for further four 
weeks and sacrificed at 16 weeks of age.   
Salmonella-specific antibody titres were evaluated in the serum and faeces over the 
course of the experiment (Figure 4-19).  ApcMin/+ mice treated with streptomycin and 
Salmonella developed higher seric antigen-specific IgA levels, while seric IgG were 
comparable among all the experimental groups (Figure 4-19).  At the fecal level, both 
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WT and ApcMin/+ mice treated with streptomycin and Salmonella had higher Salmonella-
specific IgA titres compared with mice treated only with Salmonella (Figure 4-19). 
 
 
Figure 4-19  Salmonella-specific antibody titres in treated WT and ApcMin/+ mice.  8 weeks old WT and 
ApcMin/+ mice were orally challenged with vehicle or 109 CFUs of ΔaroA S. typhimurium either coupled or not 
with streptomycin pretreatment.  The treatment was repeated for 4 times in 4 consecutive weeks and mice 
were followed-up for further 4 weeks.  Salmonella-specific IgA and IgG were detected in sera and faeces by 
ELISA assay.  Graphs show mean ± SEM.  n=6/7. 
 
Neither of the two infection protocol used had an effect on the polyp multiplicity in the SI 
of ApcMin/+ mice (Figure 4-20). On the contrary tumorigenesis in the colon of mice treated 






























WT strepto + Sal








w0 w2 w4 w6 w8 w0 w2 w4 w6 w8


















Vehicle Salmonella Streptomycin 
+ Salmonella
Vehicle Salmonella Streptomycin 
+ Salmonella
	   79	  
Figure 4-20  Salmonella administration enhances colon tumorigenesis in the colon of ApcMin/+ mice.  
8 weeks old WT and ApcMin/+ mice were orally treated with carbonate buffer alone (Vehicle), 109 CFUs of  
ΔaroA S. typhimurium (Salmonella) or streptomycin and Salmonella (Streptomycin + Salmonella) once a 
week for four consecutive weeks.  Mice were sacrificed at 16 weeks of age and tumor multiplicity in the small 
intestine and colon was assessed.  Graphs show mean ± SEM.  n=6/7.  * p<0,05.   
 
These data demonstrate that treatment with a mucus-degrading microorganism can 
enhance intestinal tumorigenesis.  The specific effect of Salmonella in inducing colonic 
rather that small intestinal polyps is possibly due to its preferential localization in the 
caecum and colon rather than in the SI and to the fact that polyposis might be at 
saturation in the SI as observed by Newman and colleagues in C. rodentium treated 
ApcMin/+ mice (Newman et al., 2001). 
 
4.4.2 Disruption of the mucus layer is detrimental in AOM/DSS colon 
carcinogenesis model 
The AOM/DSS model is widely used as model of chemically induced colitis associated 
colorectal carcinogenesis (Neufert et al., 2007).  To address whether mucus disruption 
with a chemical agent had an effect on colonic tumorigenesis we modified the classical 
AOM/DSS protocol giving the mice a mucolytic agent (N-acetyl cysteine, NAC 1%) 
dissolved in the drinking water during the recovery phases.  Mice treated with AOM/DSS 
and NAC had worsened disease symptoms during the course of the experiment, as 
documented by increased weight loss (Figure 4-21) and higher mortality (Figure 4-22). 
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Figure 4-21 Weight curve of AOM/DSS mice treated or not with mucolytic agent.  C57BL/6 females 
(n=10) aged 8 weeks were treated with azoxymethane (AOM). After 7 days control groups received 
respectively nothing and NAC 1% in drinking water (groups AOM and NAC). Two cohorts received dextran 
sodium sulphate (DSS) 2% in drinking water for 7 days (AOM/DSS and AOM/DSS NAC). Both groups were 
allowed for recovery for 14 days but while group AOM/DSS received water upon DSS stop, group AOM/DSS 
NAC received NAC 1%. This schedule was repeated for 3 cycles.  Weight was monitored throughout the 
experiment and represented as % of the initial body weight.  Graph shows mean  ± SEM.  n=10. 
 
 
Figure 4-22  Weight curve of AOM/DSS mice treated or not with mucolytic agent.  C57BL/6 females 
(n=10) aged 8 weeks were treated with azoxymethane (AOM). After 7 days control groups received 
respectively nothing and NAC 1% in drinking water (groups AOM and NAC). Two cohorts received dextran 
sodium sulphate (DSS) 2% in drinking water for 7 days (AOM/DSS and AOM/DSS NAC). Both groups were 
allowed for recovery for 14 days but while group AOM/DSS received water upon DSS stop, group AOM/DSS 
NAC received NAC 1%. This schedule was repeated for 3 cycles.  Survival was monitored daily.  n=10. 
 
At the end of the experiment colons were analysed for tumor multiplicity and histological 
parameters.  Tumor multiplicity was only slightly increased in the mucolytic treated group 
(Figure 4-23).  Histological analysis revealed that colitis grade and the number of 
ulcerative lesions and dysplastic glands was comparable with or without mucolytic 
treatment, however more polypoid adenoma/carcinoma lesions were observed in the 
mucolytic treated group (Figure 4-24).  These results confirm that disruption of the 
mucus layer is detrimental to colonic tumorigenesis.  Importantly the comparable 
inflammation grade observed in the mucolytic treated group compared to the classical 
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Figure 4-23  Tumor multiplicity is slightly increased in the mucolytic treated AOM/DSS group.  
C57BL/6 females (n=10) aged 8 weeks were treated with azoxymethane (AOM). After 7 days control groups 
received respectively nothing and NAC 1% in drinking water (groups AOM and NAC). Two cohorts received 
dextran sodium sulphate (DSS) 2% in drinking water for 7 days (AOM/DSS and AOM/DSS NAC). Both 
groups were allowed for recovery for 14 days but while group AOM/DSS received water upon DSS stop, 
group AOM/DSS NAC received NAC 1%. This schedule was repeated for 3 cycles.  At the end of the 
experiment tumor multiplicity in the colon was assessed.  Graphs show mean  ± SEM.  n=10. 
 
 
Figure 4-24  Mucolytic treatment increases the number of adenocarcinoma lesions in the AOM/DSS 
model.  C57BL/6 females (n=10) aged 8 weeks were treated with azoxymethane (AOM). After 7 days 
control groups received respectively nothing and NAC 1% in drinking water (groups AOM and NAC). Two 
cohorts received dextran sodium sulphate (DSS) 2% in drinking water for 7 days (AOM/DSS and AOM/DSS 
NAC). Both groups were allowed for recovery for 14 days but while group AOM/DSS received water upon 
DSS stop, group AOM/DSS NAC received NAC 1%. This schedule was repeated for 3 cycles.  At day 70 
mice were sacrificed and histological parameters evaluated in the colon. Panels show colitis grade, 
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ulcerative lesions, dysplastic glands and polypoid adenoma/adenocarcinoma lesions as detected by 
histological evaluation.  Graphs show mean  ± SEM.  n=10.  * p<0,05; ** p<0,01; *** p<0,001. 
 
4.4.3 Mucolytic treatment slightly alters mucin expression and does not 
modify mucus sulphonation status 
Having observed that mucolytic treatment exacerbates colonic tumorigenesis in the 
AOM/DSS model we wondered what specific alteration in the mucus barrier were elicited 
by this treatment.  To this end we treated C57BL/6 mice with plain water or NAC1% for 
four consecutive weeks and addressed mucin expression both in the small intestine and 
colon of these mice.  RT-qPCR assay in the small intestine and colon revealed no major 
changes in the expression level of the mucins analysed (Figure 4-25, Figure 4-26).  
However, interestingly, we observed a slight reduction in Muc13 and increase in Muc20 
expression (Figure 4-25) similarly to what we observe in the ApcMin/+ ilei (Figure 4-6).  In 
the colon we observed a tendency towards an increase in both Muc13 and Muc20 and a 
slight reduction in Muc3 expression level (Figure 4-26). 
 
 
Figure 4-25  Mucolytic treatment slightly modifies mucin expression in the ileum.  C57BL/6 mice were 
treated either with plain water (H2O) or with NAC 1% (NAC) in drinking water for four weeks.  Expression 
levels for Muc1, Muc2, Muc3, Muc13 and Muc20 were evaluated by RT-qPCR assay on ileal tissue.  
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Figure 4-26  Mucolytic treatment slightly modifies mucin expression in the colon.  C57BL/6 mice were 
treated either with plain water (H2O) or with NAC 1% (NAC) in drinking water for four weeks.  Expression 
levels for Muc1, Muc2, Muc3, Muc13 and Muc20 were evaluated by RT-qPCR assay on colon tissue.  
Expression levels are normalized to Rpl32.  n=5.  Graphs show mean ± SEM. 
 
We next addressed whether mucus sulphonation status could be altered by mucolityc 
treatment.  AB/HID staining on ileal and colonic sections of mice treated or not with NAC 
1% showed no major differences in sulphonation level (Figure 4-27, Figure 4-28).  
However the AB staining clearly showed that NAC 1% treatment is effective in reducing 
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Figure 4-27  Mucolytic treatment does not alter sulphonation level in the small intestine.  C57BL/6 
mice were treated either with plain water (H2O) or with NAC 1% (NAC) in drinking water for four weeks.  4 
µm ileal sections were stained with AB/HID.  Blue: sialomucins, black: sulphomucins.  Representative 
pictures are shown. 
 
 
Figure 4-28  Mucolytic treatment does not alter sulphonation level in the colon.  C57BL/6 mice were 
treated either with plain water (H2O) or with NAC 1% (NAC) in drinking water for four weeks.  4 µm colon 
H2O NAC
H2O NAC
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4.5 Dysbiosis is an early event associated with intestinal 
tumorigenesis 
4.5.1 Metagenomic analysis reveals dysbiosis in young ApcMin/+ mice 
Increasing evidence is mounting of the involvement of the microbiota in intestinal 
tumorigenesis (Zhu et al., 2013) and sequencing analysis on hCRC patients shows 
alterations of the microbial community associated with the tumor (Kostic et al., 2013).  
However a clear view of the microbial alterations occurring during tumorigenesis has not 
yet emerged, probably due to the heterogeneity of the samples analysed.  Moreover 
studies on hCRC samples give a snapshot of the microbial community once the tumor 
has established, but they do not allow the identification and characterization of the 
moment of dysbiosis onset nor the dissection of the functional meaning of this for the 
tumorigenic process.  As a matter of fact dysbiosis might only be a consequence of 
tumor formation and studies in the human system allow limited insight in the cause-effect 
relationships contributing to disease onset. 
To get an insight in the microbiota dynamics during tumorigenesis we performed 
metagenomic analysis on ApcMin/+ mice in a time course experiment.  We collected fecal 
material from WT littermates and ApcMin/+ mice at 4, 8, 12 and 16 weeks of age and 
sequenced the V5-V6 hypervariable regions of bacterial 16S rDNA.  ApcMin/+ mice were 
separated from WT littermates at 6 weeks of age to avoid microbiota exchange due to 
cohousing. 
Richness and diversity indexes were calculated on both families and genera using 
different algorithms (Figure 4-29, Figure 4-30).  The Chao1 index is a richness estimator.  
Our data showed that richness is comparable between WT and ApcMin/+ mice both at 
family and genera level at all time points considered (Figure 4-29, Figure 4-30).  
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Shannon and Simpson indexes are diversity indexes that consider both richness and 
evenness within the population analysed.  Shannon and Simpson diversity indexes 
calculated on both families and genera did not highlight differences between WT and 
ApcMin/+ mice (Figure 4-29, Figure 4-30).  This underlines that the ApcMin/+ microbiome is 
comparable to the WT one in terms of richness and diversity over the time frame 
characterized by the onset and establishment of the tumorigenic process. 
 
 
Figure 4-29  Diversity indexes relative to families.  Metagenomic sequencing was performed on fecal 
samples from WT and ApcMin/+ mice at 4, 8, 12 and 16 weeks of age. Chao, Shannon and Simpson diversity 
indexes relative to families are shown.  n=8.  Graphs show 5-95 percentile. 
 
 
Figure 4-30  Diversity indexes relative to genera.  Metagenomic sequencing was performed on fecal 
samples from WT and ApcMin/+ mice at 4, 8, 12 and 16 weeks of age. Chao, Shannon and Simpson diversity 
indexes relative to genera are shown.  n=8.  Graphs show 5-95 percentile. 
 
We then analysed genus abundance variations over the different time points tested 
(Figure 4-31).  The results showed that ApcMin/+ mice are characterized by a dysbiosis 
arising at very early time points.  In fact ApcMin/+ mice have an increase in Lactobacillus 
and a contraction in Clostridium already at 4 weeks of age (Figure 4-31).  The same 
pattern is maintained at 8 and 12 weeks of age (Figure 4-31).  At 16 weeks of age this 
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trend is inverted and Lactobacillus genus becomes less represented and Clostridium 
genus more represented in ApcMin/+ mice compared to WT (Figure 4-31).  This could be 
explained by the appearance at this late time point of symptoms related to tumorigenesis 
such as intestinal bleeding that could alter the luminal microenvironment and as a 
consequence the microbial community. 
Appendix1 lists the principal genera identified by metagenomic sequencing and their 
statistical variation at the different time points analysed. 
 
 
Figure 4-31  Genus abundance in WT and ApcMin/+ mice.  Metagenomic sequencing was performed on 
fecal samples from WT and ApcMin/+ mice at 4, 8, 12 and 16 weeks of age.  Genus abundance at the 
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4.5.2 Clostridium ID4 is underrepresented in ApcMin/+ fecal and mucus-
associated microbiome 
We then compared metagenomic data of WT and ApcMin/+ mice over the different time 
points to identify differences at the OTU level.  We found that the species Clostridium 
ID4 is underrepresented in ApcMin/+ samples at 8 and 12 weeks of age (Figure 4-32).  
Clostridium ID4 abundance was statistically reduced in ApcMin/+ fecal samples when 
considering the normalised number of assigned sequences from the metagenomic 
analysis (Figure 4-32 A).  These data were validated with qPCR assay using C. ID4 
specific primers (Figure 4-32 B).  As observed before for the Clostridium genus (Figure 
4-31) also C. ID4 abundance dramatically increased at 16 weeks of age (Figure 4-32). 
 
 
Figure 4-32  Clostridium ID4 abundance in WT and ApcMin/+ mice.  DNA was extracted from faeces of 
WT and ApcMin/+ mice at 4, 8 and 12 weeks of age.  Graphs show the A. normalised number of assigned 
sequences in the metagenomic analysis and B. as detected by qPCR valiation assay (left panel).  C. ID4  
abundance levels detected by qPCR levels are normalized to Eubacteria (EUB). Graphs show mean ± SEM.  
n=8.  * p<0,05.  **p<0,01.  ***p<0,001. 
 
Since the mucus constitutes a homing niche to many intestinal microorganisms (Derrien 
et al., 2010; Johansson et al., 2008; Ouwerkerk et al., 2013) we addressed whether the 
variation of C. ID4 observed at fecal level was present also in the mucus-associated 
community (Figure 4-33).  DNA was extracted from faeces and scraped mucus from both 
the small intestine and colon of WT and ApcMin/+ mice at 4, 8 and 12 weeks of age.  C. 
ID4 abundance was evaluated by qPCR assay.  Interestingly we found that the depletion 
of C. ID4 that we observed at 8 and 12 weeks of age at the fecal level parallels with a 
Clostridium  ID4
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reduction also at the level of mucus-associated bacteria (Figure 4-33).  These results 
show that as far as Clostridium ID4 abundance is concerned we can consider the 
dynamics observed in the faeces representative of the mucus-associated community. 
In this experiment C. ID4 level was slightly but not significantly reduced in fecal and 
mucus samples from ApcMin/+ mice at 8 weeks of age (Figure 4-33), while in the previous 
experiment it was significantly depleted by that time point (Figure 4-32).  This could be 
explained by the fact that in this second experiment ApcMin/+ mice were separated from 
WT littermates at a later time point, namely 7 weeks of age, allowing microbiota 
exchange for a longer time. 
 
 
Figure 4-33  Clostridium ID4 abundance is altered also in the mucus-associated community.  DNA 
was extracted from faeces and mucus scraped from the small intestine and colon of WT and ApcMin/+ mice at 
4, 8 and 12 weeks of age.  C. ID4 abundance was assessed by qPCR.  C. ID4 abundance levels are 
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4.6 Clostridium ID4 effects on the intestinal immune system and on 
intestinal tumorigenesis 
There is mounting evidence regarding the involvement of specific components of the 
endogenous microbiota in the differentiation of immune cell subsets in the intestinal 
microenvironment (Atarashi et al., 2013; Atarashi et al., 2011a; Ivanov et al., 2009; 
Ivanov et al., 2008).  In particular Clostridium species belonging to Clostridial groups IV, 
XIVa and XVIII have been functionally linked to the development of IL10 producing 
FoxP3 Treg cells in the colonic lamina propria (Atarashi et al., 2013; Atarashi et al., 
2011a).  Having observed that ApcMin/+ mice display depletion in one Clostridium 
species, namely Clostridium ID4, we addressed the effect of C. ID4 on the intestinal 
immune system development with monocolonization experiments in germ free mice and 
on the tumorigenic process with exogenous administration experiments in the ApcMin/+ 
model. 
 
4.6.1 Clostridium ID4 effects on intestinal immune system development 
To address the effect of Clostridium ID4 on the intestinal immune system development 
germ free ICR mice were monocolonized with C. ID4.  Five weeks after gnotobiotic 
transfer the abundance of Tregs, IL17 and IFNγ producing cells in the small intestinal 
and colonic lamina propria was evaluated by flow cytometry (Figure 4-34, Figure 4-35, 
Figure 4-36).  Germ free and SPF mice were analysed as controls.  C. ID4 colonization 
did not alter the abundance of Treg cells in the SI lamina propria compared to germ-free 
mice (Figure 4-34).  In the colon on the contrary mice monocolonized with C. ID4 had 
increased Tregs compared to germ free mice, even if these were still significantly lower 
than SPF mice (Figure 4-34).  As far as Th17 cells are concerned C. ID4 significantly 
increased the SI lamina propria Th17 population, even if the levels are lower compared 
to SPF mice, while having no effect on colonic Th17 or on IL17 producing cells in the 
CD8 subset (Figure 4-35).  No major differences were observed in the IFNγ producing 
CD4 and CD8 populations in C. ID4 monocolonized mice (Figure 4-36).  Clostridium ID4 
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monocolonization shows thus a partial effect in the expansion of colonic Treg cells and 
small intestinal Th17 cells. 
 
 
Figure 4-34  Clostridium ID4 administration slightly increases colonic Treg population.  Germ free 
ICR mice were administered with C. ID4.  5 weeks later the small intestinal (SILP) and colonic lamina propria 
(CLP) of germ free (GF), C. ID4 monocolonized (GF + ID4) and SPF mice was analysed by flow cytometry 




Figure 4-35  Clostridium ID4 administration increases small intestinal Th17 population.  Germ free 
ICR mice were administered with C. ID4.  5 weeks later the small intestinal (SILP) and colonic lamina propria 
(CLP) of germ free (GF), C. ID4 monocolonized (GF + ID4) and SPF mice was analysed by flow cytometry 
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Figure 4-36  Clostridium ID4 administration has no effect on INFγ producing cells.  Germ free ICR 
mice were administered with C. ID4.  5 weeks later the small intestinal (SILP) and colonic lamina propria 
(CLP) of germ free (GF), C. ID4 monocolonized (GF + ID4) and SPF mice was analysed by flow cytometry 
for the presence of INFγ+ cells in the CD4 and CD8 subsets.  Graphs show mean ± SEM.  n=3/5.  * p<0,05.  
** p<0,01.  *** p<0,001 
 
4.6.2 Clostridium ID4 effects on intestinal tumorigenesis 
Metagenomic data and qPCR experiments showed that Clostridium ID4 is depleted in 
ApcMin/+ mice in the time frame characterized by the onset of tumorigenesis (Figure 4-32 
Figure 4-33).  Having observed that monocolonization with C. ID4 partially increased the 
small intestinal Th17 population (Figure 4-35) and the colonic Treg population (Figure 
4-34) and given the pro-tumorigenic role of the first population (Chae et al., 2010; 
Grivennikov et al., 2012; Song et al., 2014) and the controversial role of the second 
(Blatner et al., 2012; Gounaris et al., 2009; Keerthivasan et al., 2014) in the context of 
tumorigenesis  we addressed the effect of exogenous re-colonization of ApcMin/+ mice 
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with C. ID4.  To this aim WT and ApcMin/+ mice were administered twice a week with C. 
ID4 from 6 to 12 weeks of age.  C. ID4 abundance in the faeces was assessed over the 
course of the experiment demonstrating that exogenous administration increased C. ID4 
levels in the faeces of ApcMin/+ mice even if these levels were lower than those observed 
in WT mice (Figure 4-37).  Of note, C. ID4 levels in treated ApcMin/+ mice were not 
significantly higher than in vehicle treated ApcMin/+ mice (Figure 4-37), meaning that 
probably the bacterium does not find its niche in the ApcMin/+ intestinal microenvironment.  
At 12 weeks of age mice were sacrificed and tumor multiplicity in the small intestine and 
colon assessed (Figure 4-38).  C. ID4 treatment did only slightly alter the polyp number 
in the small intestine while having no effect in the colon (Figure 4-38). 
 
 
Figure 4-37  Clostridium ID4 abundance in the faeces of WT and ApcMin/+ mice treated with vehicle or 
C. ID4.  WT and ApcMin/+ mice received either vehicle or C. ID4 (ID4) from 6 to 12 weeks of age.  C. ID4 
abundance in the faeces was assessed by qPCR.  C. ID4 abundance levels are normalized to Eubacteria 
(EUB). Graphs show mean ± SEM.  n=5.  * p<0,05. 
 
 
Figure 4-38  Tumor multiplicity in Clostridium ID4 treated ApcMin/+ mice.  ApcMin/+ mice received either 
vehicle or C. ID4 (ID4) from 6 to 12 weeks of age.  At 12 weeks of age mice were sacrificed and tumor 
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Unpublished data from our laboratory show that high levels of neutrophils correlate with 
tumor number in the ApcMin/+ model (Guglietta S., unpublished).  We therefore analysed 
the abundance of inflammatory monocytes and neutrophils in WT and ApcMin/+ mice 
treated either with vehicle or C. ID4 at the 12th week of age (Figure 4-39).  Both 
inflammatory monocytes (Ly6Chigh) and circulating neutrophils (Ly6G+ CD11b+) levels 
were not altered in C. ID4 treated ApcMin/+ mice compared to vehicle treated ones (Figure 
4-39).  However C. ID4 administration reduced the level of circulating Ly6Chigh and in 
part neutrophils in WT mice (Figure 4-39). 
 
 
Figure 4-39  Inflammatory monocytes and neutrophil abundance in WT and ApcMin/+ mice treated with 
vehicle or C. ID4.  WT and ApcMin/+ mice received either vehicle or C. ID4 (ID4) from 6 to 12 weeks of age.  
At 12 weeks of age the percentage of inflammatory monocytes (left panel: Ly6Ghigh cells in the CD45+ CD3- 
gate) and neutrophils (right panel: Ly6G+ CD11b+ cells in the CD45+ CD3- gate) was assessed by flow 
cytometry.  Graphs show mean ± SEM.  n=5.  * p<0,05. 
 
Since Clostridia have been related to the differentiation of specific immune cell 
populations in the intestine (Atarashi et al., 2013; Atarashi et al., 2011a) we analysed the 
abundance of Tregs and IL17 or INFγ producing T cells in the small intestinal and 
colonic lamina propria of WT and ApcMin/+ mice treated or not with Clostridium ID4 
(Figure 4-40, Figure 4-41, Figure 4-42). 
As far as the Treg population is concerned we observed that overall ApcMin/+ mice have 
slightly higher nTregs (Helios+) in the small intestinal lamina propria compared to WT 
mice, independently of the treatment (Figure 4-40).  C. ID4 treatment induced little 
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Figure 4-40  T regulatory cells in the small intestine and colon of WT and ApcMin/+ mice treated with 
vehicle or Clostridium ID4.  WT and ApcMin/+ mice received either vehicle or C. ID4 (ID4) from 6 to 12 
weeks of age.  At 12 weeks of age cells were isolated from the small intestinal and colonic lamina propria 
and the percentage of FoxP3+ CD25+ cells (within the CD3+ CD4+ population) and Helios+ and Helios- 
cells (within the FoxP3+ CD25+ population) evaluated by flow cytometry.  Graphs show mean ± SEM.  n=5. 
 
Analysis of the IL17 and IFNγ producing cells within the CD3+ CD4+ T helper subset did 
not point out differences elicited by C. ID4 treatment (Figure 4-41).  However, 
irrespective of the treatment we observed higher IL17+ T helper cells in the small 
intestine of ApcMin/+ mice compared to WT mice (p=0,026) (Figure 4-41).  We did not 
observe differences in the CD8 compartment between vehicle and C. ID4 treated mice, 
nor between WT and ApcMin/+ mice (Figure 4-42). 
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Clostridium ID4 exogenous administration is in conclusion producing no major effect on 
the abundance of Tregs and IL17 and IFNγ producing cells in the small intestine and 
colon of both WT and ApcMin/+ mice. 
 
Figure 4-41  IL17 and IFNγ producing T helper cells in the small intestine and colon of WT and 
ApcMin/+ mice treated with vehicle or Clostridium ID4.  WT and ApcMin/+ mice received either vehicle or C. 
ID4 (ID4) from 6 to 12 weeks of age.  At 12 weeks of age cells were isolated from the small intestinal and 
colonic lamina propria and restimulated in vitro with PMA and ionomycin in the presence of GolgiStop.  The 
percentage of IL17+ and IFNγ+ cells (within the CD3+ CD4+ population) evaluated by flow cytometry.  
Graphs show mean ± SEM.  n=5. 
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Figure 4-42  IL17 and IFNγ producing CD8+ T cells in the small intestine and colon of WT and ApcMin/+ 
mice treated with vehicle or Clostridium ID4.  WT and ApcMin/+ mice received either vehicle or C. ID4 
(ID4) from 6 to 12 weeks of age.  At 12 weeks of age cells were isolated from the small intestinal and colonic 
lamina propria and restimulated in vitro with PMA and ionomycin in the presence of GolgiStop.  The 
percentage of IL17+ and IFNγ+ cells (within the CD3+ CD8+ population) evaluated by flow cytometry.  
Graphs show mean ± SEM.  n=5. 
 
We did perform correlation analysis to highlight relations among the different parameters 
evaluated in the experiment.  Interestingly, we found that C. ID4 abundance in the 
faeces at 12 weeks inversely correlates with the tumor number in the small intestine, 
with mice having very low C. ID4 levels displaying the highest number of polyps in the SI 
(Figure 4-43).  Moreover fecal C. ID4 levels at the 12th week of age is also positively 
correlated with Tregs abundance in the SI (Figure 4-43).  Of note, both these 
correlations were found in the vehicle treated ApcMin/+ group, pointing to a physiological 








































	   98	  
 
 
Figure 4-43  Correlation between Clostridium ID4 abundance at 12 weeks and tumor number and T 
regulatory cells in the small intestine.  C. ID4 adundance in the faeces at 12 weeks of age was correlated 
with tumor multiplicity in the small intestine and with the percentage of Treg cells in the small intestine.  Both 
correlations were done for the vehicle treated ApcMin/+ group.  R2 and p value for each correlation are shown. 
 
 
4.7 miRNA profile is altered in ApcMin/+ intestine 
The mechanism through which the expression of the wild type apc allele is lost leading to 
polyposis in FAP and in ApcMin/+ mice is classically described as loss of heterozygosity, 
meaning the loss of the entire genetic locus comprising the allele of interest.  In the last 
years this hypothesis has been challenged (Amos-Landgraf et al., 2012), arguing that 
epigenetic mechanisms might be involved in the loss of expression of the normal allele. 
Since we observe that tumor bearing mice have a different microbiota compared to WT 
mice already at young age and given that bacteria are potent modulators of miRNA 
expression (Takahashi, 2014; Yang et al., 2013)(Saccheri F., unpublished) we 
investigated the possibility of miRNA being involved in the regulation of the apc pathway.  
We performed miRNA profiling of single crypts isolated by laser-assisted microdissection 
from wild type ilei (WT) and from normal (N) and dysplastic (D) crypts of ApcMin/+ mice 
(Figure 4-44) and compared miRNA expression levels of WT vs. N crypts and D vs. N 
crypts applying a 10-fold change cut-off.  We found that in ApcMin/+ normal crypts 17 
miRNAs were up-regulated while 35 were down-regulated compared to wild type ones, 
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Figure 4-44 miRNA expression is deregulated in ApcMin/+ intestines.  RNA was extracted from single 
crypts isolated with laser-assisted microdissection from wild type mice (WT) and from normal (N) and 
dysplastic (D) crypts of ApcMin/+ mice at 16 weeks of age.  miRNA expression in WT vs. N and D vs. N is 
shown.  A cut-off of 10-fold was used. 
 
Studies in the human system have demonstrated that hsa-miR-135a/b are involved in 
the regulation of human apc gene (Nagel et al., 2008).  Interestingly we observed that 
mmu-miR-135a/b were upregulated in dysplastic crypts of ApcMin/+ mice (Figure 4-45).  
However an analysis of the predicted miRNA binding sites in the 3’ UTR of murine apc 
gene using TargetScanMouse program (release 5.2) did not highlight putative mmu-miR-
135a/b binding sites.  However, among the miRNAs that were differentially expressed in 
normal or dysplastic ApcMin/+ crypts some had as putative targets molecular components 
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Figure 4-45  mmu-miR-135a/b are upregulated in ApcMin/+ dysplastic crypts.  RNA was extracted from 
single crypts isolated with laser-assisted microdissection from wild type mice (WT) and from normal (N) and 
dysplastic (D) crypts of ApcMin/+ mice at 16 weeks of age.  Expression levels of miR-135a (left) and miR-135b 
(right) are shown as fold change relative to WT and N respectively. 
 
Preliminary data produced in our laboratory demonstrate that bacterial stimuli, namely 
Salmonella, can modulate mi-RNA expression in the B16 murine melanoma cell line 
(Saccheri F., unpublished).  Having observed both a dysbiosis and deregulation in mi-
RNA expression in the ApcMin/+ model we addressed whether bacterial stimuli could be 
involved in the modulation of apc gene expression (Figure 4-46).  We stimulated WT or 
ApcMin/+ colonic mucosa using an ex-vivo organ culture protocol developed in our 
laboratory (Tsilingiri et al., 2012; Tsilingiri et al., 2013) that allows polarized stimulation of 
the intestinal mucosa.  Colonic mucosa was stimulated with either non-invasive or 
invasive Salmonella strains.  However we did not observe any changes in apc gene 
expression in the WT or ApcMin/+ colonic tissue stimulated with either Salmonella strains 
(Figure 4-46).  We stimulated the colonic mucosa also with E. coli as to mimic 
stimulation with a member of the endogenous microbiota.  However stimulation of WT 
and ApcMin/+ mucosa with either non-invasive or invasive E. coli strains did not cause 
major alterations in apc expression (Figure 4-46). 
 
 
Figure 4-46  Bacterial stimulation does not alter apc gene expression in WT and ApcMin/+ colon.  WT 
and ApcMin/+ colonic mucosa was stimulated for 2 hours with 102 CFUs of non-invasive or invasive 
Salmonella and non invasive or invasive E. coli (E. coli DH5a and E. coli DH5a pInv).  After 24 hours 




















	   101	  
expression level was normalized to Rpl32 and expressed as fold increase relative to not infected sample 
(NI).  Graphs show mean ± SEM.  n=4/5.
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4 weeks 8 weeks 12 weeks 16 weeks 
Genus WT Apc p value WT Apc p value WT Apc p value WT Apc p value 
Lactobacillus 70,39 79,75 0,0590 39,84 49,94 0,3554 40,12 62,01 0,0243 40,01 28,55 0,3398 
Clostridium 13,76 8,93 0,1438 31,13 20,97 0,3540 45,01 13,95 0,0010 36,38 46,21 0,3281 
Mucispirillum 4,66 1,86 0,1524 3,89 2,46 0,5634 1,92 6,77 0,2232 3,40 3,39 0,9993 
Bacteroides 2,54 2,01 0,5924 5,02 8,52 0,3746 1,43 4,07 0,0841 1,71 6,68 0,0322 
Alistipes 2,75 2,19 0,5102 10,55 8,07 0,2593 4,96 4,82 0,8848 6,78 7,05 0,9105 
Candidatus 
Arthromitus 
1,59 1,81 0,7571 0,19 0,60 0,0671 0,02 0,11 0,2402 0,00 0,55 0,1299 
Ruminococcus 0,64 0,24 0,0945 3,90 2,58 0,2676 2,05 1,71 0,5845 2,68 1,84 0,2573 
Eubacterium 0,56 0,94 0,4919 1,40 1,47 0,9284 1,05 2,77 0,4279 1,84 1,05 0,5153 
Appendix 1  Genus abundance in WT and ApcMin/+ mice.  The table shows the relative abundance of the principal genera in WT and ApcMin/+ metagenomic data at 4, 8, 12 and 
16 weeks of age.  Abundance is shown as percentage.  The p value for the comparison WT vs. ApcMin/+ within the same time point is shown.  Red values are p<0,05. 
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5 DISCUSSION 
 
The microbiota is the ensemble of the microorganisms living in symbiosis with the 
human body.  The study of this complex community and of its interactions with the host 
has in recent years attracted the attention of the scientific community and the interplay 
between the host and its microbiota has been demonstrated to be so mutualistic that the 
communion of the two has been described as a superorganism (Eberl, 2010). 
The stage on which the interactions between the host and the intestinal microbial 
community do take place is the intestinal barrier (Hooper and Macpherson, 2010).  A 
fundamental component of this barrier is the mucus layer that acts both as a niche to 
commensal microorganisms and as a mechanism of defence against invading 
pathogens (McGuckin et al., 2011).  Alterations in both the mucus and the intestinal 
microbiota have been described in numerous pathological conditions, among which 
colorectal cancer (Honda and Littman, 2012; Sheng et al., 2012) (Sears and Garrett, 
2014; Zhu et al., 2013).  In particular studies on hCRC patients highlight alterations in 
the mucus barrier at the level of mucin expression and glycosylation (Sheng et al., 2011) 
and alterations in the intestinal microbial community, such as the increase in 
Fusobacterium nucleatum observed in the tumor tissue compared to the healthy one 
(Kostic et al., 2012).  However, although these and other studies on hCRC patients have 
been fundamental in the dissection of the alterations associated with CRC, they do not 
allow dissection of the timing of the onset of these alterations and their cause-effect 
relationships.  For this reason we employ here murine models of intestinal tumorigenesis 
to dissect how alterations in the intestinal mucus barrier and dysbiosis are 
interconnected during tumor progression. 
 
	   104	  
5.1 The mucus barrier is altered in murine models of intestinal 
tumorigenesis 
The mucus is a fundamental but often neglected component of the intestinal barrier.  
Different studies in murine models show its fundamental role in the interaction with the 
endogenous microflora.  Muc2-/- and Muc13-/- mice are more susceptible to experimental 
colitis (Sheng et al., 2011; Van der Sluis et al., 2006).  On the contrary, Muc1-/- mice are 
protected from colitis (Petersson et al., 2011).  Interestingly Muc2-/- mice do also 
spontaneously develop colon cancer (Velcich et al., 2002).  All of these studies underline 
the importance of a proper mucus barrier for intestinal homeostasis.  As a matter of fact 
alterations in the mucus layer are documented in IBD and CRC (Sheng et al., 2012). 
The ApcMin/+ murine model is widely employed as model for human FAP (Moser et al., 
1990).  We used this model to demonstrate that in tumor-bearing mice, similarly to what 
happens in the human pathology, the mucus has altered properties.  In particular the 
expression level of mucins that are normally expressed at low levels or not expressed in 
the intestine increases (e.g. Muc1, Muc20 and Muc5ac) while the expression of those 
mucins that are gut-specific (e.g. Muc3 and Muc13) decreases.  These alterations are 
predominant in the small intestine of ApcMin/+ mice, that is the intestinal segment most 
interested by the polyposis, while in the colon they are less evident.  Alterations in mucin 
expression start arising early during tumorigenesis (e.g. 10 weeks), even though they 
become striking at late stages of the disease.  Going deeper we observed that mucin 
expression is altered already at the level of single dysplastic crypts, strictly relating 
changes in the mucus with neoplastic transformation.  Much of the alterations we 
observe in our murine model parallel the hCRC situation.  For example the increased 
expression of MUC1 has from long been associated with intestinal adenocarcinomas 
(Ajioka et al., 1996) and MUC5AC is ectopically expressed in mucinous colorectal 
cancers (Park et al., 2008).  High Muc20 expression levels are associated with 
recurrence and poor prognosis in CRC patients and its overexpression enhances 
malignant phenotype in vitro (Xiao et al., 2013).  Interestingly, a recent work focusing on 
human small bowel cancer reported increased Muc1 and Muc5ac expression, with the 
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latter correlating with poor disease outcome (Shibahara et al., 2014).  However, 
contrarily to what we do observe in our murine model, Muc13 overexpression is reported 
to correlate with malignancy in hCRC (Gupta et al., 2012). 
Regarding aberrancies at the level of mucin post-translational modifications we did not 
observe differences in glycosylation as far as sulfomucin abundance is concerned.  
However, if on one hand we detected sulphonation signal in the colon of WT and ApcMin/+ 
mice as reported in the human large bowel (Matsuo et al., 1997) we barely detected any 
signal in the small intestine even in WT mice.  Given that the small intestine is the site 
most interested by tumorigenesis in the ApcMin/+ model there could be alterations in other 
mucin post-traslational modifications that we did not consider in this work, such as 
fucosylation that has very recently been shown to regulate host-microbiota interaction 
upon TLR stimulation through ILC3 produced IL22 (Goto et al., 2014a; Pickard et al., 
2014). 
Interestingly, exogenous disruption of the mucus layer using the mucolytic N-acetyl 
cysteine (NAC) does not alter mucin expression in WT mice.  These data concomitantly 
to the previously presented ones open the way to the hypothesis that apc mutation is 
needed for mucin expression alterations in the ApcMin/+ model. 
We have thus shown that the ApcMin/+ model shows alterations at the level of mucin 
expression and many of these parallel what is reported for hCRC. 
 
5.2 The intestinal barrier is altered upon tumorigenesis 
Being the mucus a fundamental albeit often ignored component of the intestinal barrier 
we addressed whether bacterial penetrance was altered in tumor-prone mice.  Barrier 
properties towards an enteric pathogen such as Salmonella typhimurium are altered in 
ApcMin/+ mice, in that higher bacterial loads are retrieved from the small intestine, polyps 
and mLNs if compared to WT littermates.  Since we observe similar results with a non-
invasive Salmonella strain and given the comparable bacterial spreading that we 
observe when mice are challenged via the intravenous route we interpret these data as 
supporting the evidence of altered intestinal barrier properties in tumor-prone murine 
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models.  This is in accordance with the work of Grivennikov and colleagues that show 
increased colonic permeability to FITC-dextran and bacterial products in a model of APC 
driven intestinal tumorigenesis (Grivennikov et al., 2012).  In the same work the authors 
observe altered Muc2 and barrier protein expression in the tumor (Grivennikov et al., 
2012).  So neither our data nor Grivennikov and colleagues allow discrimination between 
the contribution of epithelial barrier or mucus layer in the alteration of the intestinal 
barrier properties upon tumorigenesis.  However the use in this work of Salmonella, a 
bacterium that is able to interact with the mucus (McCormick et al., 1988; Nevola et al., 
1987; Vimal et al., 2000) to investigate intestinal permeability could allow the detection of 
differences due to the diversity of the mucus barrier in tumor bearing mice.  This is 
further supported by results obtained with the non-invasive strain that has impaired 
ability to invade the epithelium but is hypothetically identical in mucus-binding properties. 
 
5.3 Mucus disruption exacerbates intestinal tumorigenesis 
Since mucus alterations are documented in hCRC and here shown to occur also in a 
murine model we addressed the functional meaning of this by exogenously altering the 
mucus layer in murine models of intestinal tumorigenesis. 
Many commensal microorganisms and enteric pathogens bind to mucins and express 
mucin-degrading enzymes that degrade the mucus barrier using it as nutrient source and 
allowing access to the epithelium (Derrien et al., 2010; Ouwerkerk et al., 2013).  
Salmonella is one of these microorganisms (McCormick et al., 1988; Nevola et al., 1987; 
Vimal et al., 2000).  Hence we used it to see whether a mucus-degrading bacterium 
could alter tumorigenesis in the ApcMin/+ model.  We did indeed observe an increase in 
colonic tumorigenesis while we detected no difference in the small intestine.  This can be 
interpreted in two ways.  On one hand Salmonella, especially in streptomycin pretreated 
mice, has a preferential tropism for the terminal ileum and large intestine (Barthel et al., 
2003) and as a consequence these could be the sites where it colonizes and acts most 
effectively.  On the other hand, since polyposis penetrance is maximal in the small 
intestine in the ApcMin/+ model, in this district the phenomenon could be at saturation not 
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allowing detection of differences at the late time point analysed (16 weeks).  However, 
we cannot exclude that the increase of colonic tumors observed here is due to colitis 
inducing effect of Salmonella, similarly to what is observed in ApcMin/+ mice infected with 
Citrobacter rodentium (Newman et al., 2001).  Of note, also in the case of C. rodentium 
infected ApcMin/+ mice the increase in polyposis is observed in the colon and not in the 
small intestine (Newman et al., 2001). 
The second approach employed here to disrupt the mucus barrier is through the use of 
the mucolytic agent N-acetyl cysteine (NAC).  We analysed in this case the AOM/DSS 
model of chemically induced colitis associated colonic carcinogenesis coupled or not 
with NAC treatment.  Treatment with the mucolytic agent exacerbated tumorigenesis 
increasing the number of adenocarcinoma lesions in the colon.  DSS is a colitis inducing 
agent that causes epithelial disruption (Perse and Cerar, 2012).  For this reason it is 
used as a promoter agent in different intestinal tumorigenesis models, such as 
AOM/DSS (Neufert et al., 2007), and has been shown to induce colonic tumorigenesis in 
the genetically driven ApcMin/+ model (Tanaka et al., 2006).  However we show here that 
treatment with NAC, that does not induce epithelial damage nor inflammation, has an 
effect in increasing the number of adenoma and carcinoma lesions found in the colon 
underlining the role of mucus disruption in the exacerbation of intestinal tumorigenesis. 
 
5.4 Dysbiosis arises early during tumor progression 
The mucus is fundamental in maintaining homeostasis between the host and the 
microbiota in that it serves as a niche for commensals that colonize it (Johansson et al., 
2008) and get nutrients from it (Derrien et al., 2010).  Alterations in the mucus as the 
ones that we do observe in the ApcMin/+ model could then lead to alterations in the 
microbial community inhabiting it.  The alteration of the microbial community homing a 
specific niche is termed dysbiosis.  This phenomenon is well documented in hCRC and 
numerous efforts are trying to link this to CRC pathogenesis itself (Arthur and Jobin, 
2013; Zhu et al., 2013).  However, only very few cases functionally linking microbial 
alterations to tumorigenesis have been reported to date.  Seminal works by Kostic and 
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colleagues identified enrichment in Fusobacterium nucleatum in the tumor samples 
compared to matched controls and further proved the ability of this particular species to 
induce both small intestinal and colonic tumorigenesis in the ApcMin/+ model (Kostic et al., 
2013; Kostic et al., 2012). 
We analysed dysbiosis occurrence in the ApcMin/+ model to address the time frame 
interested by its onset, something that is not possible to dissect in the human system.  
We performed metagenomic analysis in the faeces of wild type and ApcMin/+ mice at 
different ages (and hence stages of tumor development) to see whether we do observe a 
dysbiosis in our murine model and when it is arising.  Interestingly we found that the 
microbiota composition of ApcMin/+ mice is altered already at 4 weeks, an age at which 
the mice are completely tumor-free and are still cohoused with WT littermates.  In 
particular, we observed an expansion of the Lactobacillus genus in ApcMin/+ mice at 4, 8 
and 12 weeks of age, concomitantly with a contraction in the Clostridium genus.  At 16 
weeks this trend was inverted.  This is possibly explained by the emergence of 
secondary symptoms of the disease, such as intestinal bleeding, that may alter the gut 
microenvironment.  The finding that Clostridia are underrepresented in ApcMin/+ mice 
already at young age is of particular interest since the presence of these bacteria has 
been associated to the differentiation of functional T regulatory cells in the intestine 
(Atarashi et al., 2013; Atarashi et al., 2011a).  Absence of Clostridia could explain the 
aberrant Treg functionality observed by Gounaris et al. in the ApcΔ468/+ murine model 
(Gounaris et al., 2009). 
Hence, differential abundance of bacterial groups in tumor bearing individuals could 
arise in early phases of tumorigenesis and alter intestinal homeostasis in a way that 
favours or not the process.  Studies on hCRC samples do not allow dissection of the 
cause-effect relationship occurring between tumor formation and dysbiosis onset.  Our 
results only partially answer to this question in that we see alterations at the genus level 
already at 4 weeks, an age at which ApcMin/+ mice do not yet have polyps and are still 
cohoused with WT littermates.  However these differences become significant only at 
later time points making rather speculative the statement that dysbiosis precedes 
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tumorigenesis.  What we do observe is that dysbiosis is an early event paralleling tumor 
progression and this renders particularly intriguing the study of the interplay between the 
microbiota and the developing tumor and how each of the two can influence the other. 
 
5.5 Clostridium ID4 is depleted in ApcMin/+ mice 
Metagenomic analysis of ApcMin/+ mice over the course of tumor progression highlights 
that at the OTU level Clostridium ID4 is significantly depleted in ApcMin/+ faeces at 8 and 
12 weeks of age compared to WT littermates.  Interestingly Clostridium ID4 is reduced 
not only in the faeces, but also in the microbial communities inhabiting the mucus layer 
of the small intestine and of the colon of ApcMin/+ mice.  The finding that Clostridium ID4 
is underrepresented in tumor bearing mice is of particular relevance since Clostridia 
species belonging to clusters IV, XIVa and XVII isolated from human faeces are involved 
in the differentiation of Tregs in the intestine (Atarashi et al., 2013; Atarashi et al., 
2011a).  Clostridium ID4 does not belong to these clusters but could be species-specific 
for the mouse.  In addition to this another Clostridia-related species, such as SFB, is 
involved in the maturation of Th17 cells, another immune cell population that plays a 
fundamental role in intestinal homeostasis and in the pathogenesis of intestinal tumors 
(Chae et al., 2010; Goto et al., 2014b; Ivanov et al., 2009; Ivanov et al., 2008).  Thus the 
study of why C. ID4 is lost during tumorigenesis and which are the effects of this 
phenomenon on tumorigenesis could provide a functional link between an endogenous 
species and tumor progression. 
 
5.6 Clostridium ID4 administration does not alter tumor multiplicity 
nor immune cell populations in ApcMin/+ mice 
Kostic and colleagues have reported an increase in Fusobacterium nucleatum in tumor 
samples compared to matched controls and have demonstrated that this species 
harbour tumorigenic properties by exogenously administering it in the ApcMin/+ model 
(Kostic et al., 2013; Kostic et al., 2012).  Having observed depletion of C. ID4 in ApcMin/+ 
mice we performed a similar experiment of exogenous administration of C. ID4 to 
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ApcMin/+ mice to address whether exogenous administration of a species that, contrarily 
to F. nucleatum, gets lost during tumorigenesis could attenuate the penetrance of the 
disease.  Even though there are reports on the use of probiotics in the clinics for 
treatment of CRC (Kahouli et al., 2013) this would be to our knowledge the first report of 
an endogenous species having a protective role towards tumor development. 
We orally administered C. ID4 to ApcMin/+ and WT littermate mice from 6 to 12 weeks of 
age.  Interestingly, although treated ApcMin/+ mice have higher C. ID4 level compared to 
vehicle treated ApcMin/+ they did not reach the levels retrieved from WT mice.  This could 
mean that although exogenously administered, C. ID4 does not find its proper niche in 
ApcMin/+ mice possibly because of the alterations that we observe in the mucus 
composition.  C. ID4 treated ApcMin/+ mice displayed a slight reduction in small intestinal 
tumor multiplicity.  However C. ID4 treatment did not result in alterations in the main T 
cell populations inhabiting the gut in WT and ApcMin/+ mice and whose differentiation has 
been linked to the microbiota (Tregs, Th17, Th1) although causing an increase in colonic 
Tregs and small intestinal Th17 in gnotobiotic monocolonized mice.  Interestingly when 
we analysed individual mice we observed that C. ID4 abundance in the faeces at 12 
weeks of age inversely correlated with tumor multiplicity and positively correlated with 
Tregs abundance in the small intestine. 
Thus, Clostridium ID4 administration at the dosage and timing employed does not alter 
tumor multiplicity nor immune cell abundance in ApcMin/+ mice.  However, the results 
obtained with correlation analysis suggest that increasing the number of mice and the 
administered dose of C. ID4 could highlight subtle differences.  Hence we are currently 
analysing the effect of anticipating C. ID4 treatment to weaning age (4 weeks of age) 
and of a closer administration schedule (3 instead of 2 administrations per week). 
 
5.7 miRNA involvement in apc expression in the ApcMin/+ murine 
model 
In the human FAP the mechanism through which the normal apc allele is lost is 
described as loss of heterozygosity, a phenomenon that entails the loss of the genomic 
	   111	  
region comprising the apc locus (Markowitz and Bertagnolli, 2009).  However recent 
studies in rat models have challenged this view demonstrating that in some cases there 
is maintenance of heterozygosity at the genomic level but loss of expression of the WT 
allele (Amos-Landgraf et al., 2012).  This paves the way to the contribution of epigenetic 
mechanisms in tumor initiation.  Bacteria have recently been proposed to modulate the 
epigenome (Takahashi, 2014; Yang et al., 2013).  In particular several pathogens alter 
host miRNA response and Salmonella is one of these (Maudet et al., 2014).  Since we 
observe a higher intestinal permeability in the ApcMin/+ model and increased host-bacteria 
interaction and we have observed that the bacterium Salmonella typhimurium alters 
miRNA expression in the murine melanoma cell line B16 (Saccheri F., unpublished) we 
investigated possible bacteria mediated miRNA control of apc expression. 
We performed miRNA profiling in single crypts from wild-type mice, normal and 
dysplastic crypts from ApcMin/+ mice and observed profound alterations in both normal 
and dysplastic crypts isolated from ApcMin/+ ilei.  In the human miR-135a/b is 
overexpressed in CRC tissue and detected in patient stools when compared to healthy 
controls (Koga et al., 2010) and these miRNAs regulate the expression of human apc 
gene (Nagel et al., 2008).  Similarly we observed that both miR-135a and b are 
overexpressed in dysplastic crypts.  Given that the human and murine apc mRNA 
sequences have 87% identity, it is possible that murine miR-135a and b regulate murine 
apc transcript in a similar way to what happens in the human system even if murine apc 
has not been validated to date as miR-135a/b target.  However, among the putative 
binding sites of these miRNAs there are promoters of other components of the Wnt 
signalling pathway, such as Wnt3, suggesting possible alternative ways of regulation. In 
addition to miR-135a/b other miRNAs that we observe to be differentially expressed in 
normal or dysplastic ApcMin/+ crypts could putatively regulate components of the Wnt 
pathway, such as different frizzled receptors and WNT proteins. 
Finally we investigated whether bacterial stimuli could alter the expression of murine apc 
in colonic explants derived from both WT and ApcMin/+ mice.  We stimulated colonic 
explants with a model of enteric pathogen, Salmonella, either invasive or not and a 
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model of intestinal commensal, Escherichia coli, either invasive or not.  We did not 
observe alterations in apc gene expression in the WT or ApcMin/+ tissue under the 
different conditions analysed. 
 
5.8 Conclusions and future directions 
In conclusion we found that the intestinal barrier is altered in tumor bearing mice possibly 
due to alterations in the mucus layer.  Even though the cause-effect relationships of this 
do not emerge clearly from the present work alterations in the mucus could lead to the 
establishment of a dysbiosis.  We further hypothesised that bacterial species that are 
underrepresented in tumor bearing subjects could be protective in the context of tumor 
progression.  We tested here Clostridium ID4 that we found to be underrepresented in 
tumor bearing mice if compared to WT littermates.  However C. ID4 does not induce 
tumor regression at the dosage and administration schedule employed.  Finally, we 
addressed whether dysbiosis could induce alteration in miRNA-mediated regulation of 
apc gene expression.  Even though we observe a markedly different miRNA expression 
pattern in tumor bearing intestine compared to WT the bacterial stimuli that we 
addressed did not produce significant modulation of apc gene expression. 
Current and future work will be aimed at further analysing the contribution of Clostridium 
ID4 to tumor progression.  In particular we are analysing the effect of a closer C. ID4 
administration schedule to confirm the mild reduction in tumor multiplicity that we do 
observe.  We will then analyse the mechanism that involve Clostridium ID4 in the 
tumorigenesis process, envisaging these main possibilities: 
1. Clostridium ID4 might have an effect on the immune system.  In particular it could 
expand the Treg cell population as observed for other Clostridia species 
(Atarashi et al., 2013; Atarashi et al., 2011a) and this could ameliorate the 
intestinal inflammatory status and retard tumor progression.  In the C. ID4 in vivo 
administration experiment already performed we did not observe alterations in 
Treg abundance but this is possibly due to the lower bacterial doses employed; 
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2. The effect observed on tumorigenesis might not be due to Clostridium ID4 per se 
but this bacterium could re-establish a balance in the intestinal microbial 
community that is lost upon tumorigenesis and that is beneficial to the host and 
slows down tumor progression.  We will address this point by performing 
metagenomic sequencing in ApcMin/+ mice treated or not with C. ID4; 
3. Clostridium ID4 could have an effect on tumorigenesis through production of 
metabolites that have antitumorigenic effect, such as SCFAs or bile acids 
(Modica et al., 2008; Sears and Garrett, 2014; Smith et al., 2010). 
If we will not observe the expected difference in tumor multiplicity upon C. ID4 
administration we could hypothesize that this is due to an inability of the bacterium of 
colonizing the intestinal microenvironment.  This might be due to the fact that mucus is 
altered in ApcMin/+ mice and that C. ID4 is detected also at the level of the mucus 
associated bacterial community.  Possible scenarios will then entail alterations of the 
mucus coupled with C. ID4 treatment. 	    
	   114	  
6 BIBLIOGRAPHY 
 
Ajioka, Y., Allison, L.J., and Jass, J.R. (1996). Significance of MUC1 and MUC2 mucin 
expression in colorectal cancer. Journal of clinical pathology 49, 560-564. 
Amos-Landgraf, J.M., Irving, A.A., Hartman, C., Hunter, A., Laube, B., Chen, X., Clipson, 
L., Newton, M.A., and Dove, W.F. (2012). Monoallelic silencing and haploinsufficiency in 
early murine intestinal neoplasms. Proceedings of the National Academy of Sciences of 
the United States of America 109, 2060-2065. 
Anastas, J.N., and Moon, R.T. (2013). WNT signalling pathways as therapeutic targets in 
cancer. Nature reviews Cancer 13, 11-26. 
Arthur, J.C., and Jobin, C. (2013). The complex interplay between inflammation, the 
microbiota and colorectal cancer. Gut microbes 4, 253-258. 
Arthur, J.C., Perez-Chanona, E., Muhlbauer, M., Tomkovich, S., Uronis, J.M., Fan, T.J., 
Campbell, B.J., Abujamel, T., Dogan, B., Rogers, A.B., et al. (2012). Intestinal 
inflammation targets cancer-inducing activity of the microbiota. Science 338, 120-123. 
Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D.R., 
Fernandes, G.R., Tap, J., Bruls, T., Batto, J.M., et al. (2011). Enterotypes of the human 
gut microbiome. Nature 473, 174-180. 
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., 
Saito, T., Narushima, S., Hase, K., et al. (2013). Treg induction by a rationally selected 
mixture of Clostridia strains from the human microbiota. Nature 500, 232-236. 
Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., 
Yamasaki, S., Saito, T., Ohba, Y., et al. (2011a). Induction of colonic regulatory T cells 
by indigenous Clostridium species. Science 331, 337-341. 
Atarashi, K., Umesaki, Y., and Honda, K. (2011b). Microbiotal influence on T cell subset 
development. Seminars in immunology 23, 146-153. 
Barthel, M., Hapfelmeier, S., Quintanilla-Martinez, L., Kremer, M., Rohde, M., Hogardt, 
M., Pfeffer, K., Russmann, H., and Hardt, W.D. (2003). Pretreatment of mice with 
streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that 
allows analysis of both pathogen and host. Infection and immunity 71, 2839-2858. 
Belcheva, A., Irrazabal, T., Robertson, S.J., Streutker, C., Maughan, H., Rubino, S., 
Moriyama, E.H., Copeland, J.K., Kumar, S., Green, B., et al. (2014). Gut microbial 
metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell 158, 288-
299. 
Bergstrom, K.S., Kissoon-Singh, V., Gibson, D.L., Ma, C., Montero, M., Sham, H.P., Ryz, 
N., Huang, T., Velcich, A., Finlay, B.B., et al. (2010). Muc2 protects against lethal 
infectious colitis by disassociating pathogenic and commensal bacteria from the colonic 
mucosa. PLoS pathogens 6, e1000902. 
Blatner, N.R., Mulcahy, M.F., Dennis, K.L., Scholtens, D., Bentrem, D.J., Phillips, J.D., 
Ham, S., Sandall, B.P., Khan, M.W., Mahvi, D.M., et al. (2012). Expression of 
RORgammat marks a pathogenic regulatory T cell subset in human colon cancer. 
Science translational medicine 4, 164ra159. 
Bogaert, J., and Prenen, H. (2014). Molecular genetics of colorectal cancer. Annals of 
gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology 27, 9-
14. 
Boivin, G.P., Washington, K., Yang, K., Ward, J.M., Pretlow, T.P., Russell, R., 
Besselsen, D.G., Godfrey, V.L., Doetschman, T., Dove, W.F., et al. (2003). Pathology of 
	   115	  
mouse models of intestinal cancer: consensus report and recommendations. 
Gastroenterology 124, 762-777. 
Brestoff, J.R., and Artis, D. (2013). Commensal bacteria at the interface of host 
metabolism and the immune system. Nature immunology 14, 676-684. 
Brown, E.M., Sadarangani, M., and Finlay, B.B. (2013). The role of the immune system 
in governing host-microbe interactions in the intestine. Nature immunology 14, 660-667. 
Chae, W.J., Gibson, T.F., Zelterman, D., Hao, L., Henegariu, O., and Bothwell, A.L. 
(2010). Ablation of IL-17A abrogates progression of spontaneous intestinal 
tumorigenesis. Proceedings of the National Academy of Sciences of the United States of 
America 107, 5540-5544. 
Chung, H., Pamp, S.J., Hill, J.A., Surana, N.K., Edelman, S.M., Troy, E.B., Reading, 
N.C., Villablanca, E.J., Wang, S., Mora, J.R., et al. (2012). Gut immune maturation 
depends on colonization with a host-specific microbiota. Cell 149, 1578-1593. 
Cole, J.R., Chai, B., Marsh, T.L., Farris, R.J., Wang, Q., Kulam, S.A., Chandra, S., 
McGarrell, D.M., Schmidt, T.M., Garrity, G.M., et al. (2003). The Ribosomal Database 
Project (RDP-II): previewing a new autoaligner that allows regular updates and the new 
prokaryotic taxonomy. Nucleic acids research 31, 442-443. 
Coletta, P.L., Muller, A.M., Jones, E.A., Muhl, B., Holwell, S., Clarke, D., Meade, J.L., 
Cook, G.P., Hawcroft, G., Ponchel, F., et al. (2004). Lymphodepletion in the ApcMin/+ 
mouse model of intestinal tumorigenesis. Blood 103, 1050-1058. 
Comelli, E.M., Simmering, R., Faure, M., Donnicola, D., Mansourian, R., Rochat, F., 
Corthesy-Theulaz, I., and Cherbut, C. (2008). Multifaceted transcriptional regulation of 
the murine intestinal mucus layer by endogenous microbiota. Genomics 91, 70-77. 
Cooper, H.S., Murthy, S.N., Shah, R.S., and Sedergran, D.J. (1993). Clinicopathologic 
study of dextran sulfate sodium experimental murine colitis. Laboratory investigation; a 
journal of technical methods and pathology 69, 238-249. 
Darfeuille-Michaud, A., Boudeau, J., Bulois, P., Neut, C., Glasser, A.L., Barnich, N., 
Bringer, M.A., Swidsinski, A., Beaugerie, L., and Colombel, J.F. (2004). High prevalence 
of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. 
Gastroenterology 127, 412-421. 
Dawson, P.A., Huxley, S., Gardiner, B., Tran, T., McAuley, J.L., Grimmond, S., 
McGuckin, M.A., and Markovich, D. (2009). Reduced mucin sulfonation and impaired 
intestinal barrier function in the hyposulfataemic NaS1 null mouse. Gut 58, 910-919. 
De Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J.B., Massart, S., 
Collini, S., Pieraccini, G., and Lionetti, P. (2010). Impact of diet in shaping gut microbiota 
revealed by a comparative study in children from Europe and rural Africa. Proceedings of 
the National Academy of Sciences of the United States of America 107, 14691-14696. 
Derrien, M., van Passel, M.W., van de Bovenkamp, J.H., Schipper, R.G., de Vos, W.M., 
and Dekker, J. (2010). Mucin-bacterial interactions in the human oral cavity and 
digestive tract. Gut microbes 1, 254-268. 
Dominguez-Bello, M.G., Costello, E.K., Contreras, M., Magris, M., Hidalgo, G., Fierer, 
N., and Knight, R. (2010). Delivery mode shapes the acquisition and structure of the 
initial microbiota across multiple body habitats in newborns. Proceedings of the National 
Academy of Sciences of the United States of America 107, 11971-11975. 
Dorrestein, P.C., Mazmanian, S.K., and Knight, R. (2014). Finding the Missing Links 
among Metabolites, Microbes, and the Host. Immunity 40, 824-832. 
Eberl, G. (2010). A new vision of immunity: homeostasis of the superorganism. Mucosal 
immunology 3, 450-460. 
	   116	  
Eckburg, P.B., Bik, E.M., Bernstein, C.N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, 
S.R., Nelson, K.E., and Relman, D.A. (2005). Diversity of the human intestinal microbial 
flora. Science 308, 1635-1638. 
Elinav, E., Strowig, T., Kau, A.L., Henao-Mejia, J., Thaiss, C.A., Booth, C.J., Peaper, 
D.R., Bertin, J., Eisenbarth, S.C., Gordon, J.I., et al. (2011). NLRP6 inflammasome 
regulates colonic microbial ecology and risk for colitis. Cell 145, 745-757. 
Farin, H.F., Karthaus, W.R., Kujala, P., Rakhshandehroo, M., Schwank, G., Vries, R.G., 
Kalkhoven, E., Nieuwenhuis, E.E., and Clevers, H. (2014). Paneth cell extrusion and 
release of antimicrobial products is directly controlled by immune cell-derived IFN-
gamma. The Journal of experimental medicine 211, 1393-1405. 
Fearon, E.R., and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. 
Cell 61, 759-767. 
Frank, D.N., St Amand, A.L., Feldman, R.A., Boedeker, E.C., Harpaz, N., and Pace, 
N.R. (2007). Molecular-phylogenetic characterization of microbial community imbalances 
in human inflammatory bowel diseases. Proceedings of the National Academy of 
Sciences of the United States of America 104, 13780-13785. 
Furet, J.P., Firmesse, O., Gourmelon, M., Bridonneau, C., Tap, J., Mondot, S., Dore, J., 
and Corthier, G. (2009). Comparative assessment of human and farm animal faecal 
microbiota using real-time quantitative PCR. FEMS microbiology ecology 68, 351-362. 
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., Nakanishi, 
Y., Uetake, C., Kato, K., Kato, T., et al. (2013). Commensal microbe-derived butyrate 
induces the differentiation of colonic regulatory T cells. Nature 504, 446-450. 
Gaboriau-Routhiau, V., Rakotobe, S., Lecuyer, E., Mulder, I., Lan, A., Bridonneau, C., 
Rochet, V., Pisi, A., De Paepe, M., Brandi, G., et al. (2009). The key role of segmented 
filamentous bacteria in the coordinated maturation of gut helper T cell responses. 
Immunity 31, 677-689. 
Geuking, M.B., Cahenzli, J., Lawson, M.A., Ng, D.C., Slack, E., Hapfelmeier, S., McCoy, 
K.D., and Macpherson, A.J. (2011). Intestinal bacterial colonization induces mutualistic 
regulatory T cell responses. Immunity 34, 794-806. 
Goto, Y., Obata, T., Kunisawa, J., Sato, S., Ivanov, II, Lamichhane, A., Takeyama, N., 
Kamioka, M., Sakamoto, M., Matsuki, T., et al. (2014a). Innate lymphoid cells regulate 
intestinal epithelial cell glycosylation. Science 345, 1254009. 
Goto, Y., Panea, C., Nakato, G., Cebula, A., Lee, C., Diez, M.G., Laufer, T.M., 
Ignatowicz, L., and Ivanov, II (2014b). Segmented filamentous bacteria antigens 
presented by intestinal dendritic cells drive mucosal Th17 cell differentiation. Immunity 
40, 594-607. 
Gounaris, E., Blatner, N.R., Dennis, K., Magnusson, F., Gurish, M.F., Strom, T.B., 
Beckhove, P., Gounari, F., and Khazaie, K. (2009). T-regulatory cells shift from a 
protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in 
polyposis. Cancer research 69, 5490-5497. 
Grivennikov, S.I., Wang, K., Mucida, D., Stewart, C.A., Schnabl, B., Jauch, D., 
Taniguchi, K., Yu, G.Y., Osterreicher, C.H., Hung, K.E., et al. (2012). Adenoma-linked 
barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 
491, 254-258. 
Gupta, B.K., Maher, D.M., Ebeling, M.C., Sundram, V., Koch, M.D., Lynch, D.W., 
Bohlmeyer, T., Watanabe, A., Aburatani, H., Puumala, S.E., et al. (2012). Increased 
expression and aberrant localization of mucin 13 in metastatic colon cancer. The journal 
of histochemistry and cytochemistry : official journal of the Histochemistry Society 60, 
822-831. 
Gutzeit, C., Magri, G., and Cerutti, A. (2014). Intestinal IgA production and its role in 
host-microbe interaction. Immunological reviews 260, 76-85. 
	   117	  
Hasnain, S.Z., Evans, C.M., Roy, M., Gallagher, A.L., Kindrachuk, K.N., Barron, L., 
Dickey, B.F., Wilson, M.S., Wynn, T.A., Grencis, R.K., et al. (2011). Muc5ac: a critical 
component mediating the rejection of enteric nematodes. The Journal of experimental 
medicine 208, 893-900. 
Honda, K., and Littman, D.R. (2012). The microbiome in infectious disease and 
inflammation. Annual review of immunology 30, 759-795. 
Hooper, L.V., and Macpherson, A.J. (2010). Immune adaptations that maintain 
homeostasis with the intestinal microbiota. Nature reviews Immunology 10, 159-169. 
Iida, N., Dzutsev, A., Stewart, C.A., Smith, L., Bouladoux, N., Weingarten, R.A., Molina, 
D.A., Salcedo, R., Back, T., Cramer, S., et al. (2013). Commensal bacteria control 
cancer response to therapy by modulating the tumor microenvironment. Science 342, 
967-970. 
Iliev, I.D., Matteoli, G., and Rescigno, M. (2007). The yin and yang of intestinal epithelial 
cells in controlling dendritic cell function. The Journal of experimental medicine 204, 
2253-2257. 
Iliev, I.D., Mileti, E., Matteoli, G., Chieppa, M., and Rescigno, M. (2009a). Intestinal 
epithelial cells promote colitis-protective regulatory T-cell differentiation through dendritic 
cell conditioning. Mucosal immunology 2, 340-350. 
Iliev, I.D., Spadoni, I., Mileti, E., Matteoli, G., Sonzogni, A., Sampietro, G.M., Foschi, D., 
Caprioli, F., Viale, G., and Rescigno, M. (2009b). Human intestinal epithelial cells 
promote the differentiation of tolerogenic dendritic cells. Gut 58, 1481-1489. 
Irrazabal, T., Belcheva, A., Girardin, S.E., Martin, A., and Philpott, D.J. (2014). The 
multifaceted role of the intestinal microbiota in colon cancer. Molecular cell 54, 309-320. 
Ivanov, II, Atarashi, K., Manel, N., Brodie, E.L., Shima, T., Karaoz, U., Wei, D., Goldfarb, 
K.C., Santee, C.A., Lynch, S.V., et al. (2009). Induction of intestinal Th17 cells by 
segmented filamentous bacteria. Cell 139, 485-498. 
Ivanov, II, Frutos Rde, L., Manel, N., Yoshinaga, K., Rifkin, D.B., Sartor, R.B., Finlay, 
B.B., and Littman, D.R. (2008). Specific microbiota direct the differentiation of IL-17-
producing T-helper cells in the mucosa of the small intestine. Cell host & microbe 4, 337-
349. 
Jang, M.H., Kweon, M.N., Iwatani, K., Yamamoto, M., Terahara, K., Sasakawa, C., 
Suzuki, T., Nochi, T., Yokota, Y., Rennert, P.D., et al. (2004). Intestinal villous M cells: 
an antigen entry site in the mucosal epithelium. Proceedings of the National Academy of 
Sciences of the United States of America 101, 6110-6115. 
Jernberg, C., Lofmark, S., Edlund, C., and Jansson, J.K. (2007). Long-term ecological 
impacts of antibiotic administration on the human intestinal microbiota. The ISME journal 
1, 56-66. 
Johansson, M.E., Phillipson, M., Petersson, J., Velcich, A., Holm, L., and Hansson, G.C. 
(2008). The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of 
bacteria. Proceedings of the National Academy of Sciences of the United States of 
America 105, 15064-15069. 
Kahouli, I., Tomaro-Duchesneau, C., and Prakash, S. (2013). Probiotics in colorectal 
cancer (CRC) with emphasis on mechanisms of action and current perspectives. Journal 
of medical microbiology 62, 1107-1123. 
Kawakubo, M., Ito, Y., Okimura, Y., Kobayashi, M., Sakura, K., Kasama, S., Fukuda, 
M.N., Fukuda, M., Katsuyama, T., and Nakayama, J. (2004). Natural antibiotic function 
of a human gastric mucin against Helicobacter pylori infection. Science 305, 1003-1006. 
Kawamoto, S., Maruya, M., Kato, L.M., Suda, W., Atarashi, K., Doi, Y., Tsutsui, Y., Qin, 
H., Honda, K., Okada, T., et al. (2014). Foxp3(+) T cells regulate immunoglobulin a 
selection and facilitate diversification of bacterial species responsible for immune 
homeostasis. Immunity 41, 152-165. 
	   118	  
Keerthivasan, S., Aghajani, K., Dose, M., Molinero, L., Khan, M.W., Venkateswaran, V., 
Weber, C., Emmanuel, A.O., Sun, T., Bentrem, D.J., et al. (2014). beta-Catenin 
promotes colitis and colon cancer through imprinting of proinflammatory properties in T 
cells. Science translational medicine 6, 225ra228. 
Kelly, D., King, T., and Aminov, R. (2007). Importance of microbial colonization of the gut 
in early life to the development of immunity. Mutation research 622, 58-69. 
Knoop, K.A., McDonald, K.G., McCrate, S., McDole, J.R., and Newberry, R.D. (2014). 
Microbial sensing by goblet cells controls immune surveillance of luminal antigens in the 
colon. Mucosal immunology. 
Koga, Y., Yasunaga, M., Takahashi, A., Kuroda, J., Moriya, Y., Akasu, T., Fujita, S., 
Yamamoto, S., Baba, H., and Matsumura, Y. (2010). MicroRNA expression profiling of 
exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev 
Res (Phila) 3, 1435-1442. 
Kostic, A.D., Chun, E., Robertson, L., Glickman, J.N., Gallini, C.A., Michaud, M., Clancy, 
T.E., Chung, D.C., Lochhead, P., Hold, G.L., et al. (2013). Fusobacterium nucleatum 
potentiates intestinal tumorigenesis and modulates the tumor-immune 
microenvironment. Cell host & microbe 14, 207-215. 
Kostic, A.D., Gevers, D., Pedamallu, C.S., Michaud, M., Duke, F., Earl, A.M., Ojesina, 
A.I., Jung, J., Bass, A.J., Tabernero, J., et al. (2012). Genomic analysis identifies 
association of Fusobacterium with colorectal carcinoma. Genome research 22, 292-298. 
Lacunza, E., Baudis, M., Colussi, A.G., Segal-Eiras, A., Croce, M.V., and Abba, M.C. 
(2010). MUC1 oncogene amplification correlates with protein overexpression in invasive 
breast carcinoma cells. Cancer genetics and cytogenetics 201, 102-110. 
Lesage, S., Zouali, H., Cezard, J.P., Colombel, J.F., Belaiche, J., Almer, S., Tysk, C., 
O'Morain, C., Gassull, M., Binder, V., et al. (2002). CARD15/NOD2 mutational analysis 
and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. 
American journal of human genetics 70, 845-857. 
Li, Y., Bharti, A., Chen, D., Gong, J., and Kufe, D. (1998). Interaction of glycogen 
synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-
catenin. Molecular and cellular biology 18, 7216-7224. 
Lin, X., Chen, M., Liu, Y., Guo, Z., He, X., Brand, D., and Zheng, S.G. (2013). Advances 
in distinguishing natural from induced Foxp3(+) regulatory T cells. International journal of 
clinical and experimental pathology 6, 116-123. 
Linden, S.K., Florin, T.H., and McGuckin, M.A. (2008). Mucin dynamics in intestinal 
bacterial infection. PloS one 3, e3952. 
Linden, S.K., Sheng, Y.H., Every, A.L., Miles, K.M., Skoog, E.C., Florin, T.H., Sutton, P., 
and McGuckin, M.A. (2009). MUC1 limits Helicobacter pylori infection both by steric 
hindrance and by acting as a releasable decoy. PLoS pathogens 5, e1000617. 
Lindner, C., Wahl, B., Fohse, L., Suerbaum, S., Macpherson, A.J., Prinz, I., and Pabst, 
O. (2012). Age, microbiota, and T cells shape diverse individual IgA repertoires in the 
intestine. The Journal of experimental medicine 209, 365-377. 
Loonen, L.M., Stolte, E.H., Jaklofsky, M.T., Meijerink, M., Dekker, J., van Baarlen, P., 
and Wells, J.M. (2014). REG3gamma-deficient mice have altered mucus distribution and 
increased mucosal inflammatory responses to the microbiota and enteric pathogens in 
the ileum. Mucosal immunology 7, 939-947. 
Luo, J., Chen, J., Deng, Z.L., Luo, X., Song, W.X., Sharff, K.A., Tang, N., Haydon, R.C., 
Luu, H.H., and He, T.C. (2007). Wnt signaling and human diseases: what are the 
therapeutic implications? Laboratory investigation; a journal of technical methods and 
pathology 87, 97-103. 
	   119	  
Mackie, R.I., Sghir, A., and Gaskins, H.R. (1999). Developmental microbial ecology of 
the neonatal gastrointestinal tract. The American journal of clinical nutrition 69, 1035S-
1045S. 
Markowitz, S.D., and Bertagnolli, M.M. (2009). Molecular origins of cancer: Molecular 
basis of colorectal cancer. The New England journal of medicine 361, 2449-2460. 
Matsuo, K., Ota, H., Akamatsu, T., Sugiyama, A., and Katsuyama, T. (1997). 
Histochemistry of the surface mucous gel layer of the human colon. Gut 40, 782-789. 
Maudet, C., Mano, M., and Eulalio, A. (2014). MicroRNAs in the interaction between host 
and bacterial pathogens. FEBS letters. 
Mazzini, E., Massimiliano, L., Penna, G., and Rescigno, M. (2014). Oral tolerance can be 
established via gap junction transfer of fed antigens from CX3CR1(+) macrophages to 
CD103(+) dendritic cells. Immunity 40, 248-261. 
McCormick, B.A., Stocker, B.A., Laux, D.C., and Cohen, P.S. (1988). Roles of motility, 
chemotaxis, and penetration through and growth in intestinal mucus in the ability of an 
avirulent strain of Salmonella typhimurium to colonize the large intestine of streptomycin-
treated mice. Infection and immunity 56, 2209-2217. 
McDole, J.R., Wheeler, L.W., McDonald, K.G., Wang, B., Konjufca, V., Knoop, K.A., 
Newberry, R.D., and Miller, M.J. (2012). Goblet cells deliver luminal antigen to CD103+ 
dendritic cells in the small intestine. Nature 483, 345-349. 
McGuckin, M.A., Linden, S.K., Sutton, P., and Florin, T.H. (2011). Mucin dynamics and 
enteric pathogens. Nature reviews Microbiology 9, 265-278. 
Modica, S., Murzilli, S., Salvatore, L., Schmidt, D.R., and Moschetta, A. (2008). Nuclear 
bile acid receptor FXR protects against intestinal tumorigenesis. Cancer research 68, 
9589-9594. 
Moser, A.R., Pitot, H.C., and Dove, W.F. (1990). A dominant mutation that predisposes 
to multiple intestinal neoplasia in the mouse. Science 247, 322-324. 
Nagel, R., le Sage, C., Diosdado, B., van der Waal, M., Oude Vrielink, J.A., Bolijn, A., 
Meijer, G.A., and Agami, R. (2008). Regulation of the adenomatous polyposis coli gene 
by the miR-135 family in colorectal cancer. Cancer research 68, 5795-5802. 
Narushima, S., Sugiura, Y., Oshima, K., Atarashi, K., Hattori, M., Suematsu, M., and 
Honda, K. (2014). Characterization of the 17 strains of regulatory T cell-inducing human-
derived Clostridia. Gut microbes 5. 
Neufert, C., Becker, C., and Neurath, M.F. (2007). An inducible mouse model of colon 
carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. 
Nature protocols 2, 1998-2004. 
Nevola, J.J., Laux, D.C., and Cohen, P.S. (1987). In vivo colonization of the mouse large 
intestine and in vitro penetration of intestinal mucus by an avirulent smooth strain of 
Salmonella typhimurium and its lipopolysaccharide-deficient mutant. Infection and 
immunity 55, 2884-2890. 
Newman, J.V., Kosaka, T., Sheppard, B.J., Fox, J.G., and Schauer, D.B. (2001). 
Bacterial infection promotes colon tumorigenesis in Apc(Min/+) mice. The Journal of 
infectious diseases 184, 227-230. 
Ouwerkerk, J.P., de Vos, W.M., and Belzer, C. (2013). Glycobiome: bacteria and mucus 
at the epithelial interface. Best practice & research Clinical gastroenterology 27, 25-38. 
Park, E.T., Gum, J.R., Kakar, S., Kwon, S.W., Deng, G., and Kim, Y.S. (2008). Aberrant 
expression of SOX2 upregulates MUC5AC gastric foveolar mucin in mucinous cancers 
of the colorectum and related lesions. International journal of cancer Journal 
international du cancer 122, 1253-1260. 
	   120	  
Paszek, M.J., DuFort, C.C., Rossier, O., Bainer, R., Mouw, J.K., Godula, K., Hudak, J.E., 
Lakins, J.N., Wijekoon, A.C., Cassereau, L., et al. (2014). The cancer glycocalyx 
mechanically primes integrin-mediated growth and survival. Nature 511, 319-325. 
Pawelek, J.M., Low, K.B., and Bermudes, D. (2003). Bacteria as tumour-targeting 
vectors. The Lancet Oncology 4, 548-556. 
Pelissier, M.A., Vasquez, N., Balamurugan, R., Pereira, E., Dossou-Yovo, F., Suau, A., 
Pochart, P., and Magne, F. (2010). Metronidazole effects on microbiota and mucus layer 
thickness in the rat gut. FEMS microbiology ecology 73, 601-610. 
Perse, M., and Cerar, A. (2012). Dextran sodium sulphate colitis mouse model: traps 
and tricks. Journal of biomedicine & biotechnology 2012, 718617. 
Petersson, J., Schreiber, O., Hansson, G.C., Gendler, S.J., Velcich, A., Lundberg, J.O., 
Roos, S., Holm, L., and Phillipson, M. (2011). Importance and regulation of the colonic 
mucus barrier in a mouse model of colitis. American journal of physiology 
Gastrointestinal and liver physiology 300, G327-333. 
Pickard, J.M., Maurice, C.F., Kinnebrew, M.A., Abt, M.C., Schenten, D., Golovkina, T.V., 
Bogatyrev, S.R., Ismagilov, R.F., Pamer, E.G., Turnbaugh, P.J., et al. (2014). Rapid 
fucosylation of intestinal epithelium sustains host-commensal symbiosis in sickness. 
Nature. 
Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K.S., Manichanh, C., Nielsen, T., 
Pons, N., Levenez, F., Yamada, T., et al. (2010). A human gut microbial gene catalogue 
established by metagenomic sequencing. Nature 464, 59-65. 
Rescigno, M. (2008). The pathogenic role of intestinal flora in IBD and colon cancer. 
Current drug targets 9, 395-403. 
Rescigno, M., Urbano, M., Valzasina, B., Francolini, M., Rotta, G., Bonasio, R., 
Granucci, F., Kraehenbuhl, J.P., and Ricciardi-Castagnoli, P. (2001). Dendritic cells 
express tight junction proteins and penetrate gut epithelial monolayers to sample 
bacteria. Nature immunology 2, 361-367. 
Salzman, N.H., Hung, K., Haribhai, D., Chu, H., Karlsson-Sjoberg, J., Amir, E., Teggatz, 
P., Barman, M., Hayward, M., Eastwood, D., et al. (2010). Enteric defensins are 
essential regulators of intestinal microbial ecology. Nature immunology 11, 76-83. 
Sayin, S.I., Wahlstrom, A., Felin, J., Jantti, S., Marschall, H.U., Bamberg, K., Angelin, B., 
Hyotylainen, T., Oresic, M., and Backhed, F. (2013). Gut microbiota regulates bile acid 
metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring 
FXR antagonist. Cell metabolism 17, 225-235. 
Sears, C.L., and Garrett, W.S. (2014). Microbes, microbiota, and colon cancer. Cell host 
& microbe 15, 317-328. 
Shan, M., Gentile, M., Yeiser, J.R., Walland, A.C., Bornstein, V.U., Chen, K., He, B., 
Cassis, L., Bigas, A., Cols, M., et al. (2013). Mucus enhances gut homeostasis and oral 
tolerance by delivering immunoregulatory signals. Science 342, 447-453. 
Sheng, Y.H., Hasnain, S.Z., Florin, T.H., and McGuckin, M.A. (2012). Mucins in 
inflammatory bowel diseases and colorectal cancer. Journal of gastroenterology and 
hepatology 27, 28-38. 
Sheng, Y.H., Lourie, R., Linden, S.K., Jeffery, P.L., Roche, D., Tran, T.V., Png, C.W., 
Waterhouse, N., Sutton, P., Florin, T.H., et al. (2011). The MUC13 cell-surface mucin 
protects against intestinal inflammation by inhibiting epithelial cell apoptosis. Gut 60, 
1661-1670. 
Sheng, Y.H., Triyana, S., Wang, R., Das, I., Gerloff, K., Florin, T.H., Sutton, P., and 
McGuckin, M.A. (2013). MUC1 and MUC13 differentially regulate epithelial inflammation 
in response to inflammatory and infectious stimuli. Mucosal immunology 6, 557-568. 
	   121	  
Shibahara, H., Higashi, M., Koriyama, C., Yokoyama, S., Kitazono, I., Kurumiya, Y., 
Narita, M., Kuze, S., Kyokane, T., Mita, S., et al. (2014). Pathobiological implications of 
mucin (MUC) expression in the outcome of small bowel cancer. PloS one 9, e86111. 
Smith, D.L., Keshavan, P., Avissar, U., Ahmed, K., and Zucker, S.D. (2010). Sodium 
taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through 
activation of the farnesoid X receptor. Carcinogenesis 31, 1100-1109. 
Song, X., Gao, H., Lin, Y., Yao, Y., Zhu, S., Wang, J., Liu, Y., Yao, X., Meng, G., Shen, 
N., et al. (2014). Alterations in the microbiota drive interleukin-17C production from 
intestinal epithelial cells to promote tumorigenesis. Immunity 40, 140-152. 
Soumelis, V., Reche, P.A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, 
S., Antonenko, S., Lauerma, A., et al. (2002). Human epithelial cells trigger dendritic cell 
mediated allergic inflammation by producing TSLP. Nature immunology 3, 673-680. 
Spadoni, I., Iliev, I.D., Rossi, G., and Rescigno, M. (2012). Dendritic cells produce TSLP 
that limits the differentiation of Th17 cells, fosters Treg development, and protects 
against colitis. Mucosal immunology 5, 184-193. 
Strober, W., Kitani, A., Fuss, I., Asano, N., and Watanabe, T. (2008). The molecular 
basis of NOD2 susceptibility mutations in Crohn's disease. Mucosal immunology 1 Suppl 
1, S5-9. 
Suzuki, K., Meek, B., Doi, Y., Muramatsu, M., Chiba, T., Honjo, T., and Fagarasan, S. 
(2004). Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. 
Proceedings of the National Academy of Sciences of the United States of America 101, 
1981-1986. 
Swann, J.R., Want, E.J., Geier, F.M., Spagou, K., Wilson, I.D., Sidaway, J.E., Nicholson, 
J.K., and Holmes, E. (2011). Systemic gut microbial modulation of bile acid metabolism 
in host tissue compartments. Proceedings of the National Academy of Sciences of the 
United States of America 108 Suppl 1, 4523-4530. 
Takahashi, K. (2014). Influence of bacteria on epigenetic gene control. Cellular and 
molecular life sciences : CMLS 71, 1045-1054. 
Tanaka, T., Kohno, H., Suzuki, R., Hata, K., Sugie, S., Niho, N., Sakano, K., Takahashi, 
M., and Wakabayashi, K. (2006). Dextran sodium sulfate strongly promotes colorectal 
carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate 
results in development of multiple colonic neoplasms. International journal of cancer 
Journal international du cancer 118, 25-34. 
Thibault, R., Blachier, F., Darcy-Vrillon, B., de Coppet, P., Bourreille, A., and Segain, 
J.P. (2010). Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a 
transport deficiency. Inflammatory bowel diseases 16, 684-695. 
Thibault, R., De Coppet, P., Daly, K., Bourreille, A., Cuff, M., Bonnet, C., Mosnier, J.F., 
Galmiche, J.P., Shirazi-Beechey, S., and Segain, J.P. (2007). Down-regulation of the 
monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal 
inflammation. Gastroenterology 133, 1916-1927. 
Tsilingiri, K., Barbosa, T., Penna, G., Caprioli, F., Sonzogni, A., Viale, G., and Rescigno, 
M. (2012). Probiotic and postbiotic activity in health and disease: comparison on a novel 
polarised ex-vivo organ culture model. Gut 61, 1007-1015. 
Tsilingiri, K., Sonzogni, A., Caprioli, F., and Rescigno, M. (2013). A novel method for the 
culture and polarized stimulation of human intestinal mucosa explants. Journal of 
visualized experiments : JoVE, e4368. 
Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., and Gordon, J.I. 
(2006). An obesity-associated gut microbiome with increased capacity for energy 
harvest. Nature 444, 1027-1031. 
	   122	  
Turnbaugh, P.J., Ridaura, V.K., Faith, J.J., Rey, F.E., Knight, R., and Gordon, J.I. 
(2009). The effect of diet on the human gut microbiome: a metagenomic analysis in 
humanized gnotobiotic mice. Science translational medicine 1, 6ra14. 
Van der Sluis, M., De Koning, B.A., De Bruijn, A.C., Velcich, A., Meijerink, J.P., Van 
Goudoever, J.B., Buller, H.A., Dekker, J., Van Seuningen, I., Renes, I.B., et al. (2006). 
Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for 
colonic protection. Gastroenterology 131, 117-129. 
Velcich, A., Yang, W., Heyer, J., Fragale, A., Nicholas, C., Viani, S., Kucherlapati, R., 
Lipkin, M., Yang, K., and Augenlicht, L. (2002). Colorectal cancer in mice genetically 
deficient in the mucin Muc2. Science 295, 1726-1729. 
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillere, R., Hannani, D., Enot, D.P., 
Pfirschke, C., Engblom, C., Pittet, M.J., et al. (2013). The intestinal microbiota modulates 
the anticancer immune effects of cyclophosphamide. Science 342, 971-976. 
Vijay-Kumar, M., Aitken, J.D., Carvalho, F.A., Cullender, T.C., Mwangi, S., Srinivasan, 
S., Sitaraman, S.V., Knight, R., Ley, R.E., and Gewirtz, A.T. (2010). Metabolic syndrome 
and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328, 228-231. 
Vimal, D.B., Khullar, M., Gupta, S., and Ganguly, N.K. (2000). Intestinal mucins: the 
binding sites for Salmonella typhimurium. Molecular and cellular biochemistry 204, 107-
117. 
Weaver, C.T., Hatton, R.D., Mangan, P.R., and Harrington, L.E. (2007). IL-17 family 
cytokines and the expanding diversity of effector T cell lineages. Annual review of 
immunology 25, 821-852. 
Wen, L., Ley, R.E., Volchkov, P.Y., Stranges, P.B., Avanesyan, L., Stonebraker, A.C., 
Hu, C., Wong, F.S., Szot, G.L., Bluestone, J.A., et al. (2008). Innate immunity and 
intestinal microbiota in the development of Type 1 diabetes. Nature 455, 1109-1113. 
Willing, B.P., Russell, S.L., and Finlay, B.B. (2011). Shifting the balance: antibiotic 
effects on host-microbiota mutualism. Nature reviews Microbiology 9, 233-243. 
Wlodarska, M., Thaiss, C.A., Nowarski, R., Henao-Mejia, J., Zhang, J.P., Brown, E.M., 
Frankel, G., Levy, M., Katz, M.N., Philbrick, W.M., et al. (2014). NLRP6 inflammasome 
orchestrates the colonic host-microbial interface by regulating goblet cell mucus 
secretion. Cell 156, 1045-1059. 
Xiao, X., Wang, L., Wei, P., Chi, Y., Li, D., Wang, Q., Ni, S., Tan, C., Sheng, W., Sun, 
M., et al. (2013). Role of MUC20 overexpression as a predictor of recurrence and poor 
outcome in colorectal cancer. Journal of translational medicine 11, 151. 
Yang, K., Popova, N.V., Yang, W.C., Lozonschi, I., Tadesse, S., Kent, S., Bancroft, L., 
Matise, I., Cormier, R.T., Scherer, S.J., et al. (2008). Interaction of Muc2 and Apc on Wnt 
signaling and in intestinal tumorigenesis: potential role of chronic inflammation. Cancer 
research 68, 7313-7322. 
Yang, T., Owen, J.L., Lightfoot, Y.L., Kladde, M.P., and Mohamadzadeh, M. (2013). 
Microbiota impact on the epigenetic regulation of colorectal cancer. Trends in molecular 
medicine 19, 714-725. 
Zaph, C., Troy, A.E., Taylor, B.C., Berman-Booty, L.D., Guild, K.J., Du, Y., Yost, E.A., 
Gruber, A.D., May, M.J., Greten, F.R., et al. (2007). Epithelial-cell-intrinsic IKK-beta 
expression regulates intestinal immune homeostasis. Nature 446, 552-556. 
Zhu, J., and Paul, W.E. (2008). CD4 T cells: fates, functions, and faults. Blood 112, 
1557-1569. 
Zhu, Q., Gao, R., Wu, W., and Qin, H. (2013). The role of gut microbiota in the 
pathogenesis of colorectal cancer. Tumour biology : the journal of the International 
Society for Oncodevelopmental Biology and Medicine 34, 1285-1300. 
 
